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Abstract:  
 
This thesis is focused on the design and synthesis of analogues of thioesters of Co-
enzyme A which are involved in many important biosynthetic pathways.  
Acetyl-CoA is converted into citrate by citrate synthase in the first step of the Krebs cycle 
that is central for the cellular respiration.  
Chapter 2 is focused on the successful synthesis of five analogues of acetyl-CoA and 
their investigation as inhibitors of citrate synthase. This project is based on the finding 
that Fluorovinyl thioether-CoA (FV-CoA) is a micromolar inhibitor of citrate synthase 
(Kiapp = 4.4 µM).1 Sulfoxide-CoA, with a sulfonyl and a methylene group replacing the 
carbonyl group and the sulfur atom of acetyl-CoA, was found to be a modest micromolar 
inhibitor of citrate synthase (11.1 µM), indicating its potential as hydrogen bonding 
acceptor. The remaining compounds showed poor or too low binding affinity for the 
enzyme. Although these compounds showed poor inhibitory capacity towards citrate 
synthase, they could be potential inhibitors of other acetyl-CoA utilizing enzymes, such 
as malate synthase that catalyzes the conversion of acetyl-CoA into malate. Its activity 
is correlated to different pathogens pathway (Mycobacterium tubercolosis) and its 
regulation could potentially prevent the bacterial growth.  
Chapter 3 describes the attempted synthesis of a fluorovinyl thioacrylate derivative as 
malonyl-CoA analogue and potential covalent inhibitor of acetyl-CoA carboxylase (ACC). 
ACC catalyzes the irreversible conversion of acetyl-CoA into malonyl-CoA in the first 
step of fatty acid synthesis. The regulation of ACC is associated to many cardiovascular 
diseases such as diabetes, obesity and its inhibition can lead to the development of novel 
antibiotics for their treatment. Due to the challenging synthesis of the precursor thioester, 
this malonyl-CoA analogue could not be prepared.  
Chapter 4 reports the synthesis of α,α,β-trifluoro cyclopropane-CoA and was found to be 
a poor inhibitor of citrate synthase (Ki = 65.2 µM ). However, this compound has potential 
to be a covalent inhibitor of citrate synthase and other enzymes such as malate synthase, 
thus future investigations will be carried out to this purpose.  
Furthermore, chapter 4 reports the attempted synthesis of an α,α-difluoroethyl thioether-
CoA as an acetyl-CoA analogue. This compound bears two electronegative fluorine 
atoms, thus it could interact electrostatically with the active site residues of citrate 
synthase through hydrogen bonds, leading to its inhibition. Unfortunately, due to the 
instability of the difluoro moiety under the enzymatic reaction conditions, this was not 
converted to the corresponding acetyl-CoA analogue.  
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1. INTRODUCTION 
 
Coenzyme A and its thioesters derivatives are resourceful molecules involved in many 
biosynthetic pathways such as glycolysis, fatty acid metabolism and cell respiration. It 
has been estimated that 4% of key enzymes require Co-A or Co-A thioesters as 
substrates. Analogues of Co-A thioesters have been useful tools for the study of the 
activity and mechanism of enzymes, generally mimicking their intermediate states. This 
thesis will focus mainly on the design and synthesis of fluorinated and non-fluorinated 
acetyl-CoA analogues targeting citrate synthase.  
 
 
 
Co-enzyme A (Co-A) is a co-factor which was identified by Fritz Lipmann in 1946 and its 
structure was reported in 1953. The structure, which is highlighted in Figure 1.1, includes 
a pantetheine domain derived from pantothenic acid which is part of the Vitamin B family 
and an adenosine diphosphate moiety.2 Co-A promotes the activation and transfer of 
acyl groups in many enzymatic reactions through its thiol group (-SH), it acts as an acyl 
group carrier transferring the moiety from one enzyme catalyzed reaction to an other.3  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Co-enzyme A structure.2 
Fritz Lipmann 
2 
 
 
 
Acetyl-CoA 2 is the coenzyme-A thioester of acetate. The thioester facilitates the transfer 
of the acetyl moiety to a variety of acceptor molecules. Thioesters are less conjugated 
than amides or oxygen esters, and sulfur is an excellent nucleophile and leaving group 
more so than nitrogen or oxygen. 
  
 
 
Figure 1.2. Acetyl-CoA structure.2  
 
Acetyl-CoA 2 is synthesised in mitochondria by oxidative decarboxylation of pyruvate, 
itself originated from glycolysis and β -oxidation of fatty acids. The degradation of 
pyruvate 3 described in Scheme 1, is catalysed by an enzyme complex called pyruvate 
dehydrogenase (PDH). The reaction involves a sequence of group transfers and redox 
steps carried out by three different catalytic subunits: pyruvate dehydrogenase (E1), 
dihydrolipoyl transacetylase (E2) and dihydrolipoyl dehydrogenase (E3). 
Pyruvate interacts with thiamine pyrophosphate (TPP), prosthetic group of E1 via 
decarboxylation to generate hydroxyethyl-TPP 4. This is then simultaneously oxidised to 
acetyl and transferred to lipoamide, prostethic group of E2, to give acetyllipoamide 6. 
Transfer of the acetyl group to CoA-SH generates acetyl-CoA 2 and dihydrolipoamide 
which is re-oxidised to lipoamine by FAD prostethic group of E3. The overall reaction 
converts pyruvate 3 (three carbons) to acetyl-CoA 2 (two carbons) releasing carbon 
dioxide (CO2) and producing NADH in the process.4  
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Scheme 1.1. Two biosynthetic pathways to acetyl-CoA: A) Oxidation of pyruvate and B) β-
oxidation of fatty acids.4 
 
Acetyl-CoA is also obtained by β-oxidation, degradation of fatty acids. The catabolic 
process involves four steps. Fatty acyl-CoA 7 undergoes a dehydrogenation forming an 
α,β-unsaturated bond to form trans- Δ 2- enoyl-CoA 8 catalysed by acyl-CoA 
dehydrogenase. The second step mediated by enoyl-CoA hydratase, involves the 
hydration of the double bond to form β-hydroxyacyl-CoA 9 that undergoes oxidation to 
generate β-ketoacyl-CoA 10, catalysed by β-hydroxyacyl-CoA dehydrogenase. The forth 
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step involves a thiolysis mediated by thiolase where β-ketoacyl-CoA 10 is broken down 
into acetyl-CoA 2.4  
Acetyl-CoA is central in cholesterol synthesis and ketogenesis. Ketone bodies 
(acetoacetate 14, β-hydroxybutyrate 16, acetone 15) are produced in the mitochondria 
during fasting or triggered by low blood sugar. Both metabolic pathways have the first 
two steps in common. The first is mediated by thiolase and involves the conversion of 
two molecules of acetyl-CoA to generate acetoacetyl-CoA 12. This is then converted to 
β-hydroxy-β-methylglutaryl-CoA (HMG-CoA) 13 by condensation with an other acetyl-
CoA, in a reaction mediated by HMG-CoA synthase. 
Ketone bodies are synthesised by HMG-CoA lyase conversion of HMG-CoA 13 to form 
acetoacetate 14, the first ketone body generated. This can undergo a decarboxylation to 
generate acetone 15 or a reduction to yield β-hydroxybutyrate 16. β-Hydroxybutyrate 16 
and acetoacetate 14 are released into circulation, the ratio depends on the amount of 
NADH accumulated in the liver mitochondria whereas acetone 15 is excreted via lungs 
as a volatile waste (Scheme 1.2).6  
Cholesterol 24 is a steroid that modulates the fluidity of animal cell membranes and is 
the precursor of many steroid hormones such as progesterone, testosterone, estradiol, 
cortisol and bile acids production. Its synthesis takes place in the cytosol. 
The key step for the synthesis of cholesterol 24 is the irreversible conversion of HMG-
CoA 13 to mevalonate 18 mediated by HMG-CoA reductase. Mevalonate 18 is 
progressed to two isoprene units: isopentenyl-pyrophosphate (PP) 20 and dimethylallyl-
pyrophosphate (PP) 21. These engage in head to tail condensation reactions to give 
farnesyl-PP 22. Condensation of two farnesyl-PP 22 gives squalene 23 which undergoes 
a series of reactions to form cholesterol 24. 5 
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Scheme 1.2. The metabolic pathways to ketone bodies and cholesterol.4–6 
 
Acetyl-CoA 2 is also a key metabolite that links metabolism with cell signaling, chromatin 
structure, and transcription. It can be transferred by N-acetyltransferases (NATs) to 
arylamines, such as the aromatic amines serotonin 26 which is a neurotransmitter. 
Serotonin 25 is intermediate in the biosynthesis of melatonin 27 mediated by N-
acetylserotonin O-methyltransferase (AANAT), thus it is involved in the regulation of the 
body circadian’s rhythm. 
Histone acetyltransferases (HATs) affects N-terminal acetylation of some human 
proteins, influencing their stability, localization and function. HATs are enzymes that 
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mediate the acetylation reaction of lysines on histone proteins, key components of 
chromosomes. Acetylation of the lysine residue 28 decreases the affinity of the entire 
histone complex for DNA, exposing other areas of DNA to the transcription machinery. 
Deacetylation processes catalyzed by histone deacetylase enzymes (HDAC), play a key 
role in the repression of the transcription. Balancing the acetylation and deacetylation of 
histones is central for the control of gene transcription. Such imbalances seem to be 
associated with Huntington diseases (HD). The mutation of the Huntington protein has 
been observed to interact with HATs and HDAC enzymes deactivating them and 
consequently disrupting DNA transcription (Scheme 1.3).7  
 
 
Scheme 1.3. N-Acetyl transferase mediated acetyl group transfer reaction.7  
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Acetyl-CoA 2 is a starter unit in the chain elongation process of fatty acid biosynthesis. 
The first step in fatty acid assembly involves an irreversible carboxylation of acetyl-CoA 
2, through its enolate form 31, to malonyl-CoA 33 with biotin that acts as CO2 carrier in 
32. Malonyl-CoA is then transferred onto the fatty acid synthase (FAS) by acyl carrier 
protein (ACP), which effects a first transacylation from malonyl-CoA 33 to malonyl-ACP 
34. In turn, the malonyl unit is loaded onto the FAS complex for a series of 
decarboxylative condensations, reductions, dehydrations and reductions, extending the 
C-C backbone for the production of long-chain fatty acids.8,9 The mechanism is described 
in detail in Chapter 3. 
 
 
 
Scheme 1.4. Summary of fatty acid biosynthesis.8,9 
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Polyketide synthases (PKS) are a family of multi-domain enzyme complexes present in 
bacteria, fungi, plants and a few animal families.  
PKS exhibit Type-I, Type-II organizations as well as Type III which lacks the ACP 
domain. Similar to the FAS enzymes, the introduction of acetyl-CoA 2 (starter unit) or its 
analogues into the polyketide chain proceeds via malonyl-CoA and then a 
decarboxylative Claisen with the ACP thioester of the developing fatty acid chain, adding 
a two carbon unit with each cycle. PKS are an important source of common antibiotics 
such as tetracyclines 44, a family of antibiotics that exert antibacterial activity. They 
inhibit the synthesis of proteins by binding to the ribosome of bacteria, thus disabling the 
binding of aminoacyl-tRNA to the mRNA ribosome complex. An other useful antibiotic is 
Lovastatin 45, a fungal metabolite shown to target HMG-CoA reductase and therefore 
used to reduce cholesterol 24 levels and generally the risks associated in acquiring 
cardiovascular diseases (Scheme 1.5).10,11 
 
 
 
Scheme 1.5. Polyketides synthesis.10,11 
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Given that fluorinated compounds are rare in nature, it is interesting that 20-25% of 
marketed pharmaceuticals have at least one fluorine atom. Fluorine displays some 
advantageous properties, it has the highest electronegativity (3.98) and electron affinity 
(3.448 eV) of all the elements as it is the first element with p orbitals to achieve a noble 
gas configuration with the uptake of one electron. Its atomic radius is the smallest along 
the Period 2 elements; this contraction is due to its high nuclear charge and consequently 
fluorine is not polarisable as the 2p electrons are held closely to the nucleus. Due to 
fluorine high electronegativity, the C-F bond is highly polarised and its strength can be 
associated with an ionic more than a covalent nature of the bond with the electronic 
density significantly located on fluorine. This makes it highly polarisable, short and one 
of the strongest bond in organic chemistry compared to other common bonds (Table 
1.1).12 
 
Bond Bond dissociation 
energy (Kcal/mol) 
C-F 105.4 
C-H 98.8 
C-C 84.0 
C-O 83.1 
C-Cl 78.5 
C-N 69.7 
 
Table 1.1. The bond dissociation energy of the most common C-X bonds in organic chemistry.12 
 
The incorporation of a small and highly electronegative atom such as fluorine into a 
therapeutic or diagnostic molecule can enhance pharmacokinetic and pharmacodynamic  
properties such as metabolic stability, membrane permeability as well as increasing the 
binding affinity towards specific macromolecular target proteins.13,14  
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Fluorine substitution can affect the basicity or acidity of nearby functional groups. Van 
Niel et al.15 investigated how the incorporation of fluorine into basic molecules decreases 
their pKa. They prepared a series of 4-fluoropiperidines and 3-fluoro-4-aminopiperidines 
as analogues of propyl piperidine derivatives as a class of 5HT1D receptor ligands such 
as Sumatriptan 46. Propyl-piperazine 49 is rapidly absorbed and orally bioavailable 
compared to compound 47 which lacks these properties. Molecular modelling showed 
that piperazine 49 could be replaced by a 4-fluoropiperidine as in 48 having a similar 
electron density distribution. The introduction of fluorine lowers the pKa of the amine 
affecting oral absorption, whereas, the effect on oral bioavailability cannot always be 
accurately anticipated.15,16  
Methotrexate 50 is a potent antifolate widely used for the treatment of diverse forms of 
cancer, and for rheumatoid arthritis. Methotrexate 50 inhibits dihydrofolate reductase, an 
enzyme that reduces di-hydrofolic acid to tetra-hydrofolic acid and it is activated 
intracellularly to generate polyglutamate derivatives by addition of glutamic acid residues 
mediated by polyglutamate synthase. 
The polyglutamation of methotrexate 50 increases its retention intracellularly, thus 
enhancing its inhibitory effect as an antifolate. One of the major side effects of an 
excessive dosage of this potent antimetabolite is an elevated cytotoxicity. Fluoro 
methotrexane 51 was found to be less toxic than methotrexane 50. The lower toxicity of 
51 may be correlated to an increased acidity of the γ-carboxyl group, blocking the poly-
glutamination process (Figure 1.3).15,17 
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Figure 1.3. Fluorine substitution to tune the pKa.15–17 
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Generally, incorporation of fluorine modulates lipophilicity, a parameter in medicinal 
chemistry that influences the absorption and distribution of a drug. The lipophilicity is 
measured as the octanol/water partition coefficient P (logP), quantifying the ability of a 
molecule to pass through a lipidic membrane. High logP values are representative of 
strong lipophilicity and high hydrophobicity. It is frequently stated that in the case of 
aromatic substituents, the replacement of ring hydrogen atoms by fluorine or fluoroalkyl 
groups such as CF3, CF3O and CF3S enhances lipophilicity. Böhm et al.18 investigated 
the effect of replacing hydrogen with fluorine for 293 compounds selected from the 
Roche database and reported the results on a Gaussian distribution curve. They 
concluded that fluorine introduction on aromatics led to an increase of lipophilicity by 
0.25 logP units. Conversely, mono-, di-, and tri- fluorination of saturated alkyl 
substituents usually decreases lipophilicity due to the relative polarity of the 
corresponding fluoroalkanes and their associated dipoles (Figure 1.4A). For fluorinated 
compounds containing heteroatoms, the modulation of the lipophilicity is related to the 
distance between fluorine and the heteroatom, and a decrease in logP (not shown) is 
recorded when fluorine is at least three C-C bonds away from the heteroatom (Figure 
1.4B).18 
 
 
 
Figure 1.4. Lipophilicity modulation with the incorporation of fluorine into chemical 
compounds.18,19 
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The high polarisation of the C-F bond indicates that it reacts preferentially through 
electrostatic interactions (dipole-dipole, charge-dipole) and its incorporation into 
molecules can impact their conformation. It has been observed that 1,2-difluoroethane 
66 possesses a more stable gauche relative to anti conformation by 2.4 to 3.4 Kj/mol. 
This preference is related to the hyper-conjugative effect. This suggests that the donation 
of electron density from the σ-bonding orbital of a vicinal C-H bond to the parallel σ*-
anti-bonding orbital of the C-F bond, is regarded as the source of stabilisation. For the 
gauche isomer 66, the C-F bond (σ*-acceptor) is anti-periplanar to the C-H bond (σ-
donor), offering maximum overlap.19,20 
 
 
 
Figure 1.5. Gauche effect and hyperconjugation.19,20 
 
The conformational effects of the C-F bond are highlighted in compound 68 and 69. They 
are inhibitors of the cholesteryl ester transfer protein and thus are good candidates for 
the treatment of coronary heart disease. Compound 69 binds more efficiently to the 
target protein, due to sp3 hybridisation of the ether oxygen allowing electron density 
donation from its two lone pairs to the two σ* CF antibonding orbitals. Thus, the 
fluorinated side chain CF2CF2H in 69 adopts an orthogonal rather than a planar 
conformation which is related to the fluorine-oxygen interaction being more predominant 
than that between the ether oxygen and the aromatic ring (Figure 1.6).21  
 
 
Figure 1.6. Cholesteryl ester transfer protein inhibitors 68 and 69.21 
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Diastereoisomers 71 and 72 are analogues of HIV protease Indinavir 70, developed by 
Merck. Compound 71 shows a comparable affinity to Indinavir for the protein, whereas 
72 has a much lower inhibitory potency than 71. This is related to the F-C-C-OH gauche 
effect which in the case of 72, destabilises the bioactive chain conformation decreasing 
its affinity to the enzyme (Figure 1.7).21  
  
 
 
Figure 1.7. The Gauche effect on the conformation of HIV protease inhibitors 71 and 72.21  
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The bioavailability of pharmaceuticals can be improved by introducing fluorine into their 
metabolically labile sites. The C-F bond is less susceptible to metabolic attack than other 
bonds, thus its incorporation in the metabolic site or at an adjacent one can prevent 
undesired metabolic transformations from happening. This is the case of Ezitimibe 73 
which was developed as analogue of SCH 48461 74, a potent cholesterol adsorption 
ihibitor. In 73, fluorine is introduced as a replacement for hydrogen and methoxide that 
are subject to metabolic hydroxylation and demethylation respectively (74). Compound 
73 was found to be more metabolically stable and a more potent inhibitor than 74.22 
 
 
 
 
Figure 1.8. Introducing fluorine as metabolic blocker in drug candidates  
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Although fluorine is the 13th most abundant element in the Earth crust, fluorine containing 
natural products are extremely rare.  
The most widely distributed is sodium fluoroacetate 78, produced by a large number of 
Australian, Brazilian and African plants. Fluoroacetate 78 is responsible for their toxic 
properties. It was identified in 1943 by Marais in South Africa from the shrub Cymosum. 
In 1986, the soil bacterium Streptomyces cattleya was shown to be able to produce 
fluoroacetate 78 and the antibiotic 4-fluorothreonine 75 when grown in the presence of 
fluoride ion. The enzyme which catalyses the enzymatic C-F bond formation, was 
isolated in 2002 and was informally named “fluorinase”.13,23Fluorinase has subsequently 
had applications as a catalyst for PET radiosynthesis forming the C -18F bond from 
aqueous [18F] fluoride probe.24  
Fluoroacetate 78, as analogue of acetyl-CoA 2, exerts its toxicity upon conversion to 
fluoroacetyl-CoA 76 and then conversion to F-citrate by citrate synthase. F-citrate binds 
strongly to the enzyme aconitase interrupting the citric acid cycle.  
Nucleocidin 81 is a fluorine containing antibiotic which was isolated in 1957 from the 
bacterium Streptomyces calvus. It possesses a fairly broad antibiotic spectrum, but it 
was never approved for clinical use due to its high toxicity in mammals. The presence of 
fluorine in the molecule was established 12 years after its discovery by Morton et al.25 in 
1969 and was regarded as very surprising since no apparent fluoride source was added 
to the culture medium. Unfortunately attempts to re-isolate the antibiotic from S. calvus 
were unsuccessful for many years until recently.26 
Fluoroacetone 80 which is highly toxic, has been suggested to be the metabolite of 
Acacia georginae but the metabolite was never properly identified and characterised.  
ω-Fluorooelic acid and ω-fluoropalmitic acid 77 were isolated and identified by Peters 
and coworkers in 1959 from the seed of West African shrub D. toxicarium. For the 
synthesis of ω-fluoro fatty acids, fluoroacetyl-CoA replaces acetyl-CoA in the fatty acid 
biosynthesis.20 The toxicity of ω-fluoro fatty acids are related to their conversion to fluoro 
acetate. An other fluorometabolite, named (2R3S4S)-5-fluoro-2,3,4-trihydroxypentanoic 
acid (5-FHPA) 79, was discovered and identified from soil bacterium Streptomyces 
sp.MA37 at the University of Saint Andrews (Figure 1.9).27 Genomic analysis led to the 
identification of a gene cluster, enconding a biosynthetic pathway for 5-FHPA.  
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Figure 1.9. Fluorinated natural compounds.13,23–27 
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Fluorinated organic compounds find application in different fields ranging from 
pharmaceutical, polymers to electronic devices manufacturing. Polytretrafluoroethylene 
(PTFE) 82 was discovered by Plunkett in 1936. It is one of the most common 
fluoropolymers, chemically and thermally stable. It has been used in the fabrication of 
anti-stick frying pans and Goretex garments (low molecular weight PTFE). A second 
generation of fluoropolymers were synthetised from PTFE copolymerisation with trifluoro 
vinyl ether such as heptafluoropropyl trifluorovinyl ether PPVE 83. These polymers 
combine the unique PTFE properties (chemical, thermal stability, elasticity) and are more 
chemically accessible than PTFE.  
Fluorinated compounds have been successfully used in the design of liquid crystals due 
to the small size and high polarity of fluorine. The C-F incorporation enhances the liquid 
crystal stability without altering its characteristic ordered structure and improving 
important phisycal properties such as optical, dielectric and viscoelastic properties. The 
number and the position of fluorinated groups can affect the liquid crystal phase 
sequence and can impact its transition temperatures. Figure 1.10 shows the most 
common “super-fluorinated” materials (SFM) used for the design of LCD technology. 
They contain fluorinated aliphatic bridges as link of their mesogenic structures, 
enhancing some of the material properties such as the temperature and nematic phase 
range and reducing the rotational viscosity. Fluorine containing compounds find also 
application in the agrochemical industry as herbicides, fungicides and inceticides. 
Norflurazon 86 is a carotenoid inhibitor whose function is to block the photosynthesis 
process of plants. Primsulfuron 87 belongs to the class of herbicides and contain 
sulfonylureas wich are inihbitors of acetolactate synthase (ALS). It is commonly used in 
the planting of maize. Flutolanil 88 is a trifluoro methyl benzamide derivative and is used 
as fungicide on rice, cereal and vegetables. Fluorinated benzoylureas such as 
diflubenzuron 89 and teflubenzuron 90 are known inseticides and inhibit chitin 
biosynthesis, interfering in the moulting process (Figure 1.10).21 
 
19 
 
 
 
Figure 1.10. The versatility of organofluorine compounds.21  
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The concept of an isostere was introduced by Irving Langmuir in 1919 and defines atoms 
or group of atoms having similar physical and chemical properties. The bioisostere 
concept fits the broadest definition for isosteres but the mimetic also exhibits a similar 
biological activity. They find application in medicinal chemistry for the design of new 
drugs as the bio-isosteric replacement can modulate the pharmacokinetic properties of 
a certain molecular target. 
The electronic properties and small size of fluorine make it a versatile bioisostere of 
different functional groups or atoms. It has been found to be a good substitute for the 
hydrogen atom and the methyl group in certain circumstances, also a suitable functional 
mimetic of the carbonyl group, hydroxyl and amide moiety, when appropriately 
incorporated. As previously discussed, fluorine incorporation into drugs can influence 
many properties such as the potency, conformation, metabolism and membrane 
permeability (Table 1.2).15,18,28 
 
 
Element  
 
Electronegativity 
 
Bond 
lenght 
 
Van der 
Waals  
Radius (Å) 
 
Bond 
energy 
(Kcal/mol) 
H 2.1 1.09 1.20 99 
F 4.0 1.39 1.35 116 
O (OH) 3.5 1.43 1.40 85 
 
Table 1.2. Physical properties of fluorine.15,18,28  
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The replacement of hydrogen with fluorine has been extensively explored in drug design, 
usually replacing hydrogen atoms bound to aromatic rings or those on alkyl chains. This 
substitution can lead to minor steric perturbations of the molecular functionality but has 
consequences on the physical-chemical and biological properties of a compound. 
5-Fluorouracil 92, as a mimic of uracil 91, was one of the first fluorinated antitumor drugs 
when it was reported in 1957.  
. 
 
Scheme 1.6. 5-fluorouracil 92 as inhibitor of TS (thymidylate synthase).29,30 
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Nucleotide 94 was found to be a potent inhibitor of thymidylate synthase (TS), the 
enzyme that mediates the conversion of 2-deoxyuridine-5-monophosphate (dUMP) into 
2-deoxythimidine-5-monophosphate (dTMP), a nucleoside required for DNA replication. 
Upon accessing the cell, the fluorinated compound is converted to a variety of active 
metabolites, one of which is FdUMP (fluoro-deoxyuridine monophosphate) 94 that 
inhibits thymidylate synthase with a Ki 1000-fold lower than the Michaelis-Menten 
constant (Km) for dUMP (2 µM). Thus, the replacement of the hydrogen α C-5 with 
fluorine inhibits TS by a mechanism based inhibition process (Scheme 1.6). 29,30 
One of the first synthetic pathways to 5-fluorouracil 91 reported involved the use of 
fluoroacetic acid 78 in a reaction with propanoic acid 96 via addition-elimination to 
generate fluoroacrylate 97. A Diels-Alder [4+2] cycloaddition generated 99 that under 
acidic conditions leads to 91. Uracil 91 reacts with fluoroxy-trifluoro methane or fluoride 
(F2) to give 5-fluorouracil 92 (Scheme1.7A). For industrial scale production of 
fluorouracil, the synthetic procedure involves the direct fluorination of uracil 91 with 
nitrogen diluted fluorine gas (N2/F2 mixture) in water, followed by dehydration of the 
intermediate fluorohydrin 100 (Scheme 1.7B).31  
 
 
  
Scheme 1.7. Synthetic routes to 5-fluoro uracil.31 
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Carbonic anhydrase (CAII) is a zinc metalloenzyme that catalyses the converting carbon 
dioxide to bicarbonate. CAII inhibitors have had a significative impact in ophthalmology, 
since inhibition lowers the intraocular pressure, which is found elevated in patients 
suffering with glaucoma. One of the most potent inhibitor of CAII is 4-(aminosulfonyl)-N-
phenylmethylbenzamide (SBB) 101 with a Ki of 2.1 nM (Figure 1.11). Kim et al.32 
demonstrated that the introduction of fluorine into an aromatic ring of SBB 102 and 103, 
improved the enzyme-inhibitor binding affinity, enhancing polar interactions with Pro-202 
and Phe-131. The X-ray crystal structures of carbonic anhydrase (CAII) with inhibitors 
102 and 103 reveals a significant contribution from the fluoroaromatic ring of each 
inhibitor that moves closer to the Phe-131 residue with increasing fluorination, and 
enhancing binding affinity.32,33 
  
 
 
Figure 1.11. Modulation of the binding affinity of the enzyme-inhibitor complex by fluorination of 
SBB inhibitor of carbonic anhydrase.32,33 
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Fluoroquinolone derivates were found to be specific inhibitors of DNA gyrase which is a 
bacterial type of topoisomerase II. Topoisomerase II unwinds DNA supercoiling during 
cell replication and transcription. The inhibition of DNA gyrase leads to the death of the 
bacterial cell making it an attractive target for antibacterial agents. Nalidixic acid 110 is 
a quinolone derivative and a potent inhibitor of DNA replication. It was discovered as a 
by-product in the synthesis of chloroquinone, used for malaria treatment.  
Norfloxacin 109 inhibits DNA gyrase with a Ki 60-fold greater than nalidixic acid 110. 
Hence, the introduction of fluorine at the 6-position of the aromatic ring in 109 improves 
both binding affinity and the ability of these drugs to penetrate the bacterial cell. 
Norfloxacin 109 bears a piperazine substituent at C7 which also contributes to the overall 
improvement of the pharmacokinetic profile of the drug (Scheme 1.8).33  
 
 
 
Scheme 1.8. DNA gyrase inhibitor binding affinity enhanced by fluorine incorporation.33,34 
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Examples of methyl group-fluorine replacement providing positive effects on metabolism, 
are represented by taxoids derivatives 111 and 112. These compounds were designed 
to overcome susceptibility to multidrug resistance and the lack of tumor specificity that 
characterises the common chemotherapeutic agents such as paclitaxel 113. The iso-
butenyl groups in 112 are subject to P450 oxidation affecting their metabolic stability. 
The replacement of the two allylic methyl substituents in 112 with fluorine (111) improved 
the metabolic stability suppressing oxidation. A series of difluorovinyl taxoids were 
synthesised by Ojima-Houlton coupling of the enantiopure lactam and various baccatins 
bearing different substituents at C10 and/or C2.33  
 
 
 
Scheme 1.9. Synthesis of difluorovinyl taxoids.33 
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The C-F bond has been explored as a C=O replacement due to the similarity in bond 
lengths, dipole moments and Van der Waals radii of the two functionalities, as well the 
close electronegativity of fluorine and oxygen. An example of C-F to C=O bioisosterism 
has been observed in the case of campothecin 117, a potent alkaloid inhibitor (Ki = 0.45 
µM) of topoisomerase I that catalyses the relaxation of the left handed double helical 
form of DNA, preventing the proliferation of tumoral cells. However, campothecin 117 
was found to be metabolic unstable due to rapid hydrolysis of the lactone ring to the 
inactive carboxylic acid. To overcome this liability to hydrolysis, the C=O group was 
replaced by a C-F moiety to generate isomers 118 and 119 which were more stable at 
pH 7.4 than campothecin 117, but less potent as inhibitors of topoisomerase. The 
inhibitory potency of 119 was enhanced by introducing a cyclohexyl substituent at C7 
position of the quinolone ring to give 120 whose binding affinity was closer to 117 (Figure 
1.12).33 
 
 
 
Figure 1.12. Topoisomerase inhibitors.33 
  
27 
 
The aryl fluoride 122 was also found to be a good mimic of quinone 121. Compound 121 
acts as an inhibitor of the tissue factor VIIa enzyme complex (TF/VIIa), a protein that 
causes blood to clot in the coagulation process. Compound 122 exhibited a greater 
inhibitory potency than 123, with the fluorine acting as hydrogen bond acceptor engaging 
with the amide nitrogen of Gly-216, as observed from crystal structures of 121 and 122 
bound to TF/VIIa complexes (Figure 1.13).35 
 
 
 
Figure 1.13. Fluorine alkenyl moiety as quinone mimic in the inhibition of TF/VIIa.35 
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The replacement of an amide group with an appropriate isostere is a common strategy 
in medicinal chemistry. An ideal amide mimic has to retain both the geometry and the 
hydrogen bonding capabilities of the functional group. 
Zanda et al.33 reported the synthesis of partially modified retro peptides 124 (PMR) where 
the [NHCH(CF3)] moiety replaces the -NHC(O)- unit. The presence of the CF3 group was 
found to constrain the molecule, leading to peptidomimetics with defined conformations. 
The new mimetics 124 adopt a turn-like conformation similar to the non-fluorinated 
peptides 123 with comparable torsion angles, suggesting that the CF3 motif is important 
in stabilising the turn. Furthermore, since the C-F bond is similarly polarised with respect 
to the C=O bond, the low basicity of the NH is maintained, fundamental for peptide 
stability (Figure 1.14).33 
 
 
 
Figure 1.14. Synthesis of a retropeptide motif reported by Zanda et al.33 
 
The NHCH(CF3) moiety has also found application in the design and synthesis of potent 
inhibitors of cathepsin K, the key enzyme responsible for the degradation of Type I 
collagen in osteoporosis.33 Cathepsin K is involved in the degradation of triple helical 
collagen but its mechanism of action is still under investigation. It was demonstrated that 
Cat K interacts with glycosaminoglycan derivatives to generate high molecules weight 
oligomeric complexes that are believed to be involved in the unwinding process of triple 
helical collagens. The trifluoro-ethyl amino group was an excellent amide isostere 
generating the most potent dipeptide inhibitor of Cat K (Ki = 5 pM) 129, highly selective 
and stable to amide bond cleavage. Its compatibility as an amide bond mimetic was 
confirmed by X-ray studies showing the trifluoroethylamine N-H interacting with the 
carbonyl oxygen of Gly-66 residue of the enzyme while the trifluoromethyl moiety was 
oriented towards the bulk solvent.35  
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Figure 1.15. The CF3 group as an analogue of amide units in peptides.33,35 
 
Difluorotoluene 132 has been shown to be a mimetic of thymine 130, and the 
corresponding deoxynucleoside 134 has been explored as a substrate for the DNA 
polymerase enzyme. DNA polymerase catalyses the formation of DNA from the 
appropriate nucleotides. These enzymes operate coding a complementary DNA from a 
DNA template. Specifically, DNA polymerase inserts deoxyadenosine opposite to 
thymidine, and thus it will not incorporate thymidine, deoxyguanosine or deoxycitidine. 
When assaying difluorotoluene 132, as a template surrogate in place of thymine 130, 
deoxynucleoside 134 was efficiently inserted as a replacement of thymine 130. 
Difluorotoluene 134 retains the shape and the conformation of the natural nucleoside 
133. Furthermore, the enzyme actively recognises difluorotoluene 134 despite its non-
polar nature and the perceived wisdom that Watson-Crick-type hydrogen bonding is 
regarded as the primary source of the specificity in DNA replication (Scheme 1.10).36  
 
30 
 
 
 
Scheme 1.10. Difluorotoulene as a mimetic of thymine.36  
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The replacement of a hydroxyl group with fluorine has been extensively investigated, 
especially due to their similar bond lengths with carbon (C-F = 1.35 Å; C-O = 1.43 Å) and 
the potential for fluorine to be a hydrogen bond acceptor. 
This replacement led to the discovery of exciting therapeutic agents. Nucleosides are 
fundamental for all living organism as building blocks of DNA and RNA. The introduction 
of fluorine atoms into the ribose ring influences the structure of the nucleoside analogue. 
The C-F bond interacts with the environment through electrostatic interactions; in a 
fluorine containing drug target, the C-F bond can be oriented towards a partial positive 
charge, engaging in intermolecular electrostatic interactions. The C-F bond dipole can 
also adopt an antiparallel arrangement when interacting with other polarised bonds such 
as a carbonyl (dipole-dipole interactions). These dipole-dipole interactions stabilise or 
destabilise a conformation. Thus, antiperiplanar effects, dipole-dipole and gauche 
interactions all influence the preferential conformation adopted by a nucleoside.  
Sofosbuvir 138 was designed as an analogue of nucleoside 139. It is a potent inhibitor 
of Hepatitis C virus (HCV) whose replication is catalysed by NS5B polymerase. NS5B 
polymerase is an RNA dependent RNA polymerase involved in the viral life cycle. It 
creates double stranded RNA (ds RNA) from single stranded RNA (ssRNA). The binding 
affinity for the enzyme is correlated to the conformation adopted by the nucleoside. 
Sofosbuvir 138 bears a fluorine in 2’-β position adopting a South conformation. Whereas 
its 2’-α-fluoro isomer prefers a North conformation. The 2’-β-fluoro conformer 138 binds 
HCV NS5B while the 2’-α-fluoro analogue 136 does not. Sofosbuvir 138 (South 
conformation) interacts with the NH side chain of amino acid Asn-291 through a 
hydrogen bond and is a good analogue of nucleoside 139 in terms of the geometry and 
its interactions with the enzyme (Figure 1.16). 33 
Sofosbuvir is the largest selling small molecule in medicinal chemistry at present.  
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Figure 1.16. Fluorine as an isopolar and isoelectronic mimic of the hydroxyl group.33  
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In developing the analogy between oxygen and fluorine, vinyl fluorides have been 
explored as isoelectronic and isosteric replacements for an enol/ate. For example, 
fluorovinyl steroids 147 and 148 were investigated as mimetics of pregnenolone 140, a 
metabolic intermediate in the biosynthesis of estrogens and androgens. They are 
processed by cytochrome P450 17A1, a hydroxylase. Inhibitors of this family of enzymes 
block the synthesis of androgens whose high levels are associated with prostate cancer, 
thus cytochrome P450 17A1 inhibitors have potential as therapeutics. Pregnenolone 140 
is converted to dehydroepiandrosterone 146 as illustrated in Scheme 1.11. 
Pregnenolone 140 is believed to be an intermediate in the C17α hydroxylation step 
followed by subsequent cleavage of the C17(20) bond to generate the C17 keto androgens. 
Steroids 147 and 148 mimic the enol tautomers of pregnenolone 141 and were found to 
be potent inhibitors of P450 17A1 enzyme (Scheme 1.11).37 
 
 
Scheme 1.11. Novel steroidal fluoroalkene derivatives as enol intermediate mimetics for C17α 
hydroxylase/C17(20) lyase inhibition.37 
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3-Dehydroquinate 150 is a common intermediate in the shikimate and quinate pathways, 
in bacteria, fungi and higher plants. The pathway generates essential aromatic 
compounds from acyclic carbohydrates.  
3-Dehydroquinate 150 is irreversibly converted to dehydroshikimate 151 by the enzyme 
dehydroquinase, which occurs in two different forms: Type-I enzymes are dimers that 
mediate a syn- elimination of water from an intermediate Schiff’s base, whereas Type-II 
enzymes (found in Mycobacterium Tuberculosis) are thermally stable dodecameric 
complexes able to dehydrate a stabilised enolate 150 in an anti- manner (Scheme 1.12). 
A vinylfluoride 152 was designed as a mimic of enolate 150 and found to be a highly 
selective (1000 fold) competitive inhibitor of the Type II dehydroquinase enzyme. This 
vinylfluoride appears to be a good enolate mimetic.38 
 
 
 
Scheme 1.12. Inhibition of Type II dehydroquinase enzyme.38 
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Enzymes are macromolecular catalysts required for the processes required for 
sustaining life; they accelerate biochemical reactions by reducing the activation energy 
and thus effectively allowing these transformations to occur. A basic enzymatic reaction 
can be represented by the equation described in Figure 1.17. They are generally first 
order with respect to the substrate: 
 
 
 
Figure 1.17. The enzyme mediated reaction.5 
 
The most general evidence for the enzyme-substrate formation is the so called 
“saturation effect”. At constant concentration of enzyme, the reaction shows a maximal 
velocity (Vmax) where all the catalytic sites are occupied with substrate, thus the reaction 
rate cannot increase shifting from first order to zero order. This saturation effect is typical 
of an enzyme catalysed reaction. The first kinetic model introduced for an enzymatic 
reaction was proposed by Michaelis-Menten. They suggested that an enzyme interacts 
with a substrate with a rate costant k1 to generate the enzyme-substrate complex ES, 
necessary for enzymatic catalysis. The ES complex can dissociate to E and S with a rate 
constant k-1 or it can generate the product P with a k2 rate constant (Figure 1.18).5 
  
 
 
𝒗 =
𝑽𝒎𝒂𝒙[𝑺]
𝑲𝒎+ [𝑺]
 
 
Figure 1.18. The Michaelis-Menten equation: reaction velocity (v) vs substrate concentration(S).5 
36 
 
The Michaelis-Menten equation correlates the reaction rate (v) to the substrate 
concentration for a system where the substrate (S) binds reversibly to the enzyme (E) to 
form an ES complex that reacts irreversibly to form the product P releasing the enzyme 
E. Vmax is the maximum velocity reached by the system at maximum substrate 
concentration (saturation effect). The Michaelis-Menten equation KM is equal to the 
substrate concentration at which the reaction velocity is one half of the maximal velocity 
for the reaction. When k2 is smaller than k-1, KM measures the strength of the ES complex, 
a low KM indicates a strong binding whereas a high KM indicates a weak binding.5  
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The regulation of enzymatic activity is fundamental in order to achieve fine control of the 
particular flux along a metabolic pathway. There are many factors that control enzymatic 
activity: pH, temperature, cofactors, compartmentalisation, feedback inhibition and 
regulatory molecules are among the most important. In particular, molecules that act by 
slowing enzymatic turnover are known as enzyme inhibitors. 
1.19.1. Classification of inhibitors 
 
A compound can decrease the enzymatic activity by binding to the enzyme’s active site 
either in a transient, reversible manner, or via an irreversible covalent chemical 
modification. 
Reversible inhibitors are divided into three groups: 
Competitive inhibitors compete with the substrate for binding to the active site and once 
bound they prevent the forward reaction occurring, thus effectively reducing overall 
enzymatic turnover. 
Non-competitive inhibitors do not prevent the binding of the substrate complex to the 
active site but they will bind to another site of the enzyme (allosteric site) altering the 
enzyme activity. 
Uncompetitive inhibitors bind to and stabilise the enzyme-substrate preventing substrate 
release from the active site. 
Irreversible inhibitors generally modify an enzyme in a covalent manner, such that the 
enzyme cannot undergo turnover. This inhibition tends to be specific, in that the protein 
is not destroyed as in the case of extreme variations of temperature or pH (i.e. 
denaturation of the enzyme); usually the irreversible inhibitor contains reactive fragments 
that react specifically with residues at the active site, preventing turnover.5  
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Figure 1.19. Three modes of the reversible inhibition. V = reaction rate, S = substrate 
concentration.39  
 
Competitive inhibitors and non-competitive inhibitors can be distinguished by plotting the 
reaction rates against the corresponding substrate concentrations, as shown in Figure 
19. The curve for a competitive inhibitor shows a reduction in the slope when compared 
to the inhibitor-free curve, and at saturating substrate concentrations the characteristic 
Vmax is maintained. In the case of a non-competitive inhibitor, the initial rate slows, but 
there is also a decrease in the Vmax, indicating that the inhibitor does not compete with 
the substrate for the active site.  
  
[V] 
[S] 
Non-competitive inhibition 
Competitive inhibition 
Uncompetitive inhibition 
Without inhibition 
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A classic example of a competitive inhibitor is the antibiotic sulfanilamide 160, which 
mimics para-aminobenzoic acid (PABA) 154. PABA is an intermediate in the biosynthetic 
pathway that leads to folic acid 159, an important cofactor for various methyltransferase 
enzymes involved in the biosynthesis of purines and pyrimidines. PABA is converted to 
dihydropteroic acid by the enzyme dihydropteroate synthase, which in turn is processed 
to folic acid. Since mammals do not synthesise folic acid and depend upon external 
sources, the inhibition of the dihydropteroate synthase by sulfanilamide 160 allows for 
selective treatment of bacterial infections (Scheme 1.13).39 
 
 
 
Scheme 1.13. Sulfanilamide 160 as a competitive inhibitor of dihydropteroate synthase.39 
 
Tripanavir 163 belongs to the Protease inhibitors (PI) class and it has been approved by 
the US FDA for the HIV treatment. It is a sulfonamide dihydropyrone derivative and is 
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the first PI with a non peptidic structure. Tripanavir acts as a competitive inhibitor by 
binding directly to the active site of HIV aspartyl protease and blocking the hydrolysis of 
viral polyproteins that are involved in the HIV replication process. The mechanism of 
action of 163 is still under investigation (Scheme 1.14).40 
 
 
  
Scheme 1.14. Tripanavir 163 as HIV protease inhibitor.40   
  
Most of non-competitive inhibitors can be regarded as allosteric effectors, compounds 
that bind remote to the active site.  
Pyruvate kinase catalyses the final step of glycolysis. The reaction proceeds by transfer 
of the phosphate group from phosphoenol pyruvate (PEP) 165 to adenosine diphosphate 
(ADP) 164, yielding adenosine triphosphate (ATP). The production of ATP is 
allosterically controlled, amongst other effectors, by ATP itself which binds to an 
allosteric site on pyruvate kinase and thus inactivates the enzyme (Scheme 1.15).41  
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Scheme 1.15. The pyruvate kinase reaction.41 
 
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that mediates the 
condensation of aspartate 168 and carbamoyl phosphate 169 to generate N-
carbamoylaspartate 170 and orthophosphate 171. This reaction is the first committed 
step on pyrimidine nucleotide biosynthesis. ATCase is inhibited by cytidine triphosphate 
(CTP) 172, the final product of the enzyme-controlled pathway.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.16. Cytidine triphosphate 172 as an inhibitor of aspartate transcarbamoylase.42 
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The mechanism suggested for the allosteric regulation of the enzyme by CTP, indicates 
a conformational change of the quaternary structure of the enzyme. The enzyme exists 
in equilibrium between two conformations: the inactive form termed the tense state (T) 
and the relaxed one (R). When CTP is bound to the enzyme, it shifts the equilibrium 
towards the T, decreasing enzyme activity and reducing N-carbamoylaspartate 
production (Scheme 1.16).42  
Lansoprazole 173 is an uncompetitive inhibitor of hydrogen/potassium adenosine 
triphosphatase, an enzyme of the gastric parietal cell membrane that forms part of the 
proton pump involved in the final step of the acid secretory process. It binds covalently 
to the parietal cell, modulating the pH of the stomach and inhibiting the secretion of 
gastric acid. It received FDA approval in 1995 for the treatment of peptic ulcer disease, 
gastroesophageal reflux and Zollinger-Ellison syndrome (Scheme 1.17).43 
 
 
 
Scheme 1.17. Lansoprazole 173 as proton pump inhibitor.43 
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Suicide inhibition is a particular kind of irreversible inhibition; the enzyme binds a 
substrate analogue which is converted into a reactive intermediate that covalently 
modifies and binds permanently to the enzyme, forming a stable inhibitor-enzyme 
complex. The design of a suicide inhibitor requires an understanding of the enzyme 
mechanism, with the aim of producing a compound that is reasonably inert until triggered 
by the enzyme. 
 
 
Scheme 1.18. Penicillin 184 as a suicide inhibitor of D,D-transpeptidase (TP), PG = prosthetic 
group. 44 
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Penicillin 184 is a “suicide” inhibitor of D,D-transpeptidase, a fundamental bacterial 
enzyme involved in the biosynthesis of the bacterial cell wall. The transpeptidation 
reaction catalysed by this enzyme crosslinks chains of peptidoglycan on the surface of 
the bacterial wall, forming a 3D network that confers structural integrity to the cell. As 
shown in Scheme 20, the β-lactam nucleus of 175 mimics the terminal D-Ala-D-Ala 
sequence of the peptide subunit 176. Upon binding, the Ser-400 acts as a nucleophile 
attacking at the β-lactam in 184, irreversibly acylating Ser-400 and finally disrupting the 
cell wall synthesis.44  
α-difluoromethylornithine, known as eflornithine 188, is a fluorinated analogue of 
ornithine and acts as suicide inhibitor of ornithine decarboxylase (ODC). ODC catalyses 
the ornithine 187 decarboxylation to form putrescine. 
  
 
 
Scheme 1.19. The proposed mechanism of the interaction of eflornithine 188 within OCD active 
site. 
 
This is the rate limiting step in the biosynthesis of polyamines, essential for all prokaryotic 
and eukaryotic cells. It is suggested that eflornithine 188 binds directly to the ODC where 
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it is decarboxylated. It binds to the Cys-360 amino acid residue in the active site thus 
blocking ornithine from accessing it (Scheme 1.19). The biosynthesis of polyamines is 
essential for the parasitic replication and survival, hence 188 is used for the treatment of 
parasitic diseases such as the african sleeping sickness.12 
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Enzymatic inhibition is a spontaneous physiological process in all living organisms. The 
human pancreas, for instance, produces several proteases, enzymes responsible for the 
breakdown of proteins and thus potentially dangerous to the organ itself. In order to avoid 
self-harm, the pancreas produces a potent protease inhibitor called “pancreatic trypsin 
inhibitor” which can selectively block the digestive action of the pancreatic proteases.  
Inhibiting an enzyme can lead to essential information regarding its binding properties, 
substrate specificity and the types of reactions the enzyme can catalyse. Investigating 
metabolic pathways with the use of inhibitors as probes allows access to a more detailed 
understanding of the entire mechanism and its regulation. For example, inhibition of 
acetyl-CoA carboxylase (ACC) leads to the inhibition of fatty acid synthesis and 
stimulation of fatty acid oxidation, having the potential to affect a series of cardiovascular 
risk factors associated with metabolic diseases such as obesity, diabetes, 
atherosclerosis etc.  
Currently, most drug discovery and development efforts are focused on finding and 
optimising drug candidates that can inhibit specific enzyme targets. A classic example is 
aspirin 196, an inhibitor of the cyclooxygenase reaction which is involved in 
prostaglandins (PGs) 194 synthesis and the inflammation response (swelling, pain and 
fever). The overall synthesis of prostaglandins is catalysed by prostaglandin H2 
synthase. The substrate for this enzyme is arachidonic acid 193, a hydrophobic molecule 
generated from the hydrolysis of membrane lipids. Arachidonic acid 193 is transferred to 
the active site of the enzyme through a hydrophobic channel in the protein. Aspirin 196 
blocks this channel and prevents prostaglandin synthesis by transferring an acetyl group 
to a serine residue (Ser-530) within the active site of the enzyme (Scheme 1.20).45  
Enzymes increase the rates of reactions by stabilisation of the transition state to which 
the enzyme binds with higher affinity. “Transition state analogues” can be ideal inhibitors 
of specific enzymes and have potential as highly selective drugs. For instance, the 
inhibition of purine nucleoside phosphorylase (PNP) 199 by a tight binding inhibitor (Ki 
picomolar) called Immucillin-H (Imm-H) 203 is an instructive example. Genetic deficiency 
of PNP 200 can lead to significant T cell-mediated immunosuppression, Imm-H 203 
mimics the transition state of PNP 202 and selectively inhibits the PNP enzyme, blocking 
the growth of malignant T cell leukemia lines and inducing apoptosis (cell death) 
(Scheme 1.20).46 
47 
 
 
 
Scheme 1.20. Immucillin H 203 and Aspirin 196.45,46 
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The fluorovinyl moiety has potential as a stereo-electronic mimic of enol/ate 
intermediates which are involved in many important metabolic pathways. As said 
previously, thioesters such acyl co-enzymeAs, are central metabolites in many important 
enzymatic pathways. They can undergo condensation reactions though enols or 
enolates to form C-C bonds. Acetyl-CoA 2 is a central intermediate in the citric acid cycle 
and other essential metabolic pathways. In the citric acid cycle, citrate synthase uses 
acetyl-CoA 2 and catalyses a condensation reaction via enol/ate formation (Scheme 
1.21). 
 
 
 
Scheme 1.21: Citrate synthase condensation of acetyl-CoA 2 to citrate 208 via an enol/ate 
intermediate formation. 
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-Fluorovinyl thioethers possess spatial and electrostatic profiles compatible with the 
potential to mimic these enzyme intermediates. With this concept in mind, a theoretical 
calculation of the electrostatic profiles and dipole moments of a thioester enol 210 and a 
fluoro vinyl thioether 211 was performed. This analysis shows a similar stereo-electronic 
profile between a vinyl fluoride and an enol (Figure 1.20).47 
 
 
 
 
 
 
 
 
Figure 1.20. Electrostatic profiles and dipole moments of a enol thioester 210 and a fluorovinyl 
thioether 211.47 
 
Based on these findings, it was envisaged that fluoro vinyl thioether 212 possesses a 
spatial and electrostatic profile consistent with the potential to mimic the enol/ate 
intermediate of important thioesters such as acetyl-CoA 2 (Scheme 1.22). It would follow 
that fluoro vinyl-CoA 212 will mimic the enol/ate of acetyl-CoA and bind through 
intermolecular interactions with the amino acid residues (Asp-375 and His-274) within 
the active site of the enzyme. Compound 212 was found to be a low micromolar inhibitor 
of citrate synthase (see Chapter 2 for further details). In this context, inhibition of citrate 
synthase, became a focus. Thus, a series of acetyl-CoA analogues, modified on the acyl-
CoA fragment, will be synthesised and studied as inhibitors of citrate synthase. 47 
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Scheme 1.22. Fluorovinyl thioether 212 designed as an analogue of acetyl-CoA 2.47  
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 DESIGN OF ACETYL-COA ANALOGUES AS INHIBITORS OF CITRATE 
SYNTHASE 
 
 
 
Citrate synthase is present in nearly all living cells capable of oxidative mechanism. It is 
involved in the condensation of oxaloacetate to form citrate and it is one of a relatively 
small class of enzymes able to catalyse C-C bond formation without the presence of a 
metal ion cofactor. It plays a key role in the central metabolic pathway of aerobic 
organisms, the Krebs cycle, catalysing the irreversible conversion of oxaloacetate 1 and 
acetyl-CoA 2 to citrate by a condensation reaction. The Krebs cycle, also known as the 
TCA cycle (tricarboxylic acid cycle) or citric acid cycle, is illustrated in Scheme 1. It 
represents a central driver for cell respiration: acetyl-CoA 2 is fed through the cycle as a 
C2 carrier, in a series of redox reactions. Energy is obtained and stored as chemical 
potential into NADH, FADH2 and ATP, referred to as reduced electron carriers that in 
turn transfer their reducing equivalents into the electron transport chain, generating ATP. 
The Krebs cycle consists of 7 steps, each defined by the specific enzyme catalysing the 
transformation:1 
Citrate synthase is the first enzyme involved in the cycle. Pyruvate 3 generated from 
glycolysis is oxidised to acetyl-CoA 2 by the pyruvate dehydrogenase complex. Acetyl-
CoA 2 then enters the citric acid cycle and is converted to citrate 208 by citrate synthase.  
Aconitase: Citrate is isomerized into isocitrate 213 by a dehydration-hydration sequence 
through cis-aconitase. The reaction is mediated by aconitase, an iron-sulfur enzyme. 
Catalytic residues His-101 and Ser-642 are involved respectively in the protonation and 
deprotonation step. 
Isocitrate dehydrogenase: mediates the oxidative decarboxylation of isocitrate 213 to α-
ketoglutarate 214. The reaction proceeds by oxidation of isocitrate 213 to form 
oxalosuccinate which loses CO2 and generates α-ketoglutarate 214. 
α-Ketoglutarate dehydrogenase: A further oxidative decarboxylation converts α-
ketoglutarate 214 into succinyl-CoA 215, generating NADH.  
Succinyl-CoA synthetase: catalyses the conversion of succinyl-CoA 215 to succinate 
216. 
Succinate dehydrogenase: mediates the oxidation of succinate 216 to fumarate 217. The 
mechanism of the oxidation is not clear but it is believed to proceed by a concerted 
dehydrogenation reaction with concomitant reduction of FAD+. 
Fumarase: Fumarate 217 undergoes a stereospecific hydration reaction to form L-malate 
218.  
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Malate dehydrogenase: L-malate 218 is finally oxidised to oxaloacetate 206 with 
production of NAD+. 
  
 
Scheme 2.1. The citric acid cycle.1 
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Citrate synthase has been isolated from multiple sources. The most common form is 
porcine which consists of a homodimer of molecular weight 90-100 kDa; however a 
tetrameric form with a large subunit molecular weight (about 60 kDa) is found in some 
prokaryotic organisms.2,3 Porcine citrate synthase consisting of two identical subunits of 
437 amino acids whose structure has been determined by X-ray crystallography.4 The 
free enzyme is an open form with two domains forming a cleft that contains the substrate-
binding site; on binding oxaloacetate the smallest domain rotates by 18° leading to cleft 
closure. The existence of an open and closed structure explains the enzyme ordered 
kinetic sequence. The conformational change generates the acetyl-CoA 2 binding site 
and closes the oxaloacetate 206 binding site, preventing any interaction between the 
solvent and the bound substrate. Citrate synthase catalyses the condensation reaction 
with its open conformation, by bringing the substrates (oxaloacetate and acetyl-CoA) and 
the amino acid residues closer in the active site. Once citrate is generated, co-enzyme 
A is released and the enzyme returns to its open form. 
The proposed mechanism as described by Remington et al.3 in1986 (Scheme 2.2), 
involves the participation of three ionisable side chains in the active site for acid-base 
catalysis: His-274, His-320, Asp-375 .  
• Deprotonation step: Asp-375 acts as a base removing a proton from the methyl 
group of acetyl-CoA 2, forming its enolate 31. His-274 stabilises the acetyl-CoA 
intermediate 31 by hydrogen bonding with the enolate oxygen.  
• Condensation reaction: the enolate of acetyl-CoA 31 acts as nucleophile, 
attacking the carbonyl group of oxaloacetate 206; His-320 acts as a general acid, 
donating a proton to the oxaloacetate 206 carbonyl group in a concerted step 
with inversion of configuration, forming citryl-CoA 219 bound to the enzyme. 
• Hydrolysis reaction: in this step, citryl-CoA 219 is hydrolysed to citrate 208 and  
Co-ASH; it is suggested that residue His-320 deprotonates a nearby water 
molecule that acts as the nucleophile attacks citryl-CoA 219. Release of the CoA 
and citrate 208 involves the switch from the closed to the open conformation of 
the enzyme (Scheme 2.2)5. 
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Scheme 2.2. Citrate synthase mechanism. 3,6 
A) B) 
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The flexible domain of each subunit of the enzyme undergoes a conformational change 
on binding oxaloacetate and generating a binding site for acetyl-CoA 2: A is the open 
form of the enzyme and B is closed with oxaloacetate bound.5,6 
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Mitochondrial citrate synthase from human omental adipose tissue is associated with 
endocrinal and metabolic abnormalities like obesity and diabetes, suggesting that citrate 
synthase activity could be used as a biomarker for such diseases. The need to fully 
understand the structure and mechanism of this enzyme has stimulated the design and 
synthesis of a series of inhibitors that mimic acetyl-CoA 2 or oxaloacetate 208. 
 
 
Attention has focused on the identification of the nucleophilic intermediate in the citrate 
synthase-mediated reaction, in order to establish whether the reaction proceeds via the 
enol or enolate form of acetyl-CoA. Karpusas et al.4 proposed a mechanism for the 
condensation reaction step of citrate synthase in 1990, described in Scheme 2.2. This 
study was based on the 1.9 Å resolution structure of the ternary complex citrate 
synthase-oxaloacetate-carboxymethyl-CoA, the latter being a potent inhibitor of citrate 
synthase.4 The hydrogen bond angles, calculated from the electronic density map of the 
ternary complex, indicate that the carboxylate of carboxymethyl-CoA 220 interacts with 
Asp-375 and His-274 through almost ideal hydrogen bond geometries. This arrangement 
resembles more closely the configuration of the transition state of acetyl-CoA as shown 
in Scheme 2.3. The overall mechanism proposed is that reported by Remington et al.3 in 
Scheme 2.2. The deprotonation of acetyl-CoA by Asp-375 results in the formation of an 
enol 207 rather than an enolate 31 whose generation would have required a higher 
energy, incompatible with the observed kinetics. Enol 207 is stabilised by hydrogen 
bonding to His-274. The mechanism proposed for the condensation step suggests the 
protonation of the carbonyl oxygen of oxaloacetate 206 by His-320. The nucleophilic 
attack of the enol 207 to oxaloacetate 206 is controlled by the hydrogen bond to His-274. 
The X-ray structure obtained for the ternary complex of citrate synthase with L-malate 
and acetyl-CoA at 2.2 Å also supports the hypothesis that His-274 acted as a general 
acid in the enolization step while Asp-375 acted as a general base.4  
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Scheme 2.3. Study of the deprotonation step via enol intermediate by Karpusas et al.4 
 
Enol formation was also supported by an early theory study (1994) by O’Hagan and 
Rzepa 7 investigating the stereospecific control of the conversion of fluoroacetyl-CoA 
221 to (2R,3R)-fluorocitrate 224 by citrate synthase (Scheme 2.4). In the condensation 
step, citrate synthase appears to be highly selective favouring the abstraction of the 2-
pro-S hydrogen atom over the 2-pro-R; the condensation thus effectively proceeds with 
inversion of configuration at the prochiral centre, resulting in the attack onto the Si-face 
of the α-carbonyl of oxaloacetate 206. Kinetic isotope data for citrate synthase8 indicated 
that the rate-limiting step is the deprotonation step. Consequently, the selective 
discrimination of fluoroacetyl-CoA 221 prochiral hydrogens appears to be related to the 
relative energies of the syn or anti orientation of the C-F bond with respect to the oxygen 
atom of the newly formed neutral enol or enolate intermediates. A computational study7 
evaluated the relative energies of the two isomers enol/enolate and suggested that the 
E- configuration 222 was lower in energy than the Z- configuration 225 suggesting an 
enol rather than an enolate intermediate.  
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Scheme 2.4. Theory study of the stereospecific control of citrate synthase catalysed 
condensation reaction of fluoroacetyl-CoA 221 as mimic of acetyl-CoA.7 
 
In contrast, the work of Mulholland et al.7 supported the idea that the nucleophilic 
intermediate involved in the condensation step is indeed an enolate.7 In their work 
published in 1998, they reported a quantum mechanical/molecular mechanical (QM/MM) 
study of the enolization step of acetyl-CoA within the active site. Calculations were based 
on the 1.9 Å resolution structure of the ternary complex of chicken citrate synthase 
(closed conformation) with acetyl-CoA 2 and R-malate bound to the enzyme in the same 
conformation as oxaloacetate 206.4 It appears that His-274 and His-320, both being 
neutral, are fundamental for the stabilization of the enolate 31. As shown in Scheme 2.5, 
the carbonyl oxygen of acetyl-CoA 2 is stabilised at the active site by hydrogen bonding 
with His-274; after enolate 31 formation, this bond is further strengthened by the 
interaction with the negative charge on the enolate oxygen 31. Calculations of the 
activation energies reported for the citrate synthase reaction indicate that enolate 31 is 
stabilised relative to the substrate by ΔG = 11.5 - 15 kcal / mol. This stabilisation is crucial 
61 
 
to the catalytic strategy of citrate synthase, explaining the fastest step being associated 
with deprotonation. The enolate 31, being a good nucleophile, should react faster than 
an enol 207.9 
  
 
 
Scheme 2.5. Enolization step catalysed by citrate synthase via acetyl-CoA enolate 31 
intermediate.9 
 
Van der Kamp and Mulholland 10 also investigated the enantioselective conversion of 
fluoroacetyl-CoA to fluorocitrate described in Scheme 2.4. The QM/MM energy profiles 
obtained for the E- and Z-isomers, showed that the enantioselectivity emerges mostly 
from the energy difference between the E- and Z-enolates, hence favouring the E-
configuration, and to a lesser extent, interactions with the enzyme active site. These 
findings also suggests that the rate limiting step is the formation of citryl-CoA rather than 
the deprotonation step as previous suggested.10 
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In 1974, Johansson and Petersson reported a kinetic study on the inhibition of citrate 
synthase by adenosine triphosphate (ATP), propionyl-CoA and 2-oxoglutarate. 
Propionyl-CoA was a competitive inhibitor showing a similar binding affinity to acetyl-
CoA. The affinity of acetyl-CoA and propionyl-CoA with the enzyme seems to increase 
significantly with oxaloacetate bound. This increased binding affinity, appears to be 
associated with the interaction of enzyme-bound oxaloacetate and the acyl groups of 
acetyl-CoA and propionyl-CoA in the correct orientation for reaction. ATP and 
oxoglutarate are both competitive inhibitors of citrate synthase both binding equally 
strongly to the free enzyme or when it is bound to the other substrates. The kinetic study 
showed a cooperativity between the substrate binding sites that could explain the 
ordered nature of the reaction mechanism and the high specificity of the enzyme.10 
In 1981, Bayer et al.11 provided evidence on the conformational changes of citrate 
synthase during the catalytic cycle (Scheme 2.2). They reported the synthesis of five 
analogues of acetyl-CoA described in Figure 2.1. Carboxymethyl-CoA 220, a transition 
state analogue of acetyl-CoA, is the most powerful non-competitive inhibitor (Ki = 0.47 
µM). Carboxylate 220 has a formal negative charge as does the enolate of acetyl-CoA. 
Malonyl-CoA 230, carboxyethyl-CoA 229 and ethyl-CoA 231 are poor inhibitors of the 
enzyme, presumably not satisfying the structural requirements for analogues of any 
intermediate state. Amide 228 displays a good inhibitory potency (Ki = 2 µM) towards 
the enzyme. The increased affinity of the analogues after oxaloacetate 206 is bound, is 
consistent with the conformational change on binding oxaloacetate described previously.  
 
 
 
Figure 2.1. Inhibition studies for conformational changes of citrate synthase.11 
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Martin et al.12 have reported a combined chemical and enzymatic synthesis of a series 
of dethia analogues of acetyl-CoA, replacing the sulfur atom with a methylene group 
(Scheme 2.6).12  
 
 
 
Scheme 2.6. Chemoenzymatic synthesis of dethia acetyl-CoA analogues by Martin et al.12 
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Tosylation of sodium pantothenate 232 generated the methyl thioester 233 which was 
converted to the propyl thioester by treatment with dimethyl-(propylthio)-aluminium 
reagent. Subsequent phosphorylation generated the dimethyl phosphate 234, which was 
in turn treated with trimethylsilyl chloride and lithium bromide furnishing phosphate 235. 
This compound was then incubated with ATP and phosphopantetheine adenylyl 
transferase to generate 237 which was phosphorylated by incubation with ATP and 
dephospho-CoA kinase, yielding thioester 238. The corresponding amines 239 were 
reacted with 238 to give the acetyl-CoA analogues 241, 242 and 243.  
Carboxylate 241 was found to be a potent competitive inhibitor of citrate synthase (Ki = 
16 nM); the negative-charged oxygen of the carboxylate is spatially located to bind the 
site of the oxygen of the enolate of acetyl-CoA 2, thus approximating the latter both 
electronically and sterically. 
A strong binding affinity to citrate synthase was also observed for the amide analogue 
242, with a Ki = 28 nM. The amide group is both a good hydrogen bonding donor and 
acceptor with a polarised carbonyl and provides good binding to the enzyme with a good 
spatial positioning with respect to acetyl-CoA or its enolate. The nitro alkyl derivative 243 
exhibits a much lower affinity for citrate synthase, with a Ki = 16 µM. This is clearly a less 
ideal mimic of the enol/ate intermediate compared to the previous two substrates 241 
and 242, with nitro not being a good hydrogen bond acceptor.  
With respect to the work reported by Martin et al.12 for the synthesis of the potent 
inhibitors 241 and 242, Usher et al. 13 carried out a crystallography study on the hydrogen 
bond strength variation in the enzyme-inhibitor complexes. They found that the hydrogen 
bonds between the carboxylate oxygen of compound 241 and the carboxylate oxygen of 
Asp-375 are uncommonly short (Figure 2.2). Compound 242 displays a longer hydrogen 
bond (2.38 Å) than that of compound 241 (2.49 Å) but it also appears to be still unusually 
short. This experimental evidence suggests strong binding.  
 
 
 
Figure 2.2. Hydrogen bonding patterns of analogues 241 and 242. 13 
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The proposed role of short hydrogen bonding in enzyme catalysis is believed to be 
correlated to the pKa match between the enzymatic residues at the active site and the 
substrate. In 1995, Swartz et al. 14 explored the α-fluoro analogues of the potent inhibitors 
244 and 245, with the aim of probing their inhibitory potency towards citrate synthase 
and to investigate the effect of pKa matching on binding affinity and hydrogen bond 
length of 241 and 242 (Figure 2.3). Fluorinated analogues 244 and 245 were less potent 
inhibitors than 241 and 242. The decreased binding affinity is believed to be associated 
with the larger fluorine causing unwanted steric interactions with the amino acid residues 
in the active site. Also, the possibility of fluorine being freely solvated could affect its 
interactions in the active site. 
The data based on the crystal structures of citrate synthase with 244 and 245 showed 
that for 244, the hydrogen bond with Asp-375 was similar (2.3 Å to 2.6 Å) with respect to 
that calculated for the system 241-Asp-375 (2.4 Å), whereas for 245 only one 
stereoisomer was observed to bind, with a calculated hydrogen bonding distance also 
similar (2.51 Å) to that of 242 (2.49 Å). The results obtained did not support any 
correlation between hydrogen bond strength and hydrogen bond length in the enzyme-
inhibitor complexes.  
 
 
 
Figure 2.3. α-Fluoro acid 244 and α-fluoro amide 245 analogues of acetyl-CoA.14 
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Vogel et al. 15 described a modification of the method previously used for the synthesis 
of Co-A analogues (described in scheme 2.6);12 by preparing intermediate 248. Acyl-
CoA 248 was prepared by nucleophilic acyl substitution of 238 with amine 246. Acidic 
hydrolysis of tris-thio-ortho ester analogue 247 gave CoA analogue 248. 
  
 
 
Scheme 2.7. Synthesis of hydroxamate 249 and hydrazide 250.15 
 
Hydroxamate 249 and hydrazide 250, were prepared by nucleophilic acyl substitution of 
248 with hydroxylamine and hydrazine, respectively. Hydroxamate 249 turned to be the 
most potent competitive inhibitor of citrate synthase reported to date, with a Ki of 6 nM, 
slightly better than compounds 241 and 242 described in Scheme 2.6. Hydrazide 250 
was also found to be a good competitive inhibitor; although with a Ki = 370 nM two order 
of magnitude less potent (Scheme 2.7). 
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This project aimed to explore the stereo-electronic compatibility between a fluorovinyl 
thioether and an enol/ate thioester motif. The fluorovinyl thioether mimics the enol/ate 
motif where fluorine replaces the oxygen on the enolate. Oxygen and fluorine have 
similar electronegativity (F = 3.98 versus O = 3.44) and Van der waals radii values (F = 
1.47Å versus O = 1.52Å) sharing a similar steric and electronic profile.  
As described previously in Chapter 1, it was found a clear spacial and electronic similarity 
between thioester enol 210 and fluorovinyl thioether 211.10 
Given the close steric and electronic profiles of these motifs, our group became 
interested in designing a fluorovinyl thioether motif as a mimetic of the enol/ate form of 
acetyl-CoA 2. Thus fluorovinyl-CoA (FV-CoA) 212 was evaluated as an inhibitor of pig 
heart citrate synthase. Analogue 212 emerged to be a low micromolar inhibitor with a Ki 
of 4.4 µM and with a higher affinity for the enzyme than acetyl-CoA 2 (Km = 5.8 µM) 
(Figure 2.4). 
 
 
 
Figure 2.4. Fluorovinyl thioether 212 and defluoro hydrate 251 analogues of acetyl-CoA. 
 
The vinyl thioether 251 (Kiapp= 68.3 µM) was also synthesized as a control. By comparing 
212 and 251 a clear “fluorine effect” was demonstrated. This was supported by QM 
computational studies that calculated that fluorovinyl thioether-CoA binds more strongly 
then vinylthioether-CoA, as evidenced through shorter hydrogen bond distances (2.02 Å 
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F…H-His & 2.00 Å F…H-water). This is consistent with fluorine participating in hydrogen 
bonding interactions in the pre-organised active site and it also indicates that compound  
212 mimics an enolate rather than an enol intermediate.16 
 
 
Different strategies have been developed for the synthesis of acetyl-CoA analogues in 
the past. As described previously in Scheme 2.6, Martin et al.12 reported a combined 
chemical and enzymatic synthesis of potent inhibitors 241 and 242. A modified version 
of this method was also used by Vogel et al.15 to generate 249 and 250 reported in 
Scheme 2.7. Acetyl-CoA analogues can be also prepared from the appropriately 
modified pantothenyl motif using the protocol reported by Wright et al.17 using the 
recombinant CoA enzymes. PanK (pantothenate kinase), PPAT (phosphate adenylate 
kinase) and DPCK (dephospho coenzyme-A kinase) to generate the acetyl-CoA 
derivative. A modified procedure using the three Escherichia coli enzymes was used by 
Tosin et al.18 for the synthesis of dethiamalonyl-CoA analogues 256 (Scheme 2.8).18 
 
 
 
Scheme 2.8. Preparation of acetyl-CoA analogues by Wright et al.17,18 
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Recently, Sanichar et al.19 explored a boric acid mediated one-step transamidation 
reaction with a suitable amine under mild conditions, leading to useful CoA analogues 
from CoASH in reasonable yields and good conversions (Scheme 2.9). 
 
 
 
 
Scheme 2.9. Synthesis of acetyl-CoA derivatives via transamidation.19 
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Following from the recent inhibition of citrate synthase by fluorovinyl thioether analogue 
212 in the St Andrews laboratory,16 a dethia fluorovinyl-CoA analogue 261 was 
envisaged as a target. An acetyl-CoA-analogue can be synthesised from the 
appropriately modified pantothenyl motif using the protocol reported by Wright et al.17 
(Scheme 2.10) The synthesis of compound 260, as a non-fluorinated control, was also 
envisaged to assess any fluorine effect associated with inhibition. 
 
 
 
 
Scheme 2.10. Synthesis of dethia analogue of acetyl-CoA 261 and 262.16,17 
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The cloning and the over-expression of Pank, PPAT and DPCK enzymes were carried 
out by Dr Nouchali Bandaranayaka at the University of St Andrews, following previously 
published procedures.17 
In order to prepare the coenzyme-A analogues, the three enzymes involved in the 
biotransformation required to be over expressed. PanK and PPAT were cloned into 
pET29b and DPCK cloned into pET20b (+) plasmids by using modified primers (see 
Chapter 5, Experimental Part). These plasmids were gifted by Dr Manuela Tosin from 
the University of Warwick.18 Due to overexpression inconsistencies DPCK gene was 
PCR amplified using DPCKFP and DPCKRP and cloned into pEHISTEV plasmid.20 
PanK and PPAT recombinant plasmids were transformed into BL21 gold (DE3) cells 
(Agilent) and DPCK-pEHISTEV was transformed into BL21-codonPlus (Agilent) for over 
expression of the respective proteins according to previously published procedures.16,17 
 
 
 
Luria Broth LB (20 mL) supplemented was inoculated with kanamycin (100µg/ml for 
PanK and PPAT) or ampicillin (100µg/ml for DPCK) and incubated at 30 ̊C for 16h. 
Baffled shake flasks (2L) containing LB media (1L) and kanamycin (100 µg/mL) antibiotic 
(Pank, PPAT) or ampicillin (DPCK) and 1mL of the overnight inoculated culture (LB 
inoculated with kanamycin or ampicillin) were cultured and incubated at 37°C until the 
optical density reached (OD600) 0.6. The cultures were induced by addition of IPTG and 
incubated at 25°C with shaking for 20h before harvesting by centrifugation. The cells 
were disrupted after addition of deoxyribonuclease I from bovine pancreas and 2 tablets 
of Mini protease inhibitor cocktail. The lysate was filtrated and centrifuged. The protein 
(Pank/PPAT/DPCK) was purified by affinity chromatography using a Ni2+ Sepharose 
column. Bound protein was washed (50mM HEPES pH 7.5, 500mM NaCl+ 30mM 
imidazole pH 7.5) four times and eluted (50mM HEPES pH 7.5, 500mM NaCl+ 250 mM 
imidazole pH 7.5) three times. SDS-page analysis of all the fractions showed the elution 
fractions were freed of other proteins, thus they were pooled and dialysed against 4 L of 
buffer (50mM HEPES pH 7.5 + 100mM NaCl) to remove imidazole and other salts from 
the protein. The dialysed protein was then concentrated by filter centrifugation until the 
desired concentration (10mg/mL) was achieved. 
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Figure 2.5. SDS-page gel of purified PanK, PPAT and DPCK proteins. 16–18 
DPCK 
24kDa 
PPAT  
18kDa 
PanK  
36kDa 
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Several methods have been developed for the synthesis of fluoroalkenes but most of the 
common approaches give mixtures of E/Z diastereoisomers which can be challenging to 
separate. One of the common synthetic approaches reported for the synthesis of 
fluoroalkenes is to start from a fluoro bromo alkene 267. These can be synthetised via 
Wittig chemistry promoted by a diethyl zinc 266, with aldehydes and ketones 263. The 
first step of the reaction involves the formation of phosphonium salt 268 generated by 
the reaction between triphenylphosphine 265 and tribromofluoromethane 264 as 
illustrated in Scheme 2.11. Debromination of phosphonium salt 269, to give the key ylide 
intermediate 270, is promoted by phosphine 265 or activated zinc 271. The aldehyde or 
ketone 263 acts as a trapping agent shifting the equilibrium from the phosphonium salt 
269 towards the ylide 270.21 The reaction generally gives good yields of the E/Z products 
267 but moderate stereoselectivity. 
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Scheme 2.11. Previous synthetic approaches to fluoroalkenes.21–23 
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A stereoselective synthesis of fluoroalkenes 277 has been developed by Yang et al.22 
This is a Shapiro fluorination that involves the condensation of a N-sulfonyl hydrazine 
with a ketone, to give a N-sulfonyl hydrazone 275. An n-butyllithium promoted elimination 
generates vinyllitihum 276, that reacts with N-fluorobenzenesulfonimide (NFSI) to give 
fluoro olefins 277 in high stereoselectivity. This can be E or Z accordingly to the nature 
of the ketone used. The method has been used to access new fluorinated analogues of 
natural products including steroids.  
High regioselectivity for the synthesis of fluoroalkene motifs was also achieved by N-
heterocyclic carbene gold mediated hydrofluorination of alkynes 278,23 yielding just the 
Z isomer 279 (Scheme 2.11). 
76 
 
 
 
It was envisaged that pantothenyl precursor 259 could be prepared from fluoro vinyl 
amine 281 which itself could derive from phthalimide 282 as illustrated in Scheme 2.12.16  
 
 
 
Scheme 2.12. Retrosynthetic approach to the synthesis of pantothenyl 259.16 
 
The first synthetic method in the literature for the synthesis of phthalimide 282 
progressed via fluoro-bromination using N-bromo succinimide and triethylamine 
hydrogenfluoride to generate the bromo-fluoro regioisomers 285.24 The mechanism 
presumably proceeds via bromonium intermediate 284 followed by a nucleophilic 
substitution to give the two isomers (Scheme 2.13). However, the reaction was poor with 
low conversion and only a trace of the desired bromo fluoro alkene was generated. 
 
 
 
Scheme 2.13. Bromo-fluorination of alkyne 283: a) NBS, Et3N HF, DCM, RT.24 
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The only other method previously described for the synthesis of 282 is illustrated in 
Scheme 2.14. It involved gold catalyzed hydrofluorination of alkynes 23 using the DMPU-
HF complex as the source of hydrogen fluoride. 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-
pyrimidinone (DMPU) is a better hydrogen bond acceptor (pKBHX= 2.82) than pyridine 
(pKBHX= 1.86) or triethylamine (pKBHX= 1.98). This makes DMPU-HF complex more acidic 
than the Et3N-HF and Py-HF complexes. The gold phthalimide-complex 25 286 promotes 
the hydrofluorination and no reaction is observed without this catalyst. Terminal and 
internal alkynes were successfully monofluorinated with high control of regioselectivity 
and in excellent yields. 
  
 
 
Scheme 2.14. Gold catalyst monofluorination of functionalized alkynes .19-21,25 
  
Thus, 282 was synthesised by hydrofluorination of N-(4-pentynyl)-phthalimide 283 with 
DMPU-HF and the catalyst 286 in high yield (84%), using CHCl3 instead of DCE as 
previously reported.26 This was then treated with hydrazine monohydrate to generate the 
required fluorovinyl amine 281. This amine could be precipitated in ethanol with 
hydrochloric acid (5M) to remove any excess of hydrazine monohydrate. After solvent 
removal the crude was freeze dried. Treatment with 5M sodium hydroxide allowed the 
aqueous phase to be extracted with dichloromethane. The mixture was carefully 
concentrated under vacuum due to the high volatility of amine 281. The solution of 281 
in dichloromethane was used directly for the amide coupling step with pantothenic acid 
diacetylester 294.14,19-27 This gave amide 280 in moderate yield. Finally, the acetate 
group was hydrolysed under basic conditions to give the desired diol 259 (Scheme 2.15).  
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Scheme 2.15. Synthesis of N-(4-fluoropent-4-en-1-yl)-D-pantothenamide 259: a) DMPU-HF, Au-
1 286, dry CHCl3 ; b) hydrazine monohydrate, EtOH ; c) HOBt, EDCI, Et3N, CH2Cl2, d) NaOMe 
(5.4 M in methanol), MeOH.16,23-27 
 
The desired compound 259 was successfully prepared in moderate yield as an important 
building block for this study. It was now progressed by the three-step biotransformation, 
to generate the co-enzyme A analogue.  
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The synthesis of the co-enzyme A derivative 261 was carried out enzymatically 
according to the procedure used for FV-CoA analogue 212 (Scheme 2.16).16 
 
 
 
Scheme 2.16. Biotransformation approach to fluorovinyl-dethia-CoA 261, the yield reported is 
over 3 steps.16 
 
Intermediate 261 was prepared in a one pot/ two-step enzymatic reaction.  PanK 
mediated phosphorylation was followed by a PPAT addition of the adenine 
monophosphate. HPLC purified intermediate 296 was then progressed to its final form 
261 by DPCK mediated further phosphorylation.   
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The enzymatic biotransformation was monitored by HPLC. After 16 h, the starting 
material 259 (red) (retention time = 20.1 min) was fully converted to the PanK product 
295 (retention time = 17.6 min). The PPAT catalyzed step was slower (24 h) and did not 
progress completely to intermediate 296 (retention time = 16.4 min). Unreacted 295 was 
recovered by HPLC and could be re-used in subsequent bio-transformations for the 
synthesis of 296 (Figure 2.6).The corresponding products are highlighted in the 
chromatogram shown below, 261 highlighted in purple is the most polar with the shortest 
retention time, then 296 (green) and then 261 (blue). 
 
 
Figure 2.6. The HPLC profile of the three enzymatic reactions of N-(4-fluoropent-4-en-1-yl)-D-
pantothenamide 259. 
 
Intermediate 296 was finally purified by semi-preparative HPLC and its constitution was 
confirmed by mass spectrometry. The 1H NMR spectrum was assigned by a Double 
Quantum Filter COSY 2D experiment (DQF-COSY) as illustrated in Figure 2.7. C2 and 
C8 protons of the heterocyclic purine (H2, H8) and C1’, C4’ protons of the nucleoside 
(H1’, H4’) are characteristic of the adenosine moiety. The C2’ protons signal (H2’) is 
partially hidden by the solvent peak and the C3’ proton (H3’) is overlapping with the C23cis 
proton (H23cis) as shown in Figure 2.7A. C23cis (J = 18.5, 3.0 Hz) and C23trans (J = 50.0, 
3.0 Hz) protons of the fluorovinyl moiety (H23cis, H23trans) have been identified by their 
corresponding coupling constants. The 19F NMR spectrum shows a singlet at -75 ppm 
that belongs to trifluoro acetic acid (used as HPLC mobile phase acidic modifier) and a 
multiplet that relates to the fluoro vinyl motif coupled with C23 protons (H23cis, H23trans). 
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Figure 2.7. NMR spectra of PPAT intermediate 296: compound 296 has been characterised by 
A) 1H NMR, B) 19F NMR and C) 1H-1H-2D-COSY NMR. 
 
Intermediate 296 was then progressed to the final coenzyme-A derivative 261, by a 
further phosphorylation mediated by DPCK. A comparison of the PPAT and DPCK 
products by 1H NMR in Figure 2.8 shows that C3’, C2’, C4’ protons of the final product 
(H3’, H2’, H4’) 261 are shifted downfield. This is consistent with phosphorylation at O-3’ 
in 261.  
 
 
Figure 2.8. A comparison of PPAT 296 and DPCK 261 products after HPLC purification. 
C 
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The required product 261 was also purified by semi-preparative HPLC chromatography 
and 5 mg was isolated. Figure 2.9 shows the relevant NMR spectra for 261. All of the 
1H-NMR peaks were assigned by using Double Quantum Filter COSY 2D experiment 
(DQF-COSY) by comparison with F-CoA compound 212.16 
 
  
 
 
A 
B 
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Figure 2.9. A) 1H-NMR, B) 19F-NMR and C) 1H-1H-2D-COSY NMR data for fluorovinyldethiaCoA 
261.16 
 
  
C 
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In order to conduct a comparative inhibition study, defluoro analogue 262 was designed 
as control compound relative to fluoro-vinyl 261. This would allow any fluorine effect to 
be evaluated. In order to achieve this, pent-4-enyl-N-phthalimide 298 was prepared. This 
was made by a nucleophilic substitution of potassium phthalimide 297 with 4-bromo-1-
pentene.28  
 
 
 
Scheme 2.17. Synthesis of vinyl-dethia-CoA 262: a) DMF, 4-bromo-1-pentene, reflux ; b) 
hydrazine monohydrate, EtOH; c) HOBt, Et3N, EDCI, CH2Cl2; d) MeONa, MeOH.16,18,28–30 
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Phthalimide 298 was then treated with hydrazine monohydrate to generate 
pentenylamine 299,30 using the same work up conditions described for the fluoro 
analogue 281. Amine 299 was isolated as a solution in dichloromethane without further 
purification due its high volatility. Amide coupling then gave the diacetylated derivative 
300. Finally basic hydrolysis of 300 allowed access to diol derivative 260 which was 
progressed to the acetyl-CoA analogue 262 by the three step biotransformation, as 
illustrated in Scheme 2.17.16,18,28–30 
The HPLC profile illustrated in Figure 2.10, shows the three enzymatic products. 
Phosphorylated pantetheine 301 (retention time = 17.70 min) was converted to 
intermediate 302 (retention time = 16.30 min) but without complete consumption of 301. 
This sluggishness was also previously observed for the vinyl fluoride 296. Intermediate 
302 then was purified by HPLC and progressed to its final coenzyme-A form 262 after 
phosphorylation with DPCK (retention time = 15.10 min). The corresponding products 
are highlighted in the chromatogram shown below, 262 highlighted in purple is the most 
polar with the shorter retention time, then 302 (green) and then 301 (blue).16 
 
 
 
Figure 2.10. The HPLC profile of the three enzymatic reactions required to generate vinyl-dethia-
CoA analogue 262.16 
 
Vinyldethia-CoA 1H NMR signals were assigned using a Double Quantum Filter COSY 
2D experiment (DQF-COSY) as shown in Figure 2.11 and by comparison with the 
fluorinated dethia analogue 261 (Figure 2.9). C22 (H22) and C23 protons (H23) 
correspond to the vinyl protons with C22 proton (H22) shifted downfield. The adenine C2 
and C8 proton signals (H2, H8) and C1’, C2’, C3’, C4’, C5’ protons of the nucleoside 
(H1’, H2’, H3’, H4’, H5’) were also identified by 1H NMR and 2D-COSY. High resolution 
mass spectrometry analysis gave a further confirmation of vinyldethia-CoA structure 
262.16 
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Figure 2.11. Fully assigned A) 1H-NMR and B) 1H-1H-2D-COSY NMR analysis of vinyl-dethia-
CoA 262.16 
  
A 
B 
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In the first instance a Km value was established for acetyl-CoA. This was achieved by 
the Ellman’s reagent-based spectrophotometric assay as previously described for 
quantitative CoASH release.31,32The UV assay measures the consumption of acetyl-CoA 
by quantifying the formation of a yellow complex produced by reaction of DTNB with 
CoA-SH which is released during enzymatic turnover.  
The enzymatic activity against acetyl-CoA was determined by the calculation of the 
Michaelis-Menten constant Km. The Km was obtained by measuring the Ellman’s 
reagent-based spectrophotometric assay described above.33,32 
Thus, solutions containing OAA (250 µM), DTNB (250 µM) and increasing amount of 
acetyl-CoA (3.12 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM, 75 µM and 100 µM, respectively) 
in TRIS buffer (50 µM, pH = 8.0) were loaded in 400 µL quartz cuvettes, blanks were 
taken and the reaction were then started by adding and thoroughly mixing in a 4 µL of 
the previously prepared stock solution of citrate synthase in TRIS buffer (200 nM, pH= 
7.8) in order to achieve a final concentration of 2.7 nM (final reaction volume = 400 µL). 
The appearance of the coloured anion TNB-, obtained by cleavage of DTNB, was 
recorded by measuring the absorbance at 412 nm versus time (sampling every 2 second, 
maximum measuring time 200 seconds). The measurements were carried out in two 
repeats for each acetyl-CoA concentration. The data obtained were converted to 
concentration vs time by using the Lambert-Beer law (ε415 DTNB = 14150 M-1 cm-1) and 
plotted to XY graphs for each acetyl-CoA concentration in order to extrapolate the linear 
portions (initial velocities) of the curves. The chosen data points for each repeated 
measurement were then processed using linear regression with Graphpad® Prism to get 
the initial velocities values (µM/s). These values were finally plotted against the 
corresponding acetyl-CoA concentration using the nonlinear Michaelis-Menten enzyme 
kinetics method in Graphpad® Prism yielding the graph and values reported below: 
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Km = 5.8 (± 0.3) µM 
Vmax = 0.25 µM/s (±0.003) μM/s 
 
  
Figure 2.12. The Km value for acetyl-CoA 2  
 
The Km value found for acetyl-CoA is 5.8 µM. This value agrees with the value reported 
previously by Johansson et al. (Km = 6 µM)34 at 26.5 °C in 0.1 M Tris buffer (pH = 8.2), 
250 µM of DTNB, 0.2 nM of the enzyme, fixed concentration of oxaloacetate and varying 
the acetyl-CoA concentration from 0 to 60 µM. The same value of Km for acetyl-CoA 
was obtained by Bayer et al.11 working at 25 °C in Tris-HCl (100 µM), oxaloacetate (0.5 
µM), DTNB, citrate synthase and oxaloacetate (0.2 µM) modulating the acetyl-CoA 
concentration.11,34,35  
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The inhibitory activity of the acetyl-coA analogues described in this chapter were 
assessed by calculating the IC50 and Ki parameters. IC50 represents the concentration of 
the inhibitor needed to reduce the rate of enzymatic activity by half. IC50 were then 
converted to Ki (measures the binding affinity of the target inhibitor with the enzyme). 
Control experiments were carried out to assess the enzyme activity, without the 
presence of the inhibitor and varying other parameters such as substrates 
concentrations. 
Several initial velocities were measured for each compound maintaining a fixed 
concentration of acetyl-CoA and increasing the inhibitor concentration. Solutions 
containing OAA (250 µM), DTNB (250 µM), acetyl-CoA (25 µM) and with increasing 
concentrations of compounds 261, 262 in Milli-Q water, were placed in 400 µL quartz 
cuvettes. Blanks were taken and the reactions were started by thoroughly mixing 4 µL of 
the stock solution of citrate synthase (3nM). The appearance of the coloured complex 
was recorded measuring absorbance at 412 nm versus time (sampling every 2 seconds 
for 200 seconds). Two repeats at each concentration were carried out for both 
compounds tested. The data obtained were converted to concentrations applying the 
Lambert-Beer equation and plotted to XY graphs for each concentration of inhibitor to 
extrapolate the linear gradients (initial velocities) of the curves. 
The resultant values were converted to % of response and plotted against the logarithm 
of the inhibitor concentration. The obtained values (%) were plotted against the logarithm 
of the test compound concentration using Prism Graphpad®. Estimation of the 
corresponding logarithm of the inhibitors at 50 % response gave the IC50 for that 
compound (Figure 2.13). 16 
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Figure 2.13. General procedure for the determination of IC50 values: the image above illustrates 
the main steps of the IC50 and Ki determination of inhibitors of citrate synthase.16 
 
With these values, the apparent inhibition constants Kiapp (the binding affinity of the test 
compound for the enzyme) for each of the test compounds could be calculated using a 
web application based on the Cheng-Prussof equation shown in Figure 2.14. 36 
 
 
 
Figure 2.14. The Cheng-Prussof equation used for the calculation of Ki values for the inhibitors.36  
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Coenzyme-A analogues 261 and 262 were investigated as inhibitors of citrate synthase. 
As shown in Figure 2.15, the dethia fluorovinyl inhibitor 261 was a poor inhibitor of citrate 
synthase with a Kiapp (44.8 µM) 10 times less than the fluoro vinyl thioether analogue 212 
(Kiapp =.4.3 µM). The poorer inhibition capacity of compound 261 is clearly related to the 
replacement of the sulfur of the thioether with the CH2 moiety. The comparison of 261 
with the non-fluorinated analogue 262 (Kiapp = 53.1 µM) has highlighted a modest fluorine 
effect for compound 261.14 
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IC50 = 238.8 (± 47.9) µM 
Kiapp = 44.8 (± 9.2) µM 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50 = 281.9 (± 32.4) µM 
Ki app = 53.1 (± 6.5) µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. Ki app and IC50 values for 261 and 262.14 
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Sulfoxide 305 was previously synthesised in 1994 as a mixture of diastereomers where 
it was investigated as an inhibitor of chloramphenicol transferase as shown in Scheme 
2.18.12 It was designed as a mimic of the tetrahedral intermediate or transition state in 
the acyl transferase reaction. It was found to have a lower binding affinity than acetyl-
CoA but it was never studied as an inhibitor of citrate synthase. In this case the sulfonyl 
group is located to replace the carbonyl group of acetyl-CoA, with the polarized oxygen 
located at the enolate site of the enzyme. 
 
 
 
Scheme 2.18. Study of sulfoxide-CoA 305 as an inhibitor of chloramphenicol transferase.12 
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The reported synthesis involved amide formation of amine 308 with the analogue of co-
enzyme A 238. The synthesis of 238 has been reported previously in Scheme 2.6. In 
coenzyme A analogue 238, the thioester bond and the methyl group are respectively 
replacing the amide bond and the thiol of CoA-SH 1. Sulfoxide amine 308 was prepared 
by oxidation of methylthio-propyl-phthalimide 306 followed by deprotection to generate 
amine 308. Since the sulfoxide amine 308 was racemic, the corresponding CoA 
analogue 305 is necessarily obtained as a mixture of epimers (Scheme 2.19). 
 
 
 
Scheme 2.19. Previous synthesis of sulfoxide-CoA 305 as an epimeric mixture.12 
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In our case we developed a different route to 305. Pantothenyl sulfoxide 312 was 
prepared by synthesis and then progressed through the biotransformation to 305. 
Accordingly, 3-methylthiopropylamine 309 was coupled with diacetyl pantothenic acid 
294 to give the thiomethyl pantothenyl diacetate 310. Finally, oxidation of sulfide 310 
with mCPBA gave the mixture of diastereomers 311. Hydrolysis under basic conditions 
of diacetate 311, led to the desired compound 312 (Scheme 2.20).16 
 
 
 
Scheme 2.20. Synthesis of sulfoxide 312: a) HOBt, Et3N, EDCI, CH2Cl2; b) mCPBA, CH2Cl2;  
c) EtONa (5M in EtOH), EtOH.16,17,18 
 
The oxidation of thiomethyl pantetheine diacetyl 310 was monitored by thin-layer 
chromatography and just one equivalent of mCPBA was added to avoid sulfone 
formation. Pantetheine 310 was treated with mCPBA to give sulfoxide 311 as a mixture 
of stereoisomers. The 1H NMR (CDCl3) analysis of 311 is illustrated in Figure 2.16. It can 
be assumed that the ratio is 1:1. Comparison of the 1H NMR spectra of compound 310 
and 311 in CDCl3 suggests the generation of the isomer mixture with the two signals 
associated with the C12 proton (H12) in 311 that occurs as singlet in 310. The same 
duplicity pattern was observed for the C1 proton (H1) signal in 311.  
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Figure 2.16. 1H NMR comparison of sulfonyl 310 and sulfoxide 311 
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The isomerism for 311 shows up in CDCl3 through the duplicity of C12 and C1 protons 
(H12, H1) signals. This could be explained by H bonding interactions in 311 as shown in 
Figure 2.16. 
 
 
Figure 2.17. 1H NMR of 311 and 312 in CD3SO and D2O: the duplicity of C1 and C12 protons 
(H1, H12) observed in Figure 2.16 for CDCl3, is absent in more polar solvents. 
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The duplicity is suppressed in more polar solvents such as CD3SO (for 311) and D2O 
(for 312) that are capable of H bonding interactions themselves (Figure 2.17). 
In the attempt to prepare a single sulfoxide isomer, an asymmetric approach for the 
oxidation reaction was tentatively explored. Catalytic asymmetric oxidation of sulfides to 
sulfoxides has been investigated for many years as chiral sulfoxides are useful 
synthons.37 The method chosen here was a modified Sharpless oxidation as developed 
by Kagan and Modena using diethyl tartrate (DET) as the chiral agent, titanium 
tetraisopropoxide [Ti(OiPr)4] as a coordination catalyst and cuprene hydroperoxide 
(CHP) or tert-butyl-hydroperoxide (TBHP) as the oxidant. This method has been shown 
to give high enantioselectivity with certain substrates as illustrated in Scheme 2.21.37–40  
 
 
 
Scheme 2.21. A) Enantioselective oxidation of sulfides to sulfoxides, B) attempted 
stereoselective oxidation of 310.37–40  
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In the event, oxidation of sulfide 310 under Kagan’s conditions gave poor conversion to 
the sulfoxide 311 mixture after 16 h with no change of the ratio (1:1). This outcome could 
be related to the more complex structure of substrate 310 when compared to the aryl or 
alkyl sulfide reported with this procedure (Scheme 2.21A). The asymmetric approach 
was not explored any further. 
Sulfoxides 311 was hydrolyzed under basic conditions as shown in Scheme 2.20 and 
progressed to substrate 312 for the biotransformation. Compound 312 was converted 
into sulfoxide-CoA 305 following the same procedure described for acetyl-CoA 
analogues 260 and 261. The three-step biotransformation was monitored by HPLC and 
the DPCK mediated product (retention time = 13.6 min) 305 was purified and its identity 
confirmed by mass spectrometry, 1H NMR and 1H-1H-COSY 2D NMR experiments.16  
 
 
 
 
 
Scheme 2.22. A) The biotransformation pathway and B) the HPLC profile of 305.16 
 
The 1H NMR spectrum was assigned using a Double Quantum Filter COSY 2D 
experiment (DQF-COSY) and by comparison with the fluorinated dethia analogue 260.  
A 
B 
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Figure 2.18. A) 1H NMR and B) 2D COSY characterization of compound Sulfoxide-CoA 305: 
1HNMR signals were assigned by 2D COSY and by comparison with fluorinated dethia analogue 
260.14 
A 
B 
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As observed for 260 and 261, the adenosine moiety of coenzyme A analogue 305 is 
identified by the C2, C8 protons of the adenine (H2, H8) and the C1’, C2’, C3’, C4’ 
protons of the nucleoside (H1’, H2’, H3’, H4’). The sulfoxide presence is confirmed by 
the C23 methyl proton at 2.7 ppm (H23) directly attached to sulfur (Figure 2.18). Product 
305 structure was also supported by HR-MS.16 
 
 
Sulfoxide-CoA 305 was assayed with citrate synthase. It showed a relatively good 
inhibitory activity towards citrate synthase with a Ki of 11.1 µM, a value higher than the 
Km of acetyl-CoA (5.8 µM). The +S-O- bond is polarized with a partial negative charge 
located on the oxygen atom, displaying a better hydrogen bond acceptor capacity than 
the inhibitors bearing alkylnitrate 243 or malate 230 groups (Figure 2.1), as also 260 and 
261. 
 
Kiapp = 11.1 (± 0.9) µM 
IC50 = 59.18 (± 4.4) µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19. IC50 and Kiapp values for sulfoxide-CoA 305.14 
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The porcine citrate synthase crystallization and soaking process were performed by Dr. 
Nouchali Bandaranayaka from the University of Saint Andrews: 
Pig heart citrate synthase was crystallized from a small-molecule cocktail containing 
cystamine dihydrochloride, aspartame and benzamidine hydrochloride according to 
Larson et al. procedure. 41 
Pig heart citrate synthase was purchased from Sigma (UK) as an ammonium sulfate 
suspension and was dialyzed against water to a concentration of 10 mg ml−1. The dialysis 
procedure resulted in the formation of a substantial amount of precipitate, which was 
removed by centrifugation. The protein was concentrated with Vivaspin (Germany). The 
crystals were grown by vapor diffusion at room temperature in 96-well Intelli-Plates 
(Hampton Research, Aliso Viejo, California, USA) with 90 µl reservoirs of 25%(w/v) PEG 
3350+ 0.1 M MES pH 6.5/7.5 and 1mM of sulfoxide compound. The protein droplets 
were of 4 µl volume at 13.5mg/ml and consisted of two parts of the stock protein solution 
and one part each of the ‘cocktail’ of small molecules and the reservoir solution. All 
solutions were buffered to pH 7.8 with 0.1 M Tris–HCl. The ‘cocktail’ was made to 
concentrations of approximately 1%(w/v) of each of the small molecules, namely 
aspartame, benzamidine hydrochloride and cystamine dihydrochloride. The 
concentrations of the small molecules in the crystallization drop were approximately 
5-10 mM. Crystals appeared and grew to full size within one to two weeks. 
 
 
 
 
 
 
 
 
Figure 2.20. Sitting drop crystallization: the drop is on a pedestal separated from the reservoir 
with a high sealing of the environment for the equilibration between the drop and the reservoir to 
occur 
 
Crystals were shot by Dr Magnus Stephen Alphey (University of St Andrews) in house 
at 100K on a Rigaku 007 HFM rotating anode X-ray generator with a Saturn 944 CCD 
detector. The data set obtained showed strong electron density for the adenine moiety 
bound to the enzyme however the pantothenyl chain of 305 was not visible due to 
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disorder. Several crystals were shot, however all of them resulted in the same outcome 
and it was not possible to get any information on binding of the sulfoxide to the active 
site.  
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The Z and E conjugated thioacrylates 319 and 320 became targets: it was envisaged 
that the electrostatic nature of carboxylate group would enhance binding and that two 
geometries could be explored. The closest known inhibitor to 319 and 320 is carboxy 
ethyl-CoA 229, which has a Ki of 26 µM. 11,14 
 
 
 
Figure 2.21. Candidate inhibitors (Z)-319 and (E)-320.14 
 
 
 
The synthesis of alkylthio acrylate motifs has been reported. One of the procedures 
involved a nucleophilic substitution of E-β-tosylacrylic derivatives 323 by the 
corresponding thiols 322 in the presence of sodium hydride.42 The reaction takes place 
at the β position with retention of configuration and with high E-regioselectivity. A water 
mediated thiolation of ethyl propiolate 324 has been explored by Randive et al.43 
affording the desired product in good yield and high regio- and stereo- selectivity in 
favour of the Z isomer 326. They observed an increase of the yield with increased polarity 
of the solvent, whereas raising the temperature led to a change of the E/Z ratio towards 
the E-isomer 327. Another synthetic approach involved a Michael addition of thiols to 
electron deficient alkynes 328 bearing an acetylenic ketone using boron trifluoride diethyl 
etherate as a coordinating and activating agent for conjugated addition. Terminal alkynes 
reacted with the thiol yielding mainly the Z-isomers 329 of the resultant vinyl thioether, 
while internal alkynes gave the E-isomers 330 (Scheme 2.23)44 
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Scheme 2.23. Previous synthesis of E-and Z- thioacrylates: a) a nucleophilic substitution of tosyl-
acrylates derivatives with functionalised thiols,36 b) a thiolation mediated by water,37 and c) 
BF3.Et2O activated Michael addition. 38,45 
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In view of the previous protocols, it was contemplated to start from the diacetyl 
pantothenic acid 294.16,27 This involved a mediated coupling with cysteamine to generate 
the protected pantetheine 331 which was then conjugated to methyl propiolate. This 
gave the mixture of isomers (Z)-332 and (E)-333 (Scheme 2.24). 46 
 
 
 
Scheme 2.24. Chemo enzymatic synthesis of (Z)-319 and (E)-320 thioacrylate-CoA: a) 1,1’-
dicarbonyldiimidazole, cysteamine-HCl, THF, reflux b) DBU, methyl propiolate, THF; c) LiOH, 
THF/H2O, 0°C. 16,27,46 
 
1H NMR analysis indicated a 60:40 ratio with Z isomer 332 as the major product. The 
isomers could be separated by HPLC but it proved most convenient at this stage to take 
them as a mixture through the biotransformation protocol and separate them after the 
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second enzymatic step. Given the close retention time between the two isomers shown 
in Figure 2.22 (Z isomer 336 retention time = 14.8 min, E isomer 337 retention time = 
15.1 min), different parameters were varied to develop the best gradient HPLC method 
for their separation. Finally, the intermediate products were separated using a linear 
gradient of acetonitrile/water in 0.05% of trifluoro acetic acid (0 to 20% acetonitrile in 10 
min, then 20% acetonitrile for 10 min, then from 20% to 60% acetonitrile in 5 min to wash 
the column, then from 60% to 0% acetonitrile in 5 minutes, and 0% acetonitrile for 10 
min to re-equilibrate the column). Low volume injections (100-200 µL) were performed 
in order to achieve the best separation.  
 
 
 
 
 
Figure 2.22. The HPLC profiles of intermediate (Z)-336 and (E)-337. 
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Finally, (Z)-336 and (E)-337 were separately converted to (Z)-319 and (E)-320 and 
purified by HPLC.16 The DPCK products (Z)-319 and (E)-320 were individually 
characterised by 1H NMR and 1H-1H-2D COSY NMR.16 Figure 2.23 shows the 1H NMR 
of (Z)-319 and (E)-320 where (E)-320 has a larger coupling constant (J = 15.0 Hz) than 
(Z)-319 (J = 10.0 Hz).16 
 
 
 
Figure 2.23. 1H NMR spectra of A) (E)-320 and B) (Z)-319.16 
 
All of the 1H NMR signals of (Z)-319 and (E)-320 isomers were assigned using Double 
quantum Filter COSY 2D experiment (DFQ-COSY) as illustrated in Figure 2.24 and 
Figure 2.25.16 Of significance was the identification of C22, C21 protons (H22, H21) of 
the conjugated thioester moiety, and the C2, C8, C1’, C2’, C3’, C4’, C5’ protons of the 
adenine fragment (H2, H8, H1’, H2’, H3’, H4’, H5’) for both (Z)-319 and (E)-320, whose 
constitution was also confirmed by HR-MS.16  
 
A 
B 
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Figure 2.24. A) 1H NMR characterization of S-(Z-propenoic-3-yl)-coenzyme A 319: 1HNMR 
signals were assigned by B) 1H-1H-2D COSY NMR and by comparison with fluorinated dethia 
analogue 260.16 
 
 
A 
B 
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Figure 2.25. 1H NMR characterization of S-(E-propenoic-3-yl)-coenzyme A 320: 1HNMR signals 
were assigned by 1H-1H-2D COSY NMR and by comparison with fluorinated dethia analogue 
260.16 
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Compounds (Z)-319 and (E)-320 were separately assayed against citrate synthase, 
using the protocol described previously. However, they did not show any meaningful 
inhibition of citrate synthase. The constrained geometric isomers do not appear to 
access any relevant conformation on binding to the enzyme (Table 2.1).16 
 
 IC50 Ki app 
(Z)-319 ≥ 3 mM ≥ 500 µM 
(E)-320 ≥ 3 mM ≥ 500 µM 
  
Table 2.1. Inhibition studies of (Z)-319 and (E)-320.16 
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Following the encouraging results of the micromolar inhibition of citrate synthase by 
fluorovinyl thioether (FV-CoA) 212 in this study, five additional analogues of acetyl-CoA 
(261, 262, 305, (Z)-319, (E)-320) were successfully synthesised and investigated as 
inhibitors of porcine citrate synthase. Acetyl-CoA analogues 261, 262, 305, (Z)-319, (E)-
320 were made by synthesis of the appropriate pre-pantothenyl moieties and assembling 
the co-enzyme A structure with the three-step biotransformation protocol. Fluorovinyl 
dethia CoA 261 was prepared as an analogue of FV-CoA 212 to verify if the replacement 
of the sulfur atom with a methylene moiety would affect the binding affinity. In the event, 
the affinity was reduced by an order of magnitude. In this case, fluorine is replacing the 
oxygen atom of an enolate. Both fluorine and oxygen display high electronegativity (F = 
3.98 versus O = 3.44) and are isosteric with close van der Waals radii (F = 1.47 Å versus 
O = 1.52 Å). They also have similar electronic profiles being next to each other on the 
Periodic Table. Vinyl thioether 262 was synthesised as a control to explore any fluorine 
effect in the citrate synthase assays. Sulfoxide-CoA 305 has previously been 
investigated as an inhibitor of acyl transferase enzymes but not for citrate synthase. 
Sulfoxide-CoA 305 has the sulfoxide methyl moiety replacing the enolate of acetyl-CoA 
31. Finally, two conjugated esters isomers (Z)-319 and (E)-320 were also prepared and 
explored as inhibitors of citrate synthase. The carboxylate group was anticipated to be a 
good replacement for a citrate carboxylate as it had the potential to locate into a 
carboxylate binding site. (Z)-319 and (E)-320 can be compared spatially to historical 
inhibitor carboxy ethyl-CoA 229. However being conformationally constrained, they had 
the potential to access two different conformation in the binding site of the enzymes 
(Figure 2.26).16 
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Figure 2.26. Acetyl-CoA analogues as inhibitors of porcine citrate synthase.16 
 
With these compounds in hand, they were all explored as inhibitors of citrate synthase 
monitoring co-enzyme A release from acetyl-CoA. The inhibition data are illustrated in 
Figure 2.26 and are reported as Ki values. Fluorovinyl-dethia-CoA 261 was found to be 
a poor inhibitor of citrate synthase with a Ki value (Ki = 44.8 µM), one order higher than 
the Ki value found for micromolar inhibitor fluorovinyl-thioether CoA 212 (Ki = 4.4 µM). 
The poor inhibition potency of 261 compared to 212, suggests that the sulfur atom 
replacement with a methylene group in 261 negatively affects the binding affinity for the 
enzyme. It is believed that this replacement could lead to the disruption of the electronic 
density in 261, thus making this compound a less suitable analogue of acetyl-CoA than 
212. The inhibition studies on the hydrated vinyl-CoA 262 which was designed as a 
control for 261, indicated a residual fluorine effect (Ki 262 = 53.1 µM versus Ki 261 = 
44.8 µM). Sulfoxide 305 was a relatively good low micromolar inhibitor (Ki = 11.1 µM). 
The polarised S+-O- bond seems to exert a better hydrogen bond acceptor capacity than 
the literature inhibitors nitro-alkyl 243 and malate 229. Sulfoxide 305 was investigated 
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as mixture of diastereoisomers, thus the inhibition data is an average of the two perhaps 
indicating that one isomer might bind more tightly to the enzyme than the other. 
Unfortunately, the X-ray analysis of co-crystallized complexes of 305 with citrate 
synthase did not give any useful information about the binding. Conjugated thioacrylate 
isomers (E)-320 and (Z)-319 were finally explored as inhibitors of citrate synthase, 
however, they did not show any meaningful inhibition. The two geometries of (E)-320 
and (Z)-319, which relate spatially to known low micromolar inhibitor carboxy-ethyl 229, 
do not seem to access any relevant conformation on binding or access the carboxylate 
sites.16 Although they possess a carboxylate group bearing a located negative charge 
as well as acetyl-CoA enolate 31, the isomers do not probably fit into the enzyme cleft. 
Future work will be focused on investigating these substrates as inhibitors of other acetyl-
CoA utilising enzymes such as malate synthase whose mechanism of action is still under 
study. This enzyme pathway is crucial for understanding plant, animal and human 
pathogenesis such as M. tuberculosis. Malate synthase regulation could lead to its 
reduced growth in macrophages. Computational studies should be carried out to assess 
the fitting of the potential inhibitors into the targeted enzyme active site. Furthermore, 
(E)-320 and (Z)-319 have potential as malonate analogues and they could be studied as 
inhibitors of acetyl-CoA carboxylase (ACC) that is involved in fatty acids biosynthesis. 
Regarding the sulfoxide mixture 305, different stereoselective approaches should be 
investigated to get the two isomers separated, thus they could be assessed separately 
as inhibitors of citrate synthase and other acyl-CoA utilizing enzymes. 
116 
 
 
 
1 C. Rye, R. Wise, V. Jurukovski, J. DeSaix, J. Choi, A. Yael, Biology, 2016, 1st ed. 
2 D. P. Bloxham, D. C. Parmelee, S. Kumar, R. D. Wade, L. H. Ericsson, H. Neurath, 
K. A. Walsh, K. Titani, Proc. Natl. Acad. Sci., 1981, 78, 5381–5385. 
3 C. T. Evans, L. C. Kurz, S. J. Remington, P. A. Srere, Biochemistry, 1996, 35, 
10661–10672. 
4 M. Karpusas, B. Branchaud, S. J. Remington, Biochemistry, 1990, 29, 2213–
2219. 
5 G. Wiegand, S. J. Remington, Ann.Rev.Biophys.Chem., 1986, 15, 97–117. 
6 D. L. Cox, M. Nelson, Leningher principles of biochemistry, 2013, 3rd ed. 
7 D. O’Hagan, H. S. Rzepa, J. Chem. Soc., Chem. Commun., 1994, 2029. 
8 H. Lenz, W. Buckel, P. Wunderwald, G. Biedermann, V. Buschmeier, H. Egqerer, 
J. W. Cornforth, J. W. Redmond, R. Mallaby, Eur. J. Biochem., 1971, 24, 207–
215. 
9 A. J. Mulholland, W. G. Richards, J. Mol. Struct., 1998, 427, 175–184. 
10 D. Bello, R. A. Cormanich, D. O’Hagan, Aust. J. Chem., 2015, 68, 72–79. 
11 E. Bayer, B. Bauer, H. Eggerer, Eur. J. Biochem., 1981, 120, 155–160. 
12 D. P. Martin, R. T. Bibart, D. G. Drueckhammer, J. Am. Chem. Soc., 1994, 116, 
4660–4668. 
13 K. C. Usher, S. J. Remington, D. P. Martin, D. G. Drueckhammer, Biochemistry, 
1994, 33, 7753–7759. 
14 B. Schwartz, D. G. Drueckhammer, K. C. Usher, S. J. Remington, Biochemistry, 
1995, 34, 15459–15466. 
15 K. W. Vogel, D. G. Drueckhammer, J. Am. Chem. Soc., 1998, 120, 3275–3283. 
16 D. Bello, M. G. Rubanu, N. Bandaranayaka, J. Götze, M. Bühl, D. O' Hagan, 
ChemBioChem, 2019, 20, 1174–1182. 
17 I. Nazi, K. P. Koteva, G. D. Wright, Anal. Biochem., 2004, 324, 100–105. 
18 M. Tosin, D. Spiteller, J. B. Spencer, ChemBioChem, 2009, 10, 1714–1723. 
19 R. Sanichar, J. C. Vederas, Org. Lett., 2017, 19, 1950–1953. 
20 H.Liu, J.H. Naismith, Protein Expr Purif., 2009, 63, 102–111. 
21 X. Lei, G. Dutheuil, X. Pannecoucke, J. C. Quirion, Org. Lett., 2004, 6, 2101–2104. 
22 M. H. Yang, S. S. Matikonda, R. A. Altman, Org. Lett., 2013, 15, 3894–3897. 
23 F. Nahra, S. R. Patrick, D. Bello, M. Brill, A. Obled, D. B. Cordes, A. M. Z. Slawin, 
D. O’Hagan, S. P. Nolan, ChemCatChem, 2015, 7, 240–244. 
24 M. Lubke, R. Skupin, H. Gunter, J. Fluor. Chem., 2000, 102, 125–133. 
25 J. Han, N. Shimizu, Z. Lu, H. Amii, G. B. Hammond, B. Xu, Org. Lett., 2014, 16, 
117 
 
3500–3503. 
26 O. E. Okoromoba, J. Han, G. B. Hammond, B. Xu, J. Am. Chem. Soc., 2014, 136, 
14381–14384. 
27 D. Bello, D. O’Hagan, Beilstein J. Org. Chem., 2015, 11, 1902–1909. 
28 X. Qi, F. Yu, P. Chen, G. Liu, Angew. Chem. Int. Ed., 2017, 19, 316-319. 
29 D. P. Martin, D. G. Drueckhammer, J. Am. Chem. Soc., 1992, 114, 7287–7288. 
30 W. Du, Q. Gu, Y. Li, Z. Lin, D. Yang, Org. Lett., 2017, 19, 316–319. 
31 P. A. Srere, L. Gonen, H. Brazil, Acta Chem.Scand., 1963, 17, 129–134. 
32 V. M. Anoop, Basu.U, M. T. McCammon, L. McAlister-Henn and G. J. Taylor, Plant 
Physiol., 2003, 132, 2205–2217. 
33 P. A. Srere, Biochem. Biophys. Res. Commun., 1965, 1, 87-90. 
34 C.J. Johansson, A.Mahlén, Biochim. Acta, 1973, 309, 466–472. 
35 P. A. Srere, Methods Enzymol., 1969, 13, 3–11. 
36 R. Z. Cer, U. Mudunuri, R. Stephens, F. J. Lebeda, Nucleic Acids Res., 2009, 37, 
441–445. 
37 E. Wojaczynka, J. Wojaczynk, Chem. rev.,2009, 65, 2000-2009. 
38 T. Torn, C. Bolm, Organicsulfur Chemistry in Asymmetric synthesis, 2008, 1-29. 
39 G. E. O’Mahony, A. Ford, A. R. Maguire, J. Sulfur Chem., 2013, 34, 301–341. 
40 C. Cardellicchio, G. Fracchiolla, F. Naso, P. Tortorella, Tetrahedron, 1999, 55, 
525–532. 
41 S. B. Larson, J. S. Day, C. Nguyen, R. Cudney, A. McPherson, Acta Crystallogr. 
Sect. F Struct. Biol. Cryst. Commun., 2009, 65, 430–434. 
42 S. Blaya, R. Chinchilla, C. Nájera, Tetrahedron, 1995, 51, 3617–3626. 
43 N. A. Randive, V. Kumar, V. A. Nair, Monatsh. Chem., 2010, 141, 1329–1332. 
44 Q. F. Zhou, X. P. Chu, S. Zhao, T. Lu, W. F. Tang, Chin. Chem. Lett., 2012, 23, 
639–642. 
45 S.K. Jarchow-Choy, E. Sjuvarsson, H. O. Sintim, S. Eriksson, E.T. Tool, 
J.Am.Chem.Soc., 2009, 131, 5488–5494. 
46 Carney et al., US Patent No.4, 1989, 5488-5494. 
 
118 
 
 TOWARDS THE SYNTHESIS OF AN ACETYL-COA CARBOXYLASE INHIBITOR 
 
 
Acetyl-CoA carboxylase is a biotin dependent enzyme, involved in the synthesis and 
oxidation of fatty acids. It mediates the irreversible carboxylation of acetyl-CoA 2 to form 
malonyl-CoA 33, the rate determining step of fatty acid biosynthesis. Its structure 
consists of three functional domains. These domains are: 
The biotin carboxylase domain (BC) mediates the ATP dependent N -1’ carboxylation of 
biotin 340 to form carboxy-biotin 32. The BC structure contains three domains A, B and 
C. The active site is located at the interface between the B and the A, C domains. The B 
domain undergoes a conformational change. The closed conformation may be significant 
for the catalysis process whereas the open one appears to be associated with substrate 
binding and product release. 
The carboxyl transferase domain (CT) catalyses the carboxylation of acetyl-CoA 2 to 
form malonyl-CoA 33. The CT structure contains two central domains, the N (amino 
terminus) and the C (carboxyl terminus). It shows a dimeric structure with a head-to-tail 
arrangement such that the N domain of one monomer is connected to the C domain of 
the other. 
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Scheme 3.1: Acetyl-CoA carboxylase mediates the first step of fatty acid biosynthesis.1,2 
 
The biotin carboxyl carrier protein (BCC) carries the biotin covalently bound to the Ɛ-
nitrogen of a lysine residue from the carboxyl terminus.1 
Two main isoforms of ACC are present in mammals, ACC1 and ACC2 which differ in 
tissue distribution and function. ACC1 is found in the cytoplasm of all living cells 
monitoring the regulation of fatty acid synthesis, whereas ACC2 is present in oxidative 
tissues and mostly regulates fatty acid oxidation (Scheme 3.1).2 
 
 
Malonyl-CoA 33 is produced within the mitochondria, peroxisomes and cytosol of 
mammalian cells. It is generated by the irreversible carboxylation of acetyl-CoA 2 
mediated by acetyl-CoA carboxylase and it is an intermediate of fatty acid biosynthesis 
and fatty acid elongation (Scheme 3.1). 
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Fatty acid biosynthesis: All the reactions in the fatty biosynthesis process are catalysed 
by a multienzyme complex, the fatty acid synthase (FAS) that carries out the chain 
elongation process from acetyl-CoA 2 and malonyl-CoA 33. Fatty acid synthase exists 
in two forms, Type I and Type II. Type I is a multifunctional polypeptide enzyme 
commonly found in both animals and fungi, whereas, Type II consists of associated 
monofunctional enzymes and is found in archea and bacteria.  
Mammalian fatty acid synthase is a dimer of two 260-kD subunits. Each subunit is folded 
into three domains connected by flexible regions. Domain 1 represents the substrate 
entry and condensation unit and consists of acetyl-transferase, malonyl-transferase and 
β-ketoacyl synthase that mediates the condensation step. Domain 2 is the reduction unit 
and contains the acyl carrier protein (ACP), β-ketoacyl reductase, dehydratase and enoyl 
reductase. Domain 3 serves as the product release unit and accommodates the 
thioesterase. This multienzyme complex, consisting of covalently connected enzymes, 
is highly stable and it allows the transfer of the intermediate products from one active 
site to an another without leaving the assembly. 
Before the elongation of the fatty acids chain process starts, acetyl-CoA 2 and malonyl-
CoA 33 are loaded onto the fatty acid synthase. The acetyl group of acetyl-CoA 2 is 
transferred to a pantothenate group of the acyl carrier protein (ACP), a small peptide 
located in Domain 1 of FAS. The second transfer is from the pantothenate moiety to a 
cysteine thiol (-SH) on FAS. Malonyl-CoA 33 is also transferred in a similar manner to 
acetyl-CoA 2.  
Condensation step: The acetyl 35 and malonyl 34 thioester undergo a condensation 
reaction producing an aceto-acetyl moiety 36 which is bound to the ACP with loss of 
carbon dioxide. In the process, the acetyl-group is transferred to the malonate bound to 
thiol of ACP, forming the aceto-acetyl ACP 36. In each condensation step the acyl chain 
is extended by two carbon atoms.  
Reduction step: The aceto-acetyl moiety 36 generated in the condensation step, 
undergoes a reduction at the keto carbonyl group to form D-β-hydroxybutyryl-ACP 37, 
this reaction is mediated by β-ketoacyl-ACP reductase with hydride donated from 
NADPH.  
Dehydration step: β-Hydroxyacyl-ACP dehydratase catalyses the elimination of water 
from D-β-hydroxybutyryl-ACP 37 to yield crotonyl-ACP 38. 
Reduction step: Butyryl-ACP 39 is generated after reduction of the double bond of 
crotonyl-ACP 38 catalysed by enol-ACP reductase with NADPH as the hydride donor. 
These four reactions, are representative of the first cycle of chain lengthening during 
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fatty acid assembly. The FAS complex operates a series of decarboxylative Claisen 
condensations, extending the C-C backbone for the production of C16 – C18 chain fatty 
acids such as palmitoyl-CoA 343 and linoleoyl-CoA 344.1,3 
 
 
 
Scheme 3.2: An overview of fatty acid biosynthesis.1,3 
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3.3.1. Carnitine acyl transferase regulation: β-oxidation of fatty acids  
 
Carnitine acyl transferase is a mitochondrial enzyme whose function is to facilitate the 
transport of fatty acids across the mitochondrial membrane by converting them to 
carnitine esters. The acyl group is transferred from the acyl-CoA 345 to the hydroxyl 
group of carnitine 346 to generate acyl carnitine 347, which is transferred to the inner 
membrane and converted back to the CoA esters by carnitine palmitoyl transferase II. 
These Co-A esters participate in β-oxidation process of fatty acids, described in Chapter 
1, paragraph 1.2., to generate acetyl-CoA 2.1,4 
 
A 
 
B 
 
 
Scheme 3.3. The degradation of fatty acids: long chain fatty acids broken down into fatty acyl- 
and acetyl-CoA molecules.1,4 
 
Fatty acid synthesis and degradation are simultaneously regulated so they are not active 
at the same time. Acetyl-CoA carboxylase plays a central role in the regulation of fatty 
degradation. Malonyl-CoA 33, reaches high concentration levels and inhibits carnitine 
acyl-transferase preventing access of fatty acyl-CoA to the mitochondrial matrix. Since 
there are not any crystal structures of carnitine acyl-transferase available, its mechanism 
of action is still unclear. Studies are focused on the identification of the residues 
responsible for the inhibition of carnitine acyltransferase by malonyl-CoA 33 in order to 
gain further insight into the control of the oxidation process. Understanding the 
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mechanism of regulation of CPTI by malonyl-CoA is significant in drug development for 
controlling excessive fatty acid oxidation associated to metabolic diseases such as 
diabetes mellitus or cardiovascular diseases.4 
3.3.2. Malonyl-CoA decarboxylase deficiency  
 
Malonyl-CoA decarboxylase, found in bacteria and humans, is one of the enzymes 
responsible for the regulation of malonyl-CoA 33. It mediates the conversion of malonyl-
CoA 33 to acetyl-CoA 2 and carbon dioxide in fatty acid biosynthesis. The exact 
localization of malonyl-CoA decarboxylase remains unclear, whether it resides in the 
mitochondria, the peroxisomes or in the cytosol. Malonyl-CoA decarboxylase is a 
tetramer, each monomer consists of two domains:  
The amino terminus is involved in the oligomerization and possesses a helical structure. 
The carboxyl terminus is where malonyl-CoA catalysis takes place.1,5,6 
The enzyme plays central role in the regulation of fatty acid oxidation as well as in fatty 
acid metabolism. It is believed that the increase of malonyl-CoA decarboxylase activity 
alters malonyl-CoA levels. Variations result in an increase in fatty acid oxidation as is 
observed in diabetes and other metabolic and cardiovascular abnormalities. Dyck et al.5 
have reported the synthesis of two potent inhibitors of cardiac malonyl-CoA 
decarboxylase, CBM-300864 350 and CBM-301940 351. Data showed that MCD 
inhibitors led to an increase of myocardial malonyl-CoA levels and a decrease of fatty 
acid oxidation in both ex vivo rat hearts and pig hearts (Scheme 3.4).  
 
 
 
Scheme 3.4. Malonyl-CoA decarboxylase inhibitors designed for treatment of ischemic heart 
disease.1,3,5,6
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These results suggested that the pharmacological inhibition of malonyl-CoA 
decarboxylase could limit fatty acid oxidation. This in turn leads to an increase of glucose 
oxidation associated with an improvement in the functional recovery of the heart, for 
diseases such as ischemia (Scheme 3.4).5 
125 
 
 
 
Compound CP-640186 352 is a bipiperidinylcarboxamide analogue which has emerged 
as an important inhibitor (IC50 = 55 nM) of both isoform of mammalian acetyl-CoA 
carboxylases. Computational and kinetic studies of the inhibitor-enzyme complex 
suggested that CP-640186 352 is probably located in the biotin active site and it is 
classified as a non-competitive inhibitor. In cell cultures, as well in animal models, CP-
640186 352 seems to reduce malonyl-CoA levels, fatty acids biosynthesis and it 
stimulates fatty acid oxidation. Furthermore, it can reduce body fat mass and body weight 
improving insulin sensitivity. This highlights the potential applications of acetyl-CoA 
carboxylases inhibitors as antiobesity and antidiabetic drugs.7–9 
Acetyl-CoA carboxylase inhibitors also find applications as antibacterial agents, 
controlling the production of infecting organisms that are related to lipid synthesis for 
proliferation. Haloxyfop 353 is used as pre- and post- emergency herbicide in broad leafs 
crops, targeting the CT domain of ACC and shutting down the fatty acid biosynthesis. It 
is an aryloxyphenoxypropionate bearing a characteristic lactate moiety and only the (R)-
isomer is active as herbicide. Crystal structures of yeast ACC with Haloxyfop 353 show 
that binds to the active site, at the interface of the dimer of the CT domain. One of the 
oxygens of the carboxylate group interacts through hydrogen bonding with the amide 
groups of Ala-1627 and Ile-1735 residues. The binding of herbicide 353 leads to a 
conformational change of several residues at the interface, generating a hydrophobic 
pocket and disrupting the domain structure (Figure 3.1).10,11 
 
 
 
 
Figure 3.1: Inhibitor CP-640186 352 and Haloxifop 353 targeting the CT domain. 7–11 
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Mimics of long chain fatty acids have also been designed as inhibitors of the carboxyl 
transferase component of acetyl-CoA carboxylase, mimicking palmitoyl-CoA. A chloro 
acetylated biotin derivative (CABI) 354 was found to inhibit ACC animal and reduce lipidic 
accumulation. It was suggested that, once inside the cell, CABI reacts with endogenous 
co-enzyme A to form analogue CABI-CoA 355 that inhibits the cytosolic isoform of acetyl-
CoA carboxylase. The potential of CABI-CoA 355 to minimise the lipidic accumulation 
makes acetyl-CoA carboxylase an attractive target for the development of anti-obesity 
agents (Figure 3.2).12 Soraphen A 356 is a macrocyclic polyketide natural product 
isolated from the culture broth of Sorangium cellulosum, a soil-dwelling myxobacterium. 
Soraphen A 356 acts as a potent inhibitor of Hepatitis C inhibiting acetyl-CoA 
carboxylase activity by disabling the polymerisation process, targeting the BC domain. 
The inhibitor binds at the interface of the A and C domains of the biotin carboxylase 
component of ACC. X-Ray studies reveal that the oxygens of the methoxy groups are 
hydrogen bonded to the side chain of Arg-276 residue whereas the hydroxyl group 
interacts with the Ser-77 residue.9,13,14 
 
 
 
 
Figure 3.2: Acetyl-CoA carboxylase inhibitors CABI-CoA 355 and Soraphen 356.9,12–14 
127 
 
 
 
On the basis of our previous findings on the inhibition of citrate synthase by 
fluorovinylthioether analogue of acetyl-CoA,15 the β-fluoroacrylate thioether analogue 
357 was envisaged as a mimetic of the enolic form of malonyl-CoA 33. Compound 357 
has a close stereo and electronic profile to 33 (Figure 3.3).  
 
 
 
Figure 3.3: Malonyl-CoA analogue 357 developed as acetyl-CoA carboxylase inhibitor. 
 
Following the strategy outlined previously15,16, it was envisaged that β-fluoroacrylate 
thioether 359 could then be progressed to the full analogue 357 by the three-step 
biotransformation (Scheme 3.5). Soaking crystals of protein-inhibitor complexes will be 
carried out to investigate the inhibitor-protein binding. A non-fluorinated analogue 358 
will also be synthesised as a control compound relative to 357 to assess the “fluorine 
effect” on the binding affinity to the enzyme.  
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Scheme 3.5: Biosynthetic approach for malonyl-CoA analogue 357.15,16 
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It was envisaged that fluorovinyl thioacrylate 362 could be accessed by a silver/iodide 
promoted fluorination of the E:Z mixture of conjugated thioalkenes (E)-333 and (Z)-332. 
The diacetylated conjugated esters (E)-333 and (Z)-332 were prepared by Michael 
addition of pantetheine diacetate 331 with ethyl propiolate giving a mixture of the two 
isomers (E)-333 and (Z)-332 (40:60) in good yield. 17 However, the fluorination of the 
conjugated alkenes with silver fluoride/iodine and triethylamine, did not generate any 
fluorinated product. This is probably due to the electron deficient double bond affecting 
its reactivity towards the silver/iodide promoted fluorination. This can be contrasted with 
diacetyl thioacetylene 363 as a substrate which generated diacetylated fluorovinyl 
derivative 364 on AgF treatment (Scheme 3.6). Compound 364 was synthesised as , 
intermediate for the synthesis of F-CoA 212 ( Chapter 2, Figure 2.4). 15 
 
 
 
Scheme 3.6: The synthetic approach of fluorovinyl thioacrylate 362 from conjugated esters (E)-
333 and (Z)-332 a) methyl propiolate, DBU, THF; b) AgF, I2, Et3N, MeCN. 15,17 
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3.6.1. Synthetic approach to fluorovinyl thioacrylate 359 from thioester precursor 
365 
 
As an alternative approach, it was anticipated that pantothenyl thioether 359 could be 
prepared from thioester 365. Fluorination of 365 followed by a basic hydrolysis could 
offer access to 359 (Scheme 3.7). Due to the instability of the fluoro vinylthioether moiety 
in acidic conditions,15 an acetate protection of the diol group was used rather than the 
common acetal approach. Thus, acetate groups can be removed under basic conditions 
without compromising the stability of the vinyl fluoride in 359.  
 
 
 
Scheme 3.7. Retrosynthetic approach of fluorovinyl thioacrylate 359.15 
 
The target alkynyl thioester 365 was successfully synthesised from diacetyl thio-alkyne 
363. This acetylene was prepared via electrophilic alkynylation of diacetylated 
pantetheine thiol 331 with 1-[(trimethylsilyl)ethynyl]-1,2-benziodoxol-3(1H)-one 366 as 
developed by Waser et al.18 The pantetheine 331 was prepared from 294 with 
cysteamine (Scheme 3.8). 
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Scheme 3.8. Synthetic procedure of thioacetylene 363: a) Cysteamine, HOBt, dry THF, reflux, b) 
TBD, THF, 25 °C, c) TBAF.H2O, THF, 25 °C.18 
 
Several attempts were made to prepare the desired alkyne thioester 365 starting from 
thioacetylene 363. 
The first approach involved an electrophilic acylation of thioacetylene 363. Acetylide 
formation with n-butyllithium was followed by addition of methyl chloroformate. This 
afforded a complex and inseparable mixture of products. A copper promoted acylation 
of 363 offered milder conditions, but there was no obvious formation of the desired ester 
365 (Scheme 3.9). 
 
 
 
Scheme 3.9. Routes to thioester 365: a) n-BuLi, MeCOCl, THF, -78 °C, b) Cu(II)I, MeCOCl, Et3N, 
THF, 25 °C. 
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3.6.2. Palladium chloride oxidative carbonylation of the thioalkene derivative 
 
An alternative carboxylation method to the electrophilic acylation was explored and it 
involved a Pd mediated oxidative carbonylation catalysed by palladium chloride (II). 
Oxidative carbonylation involves the reduction of Pd (II) to Pd (0) followed by the addition 
of an oxidant CuCl2 to re-oxidise the Pd (0) to Pd (II) and rendering the reaction catalytic. 
A base is required to quench the carboxylic acid product. The first step involves the 
formation of copper acetylide 368 followed by insertion of palladium which leads to 
intermediate 369. Treatment of 369 in the presence of carbon monoxide should generate 
370. Methanolysis then generates ester 371(Scheme 3.10).19,20 
 
 
 
Scheme 3.10. General mechanism of the oxidative carbonylation.19,20 
 
Thioacetylene 363 was converted to ester 365 under an atmospheric pressure of carbon 
monoxide at 0°C and at the atmosphere pressure. This used catalytic Pd(II)Cl2 and an 
equivalent of Cu(II)Cl2 (Scheme 3.11 A). An Eglington coupling to form diacetylene 372 
resulted in a significant side product. The mechanism involves the generation of a copper 
(II) alkynyl complex 374, which undergoes dimerization generating 372. The Eglington 
coupling seems to prevail over the oxidative carbonylation affording 372 as the major 
product (Scheme 3.11B).19,20,21 
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Scheme 3.11. A) Palladium chloride(II) mediated oxidative carbonylation of 363 a) Pd(II)Cl2, 
Cu(II)Cl2, CO (1 bar) , NaOAc, MeOH, 0 °C. B) Eglington coupling mechanism.19,20,21 
 
Dimer 372 could be readily distinguished from monomer 365 by 1H NMR as shown in 
Figure 3.4 and particularly from the chemical shift of C3, C3’ (H3, H3’) protons of 372 
versus C6 proton (H6) in 365, and the disappearance of methyl group C1 protons (H1) 
in 372 (Figure 3.4).  
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Figure 3.4. 1H NMR of (A) 372 and (B) 365.  
 
In order to find the optimal conditions to favour a carbonylation over a dimerization 
process, different reaction parameters were varied (Table 3.1). All the reactions were 
monitored by 1H NMR for 18 h. The product: dimer ratio was calculated by 1H NMR. High 
pressures of carbon monoxide were used in order to increase the amount of gas 
dissolved in the reaction mixture and to promote oxidation over the dimerization. At 50 
bars, the formation of additional unidentified side products was observed, thus further 
reducing the overall product yield. 
The temperature seems to play a key role as the ratio between diacetylated thioester 
365 and dimer 372 changes significantly in favour of 372 at higher temperatures (0 °C 
to RT). It appears that the formation of dimer 372 can be minimised by carrying out the 
reaction at lower temperatures (-10 to -40 ºC) (Table 3.1). However, the reaction proved 
to be very sluggish at lower temperatures, failing to go to completion and only affording 
the desired product in low yields (13%). 
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Entry Pressure 
(atm) 
Temp Ratio 
(365:372) + 
Time 
1 1 -36 °C 15:85 18 h 
2 1 -10°C 35:65 18 h 
3 1 0°C 50:50 18 h 
4 50 0°C 32:68 18 h 
 
Table 3.1. Study of the oxidative carbonylation of 363 to generate 365 modulating the pressure 
and the temperature parameters. +The ratio of 365:372 were calculated by 1H NMR. 
 
Further investigation was carried out by changing the oxidant, the base, and the catalyst  
(Table 3.2). For example, when triethylamine replaced sodium acetate only dimer 372 
was obtained. The same result was observed when PdCl2(PPh3)2 was used in place of 
PdCl2. Most positively replacement of CuCl2 with benzoquinone as the oxidant, afforded 
a 1:1 mixture of 46:54.  
 
Entry Base Catalyst Additive Solvent Temp/Time Ratio 
(365:372) 
1 TEA PdCl2 CuCl2 MeOH 0°C/ 18h 0:100 
2 AcONa PdCl2(PPh3) CuCl2 MeOH 0°C/ 18h 0:100 
3 AcONa PdCl2 Benzoquinone MeOH 0°C/ 18h 46:54 
 
Table 3.2. Investigation of the oxidative carbonylation of 363 to generate 365 varying base and 
additive. 
 
Despite these efforts to improve the outcome of the oxidative carbonylation, the reaction 
was neither predictable or reproducible and the yields of 365 were not considered useful 
for synthetic purposes.  
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3.6.3. Synthesis of ethyl ester via imidazolium sulfurane electrophilic 
alkynylation 
 
An alternative synthetic procedure involved an electrophilic alkynylation of thiols using 
an alkynyl imidazolium sulfurane 382 as described by Alcarazo et al.22,23 These 
interesting reagents have been investigated in electrophilic group transfer reaction such 
as electrophilic cyanation. Generally yields are good (Scheme 3.12).22,23 
 
 
 
Scheme 3.12. Study of imidazolium sulfuranes as electrophilic group transfer reagents.22,23 
 
Given the similarity in electronic structure between cyanides and alkynes bearing 
electron withdrawing substituents, imidazolium thioesters were also studied as 
electrophilic group transfer reagents. The imidazolium sulfurane 382 mediated 
electrophilic alkynylation of different sulfides, bearing electron rich and electron poor 
substituents also gave good results.  
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The mechanism suggested for this reaction, is an electrophilic substitution process as 
described by Frei et al.18,24 for the hypervalent iodine reagent. The reaction is believed 
to proceed via a triangular atomic arrangement between thiol sulfur thiolate 388, the 
iodine of the hypervalent reagent (I (III)) 386 and the α-carbon atom of the protected 
acetylene derivative 387. Nucleophilic addition of the anion sulfide in 388 to the α-carbon 
atom of the acetylene derivative in 387 with concomitant cleavage of the S(imidazolium)-
C bond, generates thioacetylene 391 (Scheme 3.13). 
 
 
 
 
Scheme 3.13. Mechanism of the hypervalent iodine agent (TMS-EBX) with a thiol as reported by 
Frei et al.18,22–24 
  
138 
 
The alkynyl imidazolium sulfurane 382 described by Alcarazo et al.,22 was prepared from 
diisopropylthiourea 392 and acetoin 393 to generate 394. When treated with bromine 
this gave dibromide 395. 
  
 
 
Scheme 3.14. Route to ethyl thioester 398 using imidazolium 382: a) 1,3-diisopropyl-2-thiourea 
393, 1-hexanol, 158 °C b) Br2, dry DCM, 0°C, c) and d) silver ethyl propiolate 396, silver 
hexafluoro antimonate, dry DCM, 25 °C, e) DIPEA, 25 °C.22,23 
 
Silver propiolate 396 was added to a solution of 395 in dichloromethane which led to the 
alkynylated imidazolium 397 as a dibromo-argentate salt, which in the presence of 
AgSbF6- afforded 382. Treatment of the diacetylated pantetheine 331 with 382 resulted 
in a rapid conversion of the starting material over 10 min yielding product 398 although 
in low yield (10%), along with a complex mixture of by-products which proved hard to be 
separated and identify. 1H NMR analysis indicated that the ratio of product 398 : by-
products was roughly 15:85 (Scheme 3.14).22 
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Screening of different bases and solvents was performed to optimize the yield of the 
reaction and to minimize side reactions. 
 
 
Entry 
 
Base 
 
Temp. 
 
Time 
 
Solvent 
Ratio 
(398: side-
products) 
1 Pyridine RT 30 min DCM 13:87 
2 NaHCO3 RT 30 min Dioxane 10:90 
3 DBU RT 30 min DCM 0:100 
4 DIPEA -78 °C 30 min DCM 0:100 
5 DIPEA 0 °C 30 min DCM 16:84 
6 DIPEA 40 °C 30 min DCM 0:100 
 
Table 3.3. Exploring different bases and solvents for the preparation of 398 
 
As shown in Table 3 (Entry 1-3), modulation of base strength did not improve the product 
ratio, indicating that the best base was DIPEA. Also varying the temperature did not 
seem to affect the ratio significantly (Entry 4-6). Furthermore, scale up of the reaction 
seemed to significantly decrease the yield of the product with the promotion of the side 
reactions. Therefore, due to this problem and the lack of reproducibility, this synthetic 
procedure was not developed any further. The sulfide substrates reported by Alcarazo 
et al.23 are generally aryl-substituted except for 385 reported in Scheme 3.12, thus the 
low yield with pantetheine 331 could be related to its more complex and acyclic structure.  
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The fluorination of alkyl thioester 365 was investigated analytically due to the limited 
amount of material available.  
Thus, compound 362 was prepared by conjugate addition of hydrogen fluoride to ester 
365 as reported by Li et al. 25 using silver fluoride (AgF) in a mixture of water and 
acetonitrile. This gave the (E)-stereoisomer 362 only in moderate yield. The E-
stereoisomer was identified by 1H NMR (C3 proton, J = 33.6 Hz) , 19F NMR (with proton 
decoupled -70.51 ppm) and High-Resolution electron spray ionisation mass 
spectrometry (HR-ESI-MS). The molecular ion (M+) peak found for 362 is 487.1507 
which corresponds to [M + Na] + equal to C19H29O8N2FNSNa (Scheme 3.15). The ability 
of silver fluoride to introduce a fluorine atom into compound 365, lies mostly within the 
electrophilic character of the alkynyl ester moiety, which reacts as a Michael acceptor 
and allows the reaction to occur even in the presence of water, which lowers the 
nucleophilicity of fluoride anion; however silver fluoride could be acting as a Lewis acid, 
activating the alkyne and therefore increasing its reactivity. 
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Scheme 3.15. The A) 1H NMR, B) 19F NMR and HR-ESI-MS spectra of fluorovinyl thioacrylate 
362.25 
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Treatment of compound 362 with lithium hydroxide in methanol gave methyl ester 399 
as a result of an addition/elimination reaction. (Scheme 3.16).26 Compound 399 was 
detected by HR-MS ( the molecular ion peak (M+) found is equal to 415.1509 which 
corresponds to [C16H28O7N2NaS]). A THF/H2O mixture, as used for the hydrolysis of (Z)-
332 and (E)-333 in Chapter 2, instead of MeOH as solvent may overcome the addition-
elimination reaction.  
 
 
 
Scheme 3.16. Addition-elimination reaction of 359: a) LiOH 2M, MeOH, 25 °C.26 
 
Access to acetylenic ester 365 and 398 proved to be challenging. The synthetic 
approaches reported gave the desired product in low yield and lacked reproducibility. 
Consequently, these synthetic methods were not useful for scale up. Fluorovinyl 
thioacrylate 362 was prepared analytically but could not be hydrolysed to 359 and 
consequently it could not be progressed to the desired malonyl-CoA analogue 357.  
143 
 
 
 
Chapter 3 focused on the attempted synthesis of fluorovinyl thio-acrylate-CoA 357 as an 
analogue of malonyl-CoA 33. It was envisaged that fluorovinyl thio-acrylate-CoA 357 
could be accessed from hydroxylated pantothenyl precursor 359. 
 
 
 
Scheme 3.17. Design of a malonyl-CoA analogue as inhibitor of acetyl-CoA carboxylase 
 
A silver mediated fluorination of conjugated thioesters (E)-333 and (Z)-332 mixture, 
precursors of acetyl-CoA (E)-320 and (Z)-319 analogues reported in Chapter 2, did not 
give the desired products and not side products were detected. The starting material 
proved to be unreactive under these conditions. The presence of an electron withdrawing 
group such as an ester moiety in (E)-333 and (Z)-332 may affect the electrophilic addition 
on the alkenyl moiety, limiting silver activation of the double bond.  
Then, it was anticipated that target 362 could be also accessed from thioester 365. Three 
main synthetic approaches were attempted to access thioester 365. 
The first synthesis was an electrophilic acylation of thioacetylene 363 which did not 
generate the desired thioester 365. 
The second approach chosen involved a palladium catalysed oxidative carbonylation of 
acetylene 363. The reaction gave thioester 365 in low yield and also dimer 372 as the 
major product.20,21,22 Dimerization was minimized by working at a higher pressure of 
carbon monoxide. These results were however not reproducible and did not prove useful 
for a reliable synthesis. Finally a synthesis of thioester 365 was explored involving 
electrophilic alkylation of pantetheine 331 with imidazolium sulfurane 382 which was 
used as an electrophilic transfer reagent.22,23 The alkynylation gave thioester 398 
however in poor yield and as a mixture of side products which could not be identified. A 
wide range of parameters were varied to optimize the yield of the product and minimize 
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the side reactions. However, the attempted scale up of the product led to a poor outcome 
and the method was not pursued.  
 
 
 
Scheme 3.18. Attempted synthesis of diacetyl thioester precursor 365 and 398.20-24 
 
Fluorovinyl thioacrylate 362 was synthesised in analytical scale by silver mediated 
fluorination of diacetylated thioester 365. E-fluorovinyl thioacrylate 362 25 was identified 
and characterized by NMR and mass spectrometry. The attempted hydrolysis of E-
fluorovinyl thioacrylate 362 with sodium methoxide in methanol however did not give the 
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desired compound 359, but 399 as a result of a nucleophilic attack by methoxide followed 
by fluoride elimination. (Scheme 3.19) 
 
 
 
Scheme 3.19. The analytical scale investigation of the fluorination and the hydrolysis step for the 
synthesis of derivative 359.  
 
The synthesis of thioester 365 and 398 proved to be challenging. The synthetic 
approaches adopted gave 365 and 398 in low yields and lacked reproducibility despite 
the optimization efforts. Thus, fluorovinyl thioacrylate could not be progressed to its 
coenzyme-A form 358. Further work should be focused on the optimization and 
reproducibility of the oxidative carbonylation reaction. A parameter that has not been 
investigated is the concentration of the solution, thus working with more diluted 
concentrations might overcome the dimerization. A different synthetic approach could be 
used for the synthesis of 365. The thioester could be accessed from the coupling reaction 
of 294 and amine 402 to generate 403. Finally, deprotection of 403 should give the 
desired product 365. The protection of the ester in 402, should overcome any potential 
cyclization from the reduction of azide 401 to amine 402 (Scheme 3.20).   
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Scheme 3.20. The proposed alternative synthetic route to 365. 
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 SELECTIVELY FLUORINATED ANALOGUES OF ACETYL-COA 
 
 
The difluoromethylene moiety has been explored as a bio isostere of the carbonyl group 
in a wide range of bioactive molecules. It was found to be an effective mimic of a ketone 
when incorporated into inhibitors of the FKBP proteins, belonging to the immunophilin 
family. FKBP is a prolyl isomerase which catalyses the interconversion between cis and 
trans isomers of peptide bonds at the amino acid proline and it assists the folding of 
these proteins. Due to their properties, FKBP has been associated with many 
inflammatory diseases such as atherosclerosis, arthritis and viral infections. Tacrolimus 
404 is an immune suppressive drug that inhibits prolyl isomerase activity by binding 
FKBP12 and promoting the production of T-cells stimulating for the body’s immune 
response. Immunosuppressive inhibitors GPI-1046 405 and V-10367 406 were also 
designed as FKBP12 inhibitors. These are analogues of tacrolimus 404, replacing the 
macrolide moiety with a pyrrolidine ring in 405 and a piperidine ring in 408. The 
replacement of the α-ketone in derivatives 405 and 408 with a CF2 moiety led to the 
synthesis of derivatives 406 and 407 which are more potent inhibitors of FKBP12 than 
407 and 408. 2-Aryl-2,2-difluoroacetamide 407 was designed as mimic of the inhibitor V-
10367 408 of FKB12. The X-ray studies of the crystal structure of the protein with inhibitor 
407 indicated that one of the fluorine atoms mimics the hydrogen bonding interaction of 
the ketone in 408 with the hydroxyl of Tyr-26 on the enzyme, whereas the other fluorine 
atom interacts with a meta hydrogen of Phe-36 (Figure 4.1).1 
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Figure 4.1. Difluoromethylene analogues of the non-immunosuppressive inhibitors of FKBP 
binding proteins.1 
 
CF2 incorporation has also found applications in the development of inhibitors targeting 
the Ɣ-secretase as shown in Figure 4.2. Ɣ-secretase is a multi-subunit protease complex 
responsible for the cleavage of the transmembrane domain of the amyloid-β-protein 
precursor into the amyloid β-protein (Aβ), the main component of the amyloid plaques 
found in Alzheimer patients. The design of Ɣ-secretase inhibitors failed due to their side 
effects such as skin cancer and they seemed to be related to the inhibition of NOTCH 
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processing activity. The NOTCH receptor is a transmembrane protein vital for many 
cellular systems, its inhibition is usually associated with a wide range of disorders and 
malignancies. The introduction of a difluoro moiety in 410, as a replacement for the 
carbonyl group, enhanced metabolic stability over 411 to cytochrome P450 3A4 
enzymatic oxidation. 2,3 
 
 
 
Figure 4.2. Increase of the metabolic stability of Ɣ-secretase inhibitors by incorporation of the 
difluoro methyl moiety.2,3 
 
Xiamuxi et al.4 reported the study of tetrahydropyridomidinone derivatives as potential 
antipsychotics bearing an arylpiperidine ring, as D2, 5-HT1A, 5-HT2A receptors 
antagonists. Compound 412 was prepared as a derivative of 413 with a difluoro moiety 
replacing C=O; it showed higher agonist activity than ketone 413 (Figure 4.3). 
 
 
 
Figure 4.3. The higher potency of difluoro 412 as D2 and 5HAT2A receptor antagonist than ketone 
413.4 
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The difluoro ethyl thioether motif possesses a methyl group bound to a carbon bearing 
two strong electron withdrawing fluorine atoms. Consequently, the methyl group 
hydrogens are highly polarised and can act as hydrogen bond donor, although more 
lipophilic than hydroxyl or amine. The incorporation of this motif into a molecule can 
impact its chemical and biological activity. Based on the encouraging results obtained 
for the inhibition of citrate synthase by FV-CoA 212,5 a α,α-difluoroethyl-CoA analogue 
of acetyl-CoA 414 became a target to assess the electronic interaction within the active 
site of the enzyme. It was envisaged that the α,α,-difluoroethyl-CoA analogue 414 could 
be accessed from difluoroethyl thioether 415 by the three-step biotransformation used 
for the synthesis of previous Co-A analogues (Scheme 4.1).16 
 
 
 
Scheme 4.1. Design of a difluoroethyl thioether-CoA 414 analogue of acetyl-CoA.  
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One of the most common strategies for gem-difluorination, is the conversion of 
aldehydes and ketones 416 with nucleophilic fluorinating agents such as 
diethylaminosulfur trifluoride (DAST) or Deoxo-fluor. A DAST mediated nucleophilic 
substitution has also been applied to the synthesis of β,β-difluoro-α-keto esters 419 as 
serine protease inhibitors by Parisi et al. 32 The β,β-difluoro-α-keto esters derivatives can 
generate difluoro hemiacetals 418 that mimic intermediate 420 in the serine protease 
inhibition process (Scheme 4.2).6,7 
 
 
 
Scheme 4.2. Difluoromethylene motif as serine protease inhibitors.6,7 
 
Another synthetic approach to difluoromethylene motifs involves electrophilic fluorination 
of activated methylene groups bearing electron withdrawing groups such as β-keto 
esters or amide 421. The most common fluorinating agents are Selectfluor 428, N-fluoro 
benzensulfonimide (NFSI) 427 and N-fluoro-o-benzenedisulfonimide (NFOBS) 426. 6 
Umemoto et al 35 has achieved 2,2-difluorination of malonate derivative 422 with the N-
fluoro pyridinium reagent 423 in the presence of a strong Lewis acid catalyst such as 
aluminium trichloride (Scheme 4.3).8   
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Scheme 4.3. Difluoromethylene formation from carbonyl from β-keto esters.6 
 
Prakash et al.9 have reported the reaction of 2,2-diaryl-1,3-dithiolanes 429 with 
Selectfluor and pyridinium polyhydrogen fluoride (PPHF) under mild condition to give the 
gem-difluoro compounds 430 in good yields (Scheme 4.4). 
 
 
 
Scheme 4.4. The difluorination reaction of dithiolanes with Selectfluor/PPHF.9 
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Bello et al.10 reported that the treatment of substituted alkenyl sulfide derivatives 431 with 
an excess of Olah’s reagent promotes difluorination over monofluorination. Thus, it was 
considered that difluoro ethyl thioether 415 could be accessed by difluorination of 
thioacetylene 363 followed by basic hydrolysis (Scheme 4.5).  
 
 
 
Scheme 4.5. A) Olah’s reagent mediated fluorination,10 B) approach to the synthesis of 415 
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α,α,-Difluoroethyl thioether 415 was prepared by hydrofluorination of thioacetylene 363. 
This synthesis was achieved by reaction of 363 with Olah’s reagent (70 % Hydrogen 
fluoride pyridine).11 Using an excess of HF pyridine, double addition to 363 generated 
the difluoro ethyl ether 433. A side product of the reaction is suggested to be the thioester 
434 due to the instability of the difluoro moiety under the acidic conditions. The mixture 
could not be separated by column chromatography due to their closer retention times. 
However, purification could be achieved by HPLC (reverse phase). Difluoroethyl 
thioether 433 was hydrolysed under basic conditions generating diol 415 in good yield 
(69%) (Scheme 4.6).11 
 
 
 
 
Scheme 4.6. Synthesis of 415. a) Olah’s reagent (70 % HF pyridine, dry CH2Cl2, 25 °C, b) MeONa 
(5.4 M in MeOH), MeOH, 0 °C.11  
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Difluoroethyl thioether 415 was incubated with the ATP dependent enzymes, PanK and 
PPAT, respectively to achieve the first and second steps of the biotransformation to the 
CoA analogue 414.5 However, no fluorine signal could be detected by 19F NMR after 16 
h of this incubation (Scheme 4.7). 
  
 
 
Scheme 4.7. Attempted progression of compound 415 to co-enzyme-A form 414 by the three-
step biotransformation.  
 
The loss of the fluorines in 415, is presumably related to the instability of the difluoroethyl 
moiety in the buffer solution used (pH 7-8) or to its vulnerability in the enzymatic 
environment. In order to investigate this, two experiments were set up and monitored by 
19F NMR: 
Compound 415 was incubated in buffer at pH 7-8 with ATP and MgCl2 (essential for ATP 
activation) and the solution was monitored for 16 h. In the second experiment, 415 was 
incubated with buffer (pH 7-8), ATP, MgCl2 and pantothenate kinase (PanK), the first 
enzyme involved in the biosynthetic pathway of acetyl-CoA. The reaction was also 
monitored for 16 h. As illustrated in Figure 4.4, the 19F NMR spectra of both solutions 
show the gradual disappearance of the organic fluorine signal. 
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Experiment 1: compound 415 + ATP + MgCl2 + Tris-HCl + water, incubation at 37 °C 
 
 
Experiment 2: compound 415 + ATP + MgCl2 + Tris-HCl + PanK + water, incubation at 37 °C 
 
 
Figure 4.4. The 19F NMR study of difluoro ethyl thioether 415 stability.  
 
It can be assumed that the α,α-difluoroethyl thioether moiety 415 is not stable in the 
buffer solution at pH 7-8 and that the instability of 415 under these conditions leads to 
fluorine loss, hence it cannot be progressed to its coenzyme-A analogue 414. 
2 h incubation 
4 h incubation 
16 h incubation 
 
 
16 h incubation 
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Cyclopropane has a ring strain due to the 60°C bond angle. It also possesses significant 
torsional strain due to the eclipsing of its hydrogen atoms.12 
 
 
Figure 4.5. The cyclopropane structure.12 
 
Cyclopropane is the smallest and most conformationally constrained cycloalkane. A 
motif that is present in a wide range of natural products and biomolecules. The 
incorporation of a cyclopropane ring offers rigidity and hydrophobicity as a motif for the 
development of drugs. The introduction of fluorine into a cyclopropane, combining the 
unique properties of the cyclopropane ring and the fluorine atom, can offer new scaffolds 
for the synthesis of bioactive molecules. Lemonnier et al.13 have reported the synthesis 
of monofluorinated cyclopropanes as analogues of glutamic acid 439 and tested these 
as antagonists mGluR4 receptor. mGluR4 belongs to the family of the metabotropic 
glutamate receptors in which glutamate is an excitatory transmitter. 
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They feedback by inhibiting the production of cyclic adenosine monophosphate (cAMP) 
by adenylyl cyclase, minimizing glutamate release in the synapse whose excessive 
production is associated with many neurodegenerative disorders such as Parkinson’s 
disease. Cyclopropane (±) (Z)-FAP4 440 displayed an antagonist activity towards 
mGluR4 with an EC50 of 340 nM (Figure 4.6).13 
 
 
 
Figure 4.6. Applications of monofluorinated cyclopropane motifs in drug development.13,14 
 
Furthermore, the fluorinated cyclopropane 442 was designed as a valproic acid analogue 
441 to compensate the teratogenicity and hepatotoxicity associated with this 
anticonvulsant drug. This analogue presented no teratogenic effect and the two 
quaternary carbons at the β position of the carboxyl group block its degradation to 
hepatotoxic metabolites.14 
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The selective introduction of fluorine into a molecule will increase its polarity and 
modulate its lipophilicity. 14 The synthesis of aryl α, α, β-trifluoro cyclopropane derivatives 
was investigated by Thomson et al.15 at the University of Saint Andrews as potential 
building blocks in drug design.  
 
 
 
Scheme 4.8. Previous synthesis of trifluoro cyclopropane derivatives.38,39,40 
 
Two syntheses of this motifs were reported so far. Oshiro et al.16 described the 
preparation of trifluoro cyclopropane 448 as minor product after the addition of 
difluorocarbene to silyl enol ethers to generate 448. The second synthetic approach 
involved the addition of phenyl(trifluoromethyl)mercury to vinyl fluorides 443 to generate 
444,17 however the toxicity of mercury reagents makes this approach less attractive 
(Scheme 4.8). 
The St Andrews group reported the synthesis of aryl α,β,β-trifluoro cyclopropane 
derivatives 452 from α-fluoro styrenes 449 bearing different functionalities in the para- 
position of the phenyl ring. Bromo-fluorination of styrene 449 followed by dehydro-
bromination gave access to the α-fluoro styrenes 451. Reaction then with 
difluorocarbenes, generated from the Ruppert-Prakash reagent, to vinyl fluorides offered 
a good route to the α,α,β-trifluoro cyclopropane derivatives 452. These cyclopropanes 
are robust enough to be derivatised in palladium (III) coupling reactions (Scheme 4.9).15 
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Scheme 4.9. Synthesis and reactivity of the aryl α,α,β-trifluoro cyclopropane derivatives.15 
 
RuCl3/NaIO4 mediated aryl oxidation generated the corresponding α,β,β-
trifluorocyclopropane carboxylic acid 457, which was used to prepare a wide range of 
amides 458 (Scheme 4.10A). Amide 458 were found to undergo an elimination-addition 
reaction with phenols and thiophenols as nucleophiles presumably through the formation 
of intermediate 459 although this cyclopropane intermediate was not observed. This 
reactivity is believed to be associated with the polar nature of the α,β,β-
trifluorocyclopropyl ring conferring reactivity and offers potential for the design of suicide 
inhibitors with nucleophiles on enzyme active sites (Scheme 4.10B).15 
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Scheme 4.10. A) The synthesis of the α,β,β-trifluorocyclopropane carboxylic acid by RuCl3/NaIO4 
mediated oxidation and investigation of its reactivity. B) the study of the amide derivatives 
reactivity with thiols and alcohols.15 
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It was anticipated that the α,β,β-trifluoro-cyclopropane motif could be introduced as 
acetyl-CoA analogue 462 where the sulfur atom is replaced by an amide bond. This 
substrate will then be investigated as an inhibitor of citrate synthase. It has the potential 
to act as a mechanism based covalent inhibitor (Scheme 4.11).  
α,β,β-Trifluorocyclopropane is polar due to the presence of the three fluorine atoms on 
the ring and it is already demonstrated to be reactive towards alcoholates and thiolates.  
  
 
 
Scheme 4.11. Design of α,β,β-trifluorocyclopropane-CoA 462 as an analogue of acetyl-CoA. 
  
165 
 
 
 
Cyclopropyl analogues of acyl-CoA have been reported in the past. Hypoglicin A 464 is 
found in mature ackee fruit which causes Jamaican vomiting sickness and it is identified 
as (+)-α-amino-2-methylenecyclopropaepropionoic acid 464. Hypoglycin A 464 is 
converted to methylenecyclopropanepyruvic acid by transamination followed by an 
oxidative decarboxylation to give highly toxic (R)-2-methylenecyclopropaneacetic acid 
(MCPA) 465. The coenzyme ester MCPA 466 interacts irreversibly with the FAD cofactor 
of pig kidney acyl-CoA dehydrogenase, generating a complex that inactivates the 
enzyme. 
Medium chain acyl-CoA dehydrogenase is involved in the first step of the β-oxidation of 
fatty acids. It catalyses the first dehydrogenation reaction to generate a α,β-unsaturated 
double bond. Medium chain acyl-CoA dehydrogenase deficiency is associated with the 
inability of the body to carry out fatty acid degradation. This deficiency is usually 
associated with hypoglycemia (low blood sugar) and to sudden death.  
 
 
 
Scheme 4.12. Inhibition of acyl-CoA dehydrogenase by MCPA-CoA.19 
 
The inhibition of the enzyme by exo-methylene cyclopropene 466 has been investigated. 
Baldwin et al.18 reported that inhibitor 466 reacts with the flavin co-factor rather than 
amino acid residues of the active site. Wenz et al.19 proposed an initial α-deprotonation 
166 
 
of the cyclopropane of 466 followed by ring opening to give intermediate enolate radical 
469. The reaction of 469 with the active site flavin then generates adduct 470 (Scheme 
4.12). 
In 1996, Li et al.10 reported that methylenecyclopropylformyl-CoA (MCPF-CoA) 472 
inhibits irreversibly enoyl-CoA hydratase (Chapter 1), from bovine liver, which is involved 
in the β-oxidation of fatty acids and in the catabolism of branched chain amino acids 
(BCAA). It was suggested that methylenecyclopropylglycine (MCPG) 471, extracted from 
litchi fruits, is converted to toxic metabolite MCPF-CoA 472, blocking the β-oxidation 
process. The proposed mechanism for the inactivation of enoyl-CoA hydratase by 
MCPF-CoA 472 may involve a nucleophilic attack on the electrophilic cyclopropyl moiety 
of MCPF-CoA, bearing electron-withdrawing groups, followed by a ring-opening reaction 
(Scheme 4.13).  
 
 
 
Scheme 4.13. MCPF-CoA 472 as an irreversible and covalent inhibitor of enoyl-CoA hydratase.10 
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Trifluoro-cyclopropane-CoA 462 was prepared from the hydroxylated precursor 479 by 
the three-step protocol described previously for the synthesis of the other analogues of 
acetyl-CoA. The synthetic approach chosen for the preparation of 479 involved amide 
coupling using α,β,β-trifluorocyclopropane carboxylic acid 457 (prepared by Dr Q.Zhang 
from the University of St Andrews) 15 and Boc-protected amine 475 to generate the 
corresponding amide 476. Amide 476 was then treated with an excess of trifluoro acetic 
acid in dichloromethane to give amine 477 as a salt. Excess trifluoroacetic acid in the 
product was reduced by co-evaporation with toluene under high pressure followed by a 
C-18 cartridge purification.  
 
 
 
Scheme 4.14. Synthesis of hydroxylated trifluoro cyclopropane derivative 479: a) HOBt, EDCI, 
Et3N, DMF, 0 ° to 25 °C, b) TFA excess, DCM, 25 °C, c) HOBt, EDCI, Et3N, DCM, 0° to 25 °C, d) 
AcONa (5.4 M in MeOH), MeOH, 0°C, e) HOBt, EDCI, Et3N, DMF, 0° to 25 °C, f) pTsOH, 
THF:H2O, 0 °. 
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The next step involved the coupling of amine 477 with pantothenic acid derivative 294 to 
generate the resulting amide 478. This was achieved but in low yield. It was found that 
the trifluorocyclopropane moiety is unstable under basic conditions while it is relatively 
stable under acidic conditions. Thus, a derivative of pantothenic acid bearing the 
acetonide moiety as the protecting group 480, was used for the coupling reaction with 
amine 477.20 The acetonide protecting group was then removed under acidic hydrolysis 
conditions without compromising the integrity of the fluorinated cyclopropane. Thus, 
treatment of compound 481 with pTsOH, gave the free diol 479 in good yield (Scheme 
4.14). 
Cyclopropane 479 was finally progressed to its co-enzyme A analogue 462 by the three-
step biotransformation described by Wright et al.5,21 Pank and PPAT mediated enzymatic 
reactions gave intermediate 483, which was isolated by HPLC and identified by the 1H 
NMR and 19F NMR spectra reported in Figure 4.7. 
  
 
 
Scheme 4.15. The three-step biotransformation to 462 
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Figure 4.7. A) The 1H NMR and B) 19F NMR spectra of 483. 
 
The 1H NMR spectra of 483 shows the characteristic signals of the two non-equivalent 
cyclopropyl ring C21cis, C21trans protons (H21cis, H21trans) and of the adenosine moiety 
 
 
A 
B 
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protons with C2, C8 protons (H2, H8) belonging to adenine and C1’, C2’,C3’,C4’ and C5’ 
protons (H1’, H2’, H3’, H4’, H5’) to the nucleoside. 19F NMR (with proton decoupled) 
shows the non-equivalent CF2 and CF signals of the cyclopropyl ring. The ABX pattern 
at -140 ppm belongs to the CF2 (2JFF = 165.1 Hz, 3JFFcis = 11.5 Hz) whereas the doublet 
of doublets at -200 ppm relates to the CF (3JFFcis = 11.0 Hz, 3JFFtrans = 3.0 Hz).  
Intermediate 483 underwent a DPCK mediated phosphorylation at the 3’-hydroxyl group 
to successfully generate α,β,β-trifluorocyclopropyl-CoA 462.This compound (3 mg) was 
purified by HPLC (retention time =16.20 min). The 1H NMR of α,β,β-trifluorocyclopropyl-
CoA 462 illustrated in Figure 12 shows that C2’,C3’ protons (H2’, H3’) are shifted 
downfield compared to C2’,C3’ protons (H2’, H3’) in the H1 NMR spectra relative to 
precursor 483 (Figure 4.7). The downfield shift for C2, C3’ protons for compound 462 is 
associated with the further phosphorylation on the hydroxyl group (O3’) of the ribose 
ring.  
 
 
 
Figure 4.8. 1H NMR spectra of 462  
 
All the peaks relative to 462 were assigned by 1H NMR, 1H-1H-2D-COSY NMR spectra 
and by comparison with dethia fluorovinyl-CoA. As for 483, the non-equivalent protons 
of the cyclopropyl were significant for the identification of 462. The 19F NMR (with proton 
coupled) spectra, shown in Figure 4.9B, confirms the ABX pattern at – 140 ppm for the 
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CF2 and the quintet for CF due to the coupling with C21cis and C21trans protons (H21cis, 
H21trans).  
 
 
 
 
 
Figure 4.9. A) 2D-COSY and B) 19F NMR spectra of α,β,β-trifluorocyclopropyl-CoA 462. 
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α,β,β-Trifluorocyclopropyl-CoA 462 was successfully synthesized in good yield and was 
investigated as an inhibitor of citrate synthase using the protocol described in Chapter 
2. 
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The inhibitory activity of 462 was assessed by calculating its IC50 with citrate synthase. 
The IC50 value (346.1 µM) was rather high with a Ki of 65.2 µM. This can be compared 
to the Km of acetyl-CoA (Km = 5.8 µM). Although there is some affinity with the enzyme, 
the steric effect of the cyclopropane is most probably impeding good binding (Figure 
4.10). 
IC50 = 346.1 (± 56.4) µM 
Kiapp = 65.2 (± 11.0) µM 
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Figure 4.10. The IC50 and Ki computed values for α,β,β-trifluorocyclopropyl-CoA 462. 
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Chapter 4 focused on the design of a difluoro ethyl thioether-CoA and a trifluoro 
cyclopropyl-CoA analogues of acetyl-CoA. Both acetyl-CoA analogues were accessed 
from their pantothenyl precursors via the three step biotransformation. 22,5  
Difluoro ethyl thioether diol 415 was prepared by the synthesis reported previously in 
Scheme 4.5. Precursor 415 was found to be unstable in the buffer conditions used for 
the biotransformation (pH 7-8) leading to fluorine elimination (Scheme 4.16).  
 
 
 
Scheme 4.16. Attempted synthesis of difluoro ethyl thioether-CoA 414 
 
As shown in Figure 4.4, paragraph 4.6, two experiments were set up to understand if the 
loss of fluorine was related to the buffer conditions used or whether something was 
happening in the enzymatic environment. From the test results, it is believed that the 
difluoroethyl moiety is unstable under the buffer conditions (pH 7-8) used for the 
enzymatic assay. 
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α,β,β-Trifluorocyclopropyl-CoA 462 was prepared by the three step biontrasformation 
from cyclopropane α,β,β-trifluorocyclopropyl pantetheinyl derivative 479 following the 
procedure described in Scheme 4.14. α,β,β-trifluorocyclopropyl-CoA 462 was found to 
be a poor inhibitor of porcine citrate synthase (Ki = 65.2 µM). It can be assumed that the 
α,β,β-trifluorocyclopropyl moiety does not fit properly in the enzyme cleft due to its 
bulkiness , hence affecting its binding affinity for the enzyme.  
 
 
 
Scheme 4.17. The synthesis of α,β,β-trifluorocyclopropyl-CoA 462 and its investigation as 
inhibitor of porcine citrate synthase 
 
Future work should be focused on the investigation of 462 as covalent inhibitor of citrate 
synthase and other acyl-CoA utilising enzymes such as malate synthase. Compound 
462 will be incubated with the selected protein. Its molecular weight will be monitored by 
mass spectroscopy to detect any kind of variation.  
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 EXPERIMENTAL SECTION 
 
 
All commercially available reagents were purchased from Acros, Alfa Aesar, Fisher 
Scientific, Fluorochem or Sigma-Aldrich and used without further purification. 
Reactions were performed under an atmosphere of argon using standard vacuum line 
techniques, unless otherwise stated. All glassware was oven-dried and allowed to cool 
down under high vacuum. All reactions that involved the use of HF-containing reagents 
were conducted in teflon round bottom flasks previously oven-dried and allowed to cool 
under high vacuum. Dry solvents dichloromethane, tetrahydrofuran, methanol were 
obtained from the MBraun SPS-800 Solvent Purification System, by passing the solvent 
through two drying columns under an argon atmosphere. Temperature of 0 °C was 
obtained using an ice/water bath. Reactions requiring heating or reflux were carried out 
using a heating block with a contact thermometer. 
Thin layer chromatography (TLC) was performed using Merck TLC silica gel 60 F254 
glass-backed plates. Compounds were visualised by either UV light (254 nm) or by the 
use of potassium permanganate stain or molybdenum-based stain. Reverse-phase 
preparative HPLC column chromatography were performed using a Shimadtzu 
Prominence® HPLC system (either using UV-Vis or diode array detectors), a Waters 
600E multisolvent HPLC system coupled to a Waters 2487 dual wavelength absorbance 
detector or a Waters 2795 HPLC system coupled to a Waters LCT-MS mass detector, 
and a semipreparative Phenomenex Synergi® 4μ Polar-RP 80Å 250 x 10.0 mm column, 
eluting with mixtures of acetonitrile and water with or without using trifluoroacetic acid as 
a modifier. Optical rotations were measured in a 10 cm length cuvette using the Na589nm 
on a Perkin Elmer 341 Polarimeter.  
NMR spectra were recorded on Bruker Avance II 400 spectrometers (1H at 400 MHz, 13C 
at 100 MHz, 19F at 376 MHz), or Bruker Avance III 500 spectrometers (1H at 500 MHz, 
13C at 126 MHz, 19F at 470 MHz) or Bruker Avance III spectrometer (1H at 700 MHz, 13C 
at 175 MHz, 19F at 658 MHz).  
Chemical shifts (δ) are reported in parts per million (ppm) and are quoted relative to the 
residual peak of CDCl3, (CD3)2SO, CD3OD, D2O. Coupling constants (J) are given in 
Hertz (Hz). 13C NMR were recorded with 1H decoupling, and 19F NMR spectra were 
recorded either with or without 1H decoupling. Signal splitting patterns are described as: 
s – singlet, br s – broad singlet, d – doublet, t – triplet, tt – triplet of triplets, m – multiplet. 
Mass spectrometric data were acquired by electron impact ionisation (EI), electrospray 
ionisation (ESI), and nano- electrospray ionisation (NSI) or chemical ionisation (CI), 
using Waters Micromass LCT (ESI) or GCT (CI) spectrometers (University of St 
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Andrews), or a Thermofisher LTQ Orbitrap XL spectrometer (APCI) (National Mass 
Spectrometry Service Centre, Swansea). Values are reported as a ratio of mass to 
charge (m/z). Melting points were determined in Pyrex capillaries using a Griffin Melting 
Point Apparatus and are uncorrected. 
Enzymatic activity assays were carried out using a Thermo Scientific Evolution 220 UV-
Vis spectrophotometer.1 
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Compound 294 was synthesised according to the procedure reported by Tosin et al.2 
D-Pantothenic acid hemicalcium salt (5.0 g, 21.0 mmol, 14 equiv.) was suspended in 
acetic anhydride (100 mL), iodine (0.37 g, 1.5 mmol, 1 equiv.) was added and the 
resulting brown mixture was stirred for 16 hours at room temperature. The resulting gel 
was broken into pieces using a spatula and cooled down using an ice bath before adding 
a saturated solution of sodium hydrogen sulfite (50 mL) and water (100 mL). The mixture 
was strongly stirred for 1 hour and then concentrated under reduced pressure to remove 
the excess of acetic acid. Dichloromethane (100 mL) was added and the layers were 
separated. The aqueous layer was extracted with dichloromethane (50 mL), and the 
combined organic layers were dried onto magnesium sulfate, filtered and concentrated 
under reduced pressure to give a yellow oil. This material was dissolved in a 3:1 
tetrahydrofuran/water mixture (100 mL) and stirred for 16 hours at room temperature. 
The mixture was then concentrated under reduced pressure. The crude was then 
dissolved in dichloromethane (100 mL), the layers were separated and the aqueous layer 
extracted with dichloromethane (50 mL). The combined organic layers were dried onto 
magnesium sulfate, filtered and concentrated under reduce pressure to afford a clear oil 
that crystallised into a colourless solid (obtained 4.10 g, 0.97 mmol, 65% yield). Diacetyl 
pantothenic acid was used either in both forms without affecting the reaction outcome. 
Mp: 102-104 ºC; [α]20D = + 11.0 ° (c 0.01, CHCl3) 
1H NMR (500 MHz, CDCl3) δ 6.64 – 6.62 (t, J = 6.10 Hz, 1H, NH,), 4.96 (s, 1H,CH, H6), 
4.03 (d, J = 10.9 Hz, 1H,CH2, H8a, H8b), 3.82 (d, J = 10.9, 1H, CH2, H8a, H8b), 3.62 - 
3.56 (m, 1H, CH2, H3), 3.52 - 3.46 (m, 1H, CH2, H3), 2.60 (t, J = 5.44, 2H, CH2, H2), 2.14 
(s, 3H, CH3, H11), 2.07 (s, 3H, CH3, H14), 1.06 (s, 3H, CH3, H16), 1.03 (s, 3H, CH3, 
H15).  
These data are in good agreement with the literature values.1,2 
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D-pantothenic acid diacetate 294 (2.52 g, 8.20 mmol, 1 equiv.) was dissolved in dry 
tetrahydrofuran (30 mL) under an atmosphere of argon and 1,1-carbonyl diimidazole 
(1.34 g, 8.20 mmol, 1 equiv.) was added portion wise to the reaction mixture which was 
then stirred for 2 hours at room temperature. After the production of gas had ceased, 
cysteamine hydrochloride (0.93 g, 8.20 mmol, 1 equiv.) was added and the resulting 
mixture was heated under reflux for 6 hours. The mixture was then cooled down to room 
temperature and concentrated under reduced pressure. The resulting crude was then 
dissolved in dichloromethane (60 mL). This mixture was then washed with saturated 
brine (50 mL), 2.0 N hydrochloric acid (50 mL), saturated sodium hydrogen carbonate 
aqueous solution (50 mL) and saturated brine (50 mL). The residue was dried onto 
magnesium sulfate, filtered and concentrated under reduced pressure to afford a 
colourless solid residue which was purified by silica gel flash chromatography eluting 
with a mixture of 5/95 methanol/dichloromethane, to give the desired compound as a 
colourless solid (obtained 1.97 g, 5.11 mmol, 66% yield).1 
 Mp: 58-60 ºC;  
1H NMR (500 MHz, CDCl3) δ 6.96 - 6.93 (t, J = 6.3 Hz, 1H, NH), 6.56 - 6.54 (t, J= 6.5 Hz, 
1H, NH), 4.84 (s, 1H, CH, H10), 3.98 (d, J = 11.5 Hz, 1H, CH2, H12a, H12b), 3.79 (d, J = 
11.5 Hz, 1H, CH2, H12a, H12b), 3.53 - 3.30 (m, 4H, CH2, H5, H3), 2.67-2.57 (m, 2H, CH2, 
H2), 2.37 (t, J = 5.66 Hz, 2H, CH2, H6), 2.10 (s, 3H, CH3, H18), 2.02 (s, 3H, CH3, H15), 
1.40 (t, J = 8.37 Hz, 1H, SH), 1.01 (s, 3H, CH3, H19), 0.98 (s, 3H, CH3, H20); 
13C NMR (126 MHz, CDCl3) δ 171.8 (COCH3, C17), 171.0 (CONH, C9), 170.3 (COCH3, 
C14), 168.2 (CONH, C5), 77.1 (CH, C10), 69.3 (CH2, C12), 42.4 (CH2, C3), 35.3 (CH2, 
C6), 35.2 (CH2, C7), 24.5 (CH2, C2), 21.4 (CH3, C18), 21.0 (CH3, C15), 20.9 (CH3, C20),  
20.8 (CH3, C19); 
m/z (ESI+): Found [M+Na]+ 385.1394. C15H26O6N2NaS requires M+ 385.1404 
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5.4.1. Gold phthalimide complex (Au-1) L= John Phos (286)3 
 
 
 
 
The catalyst was prepared according to the procedure reported by Han et al. 3 
Chloro (1,1’-biphenyl-2-yl)-di-tert-butyl phosphine gold (I) (0.30 g, 0.56 mmol, 1 equiv.) 
and potassium phthalimide (0.16 g, 0.85 mmol, 1.5 equiv.) were dissolved in acetone (6 
mL) and the suspension was stirred for 3h at 45 °C. Upon completion, the mixture was 
filtered and the solid was washed with acetone (10 mL). Acetone was evaporated under 
pressure and the residue was further washed with water. The catalyst was obtained as 
a white solid (obtained 0.12 g, 0.19 mmol, 99 % yield). 
1H NMR (500 MHz, CDCl3) δ 7.89 (td, 1H, J = 8.0 Hz, 1H, CH, H10 ), 7.67 (dd, J = 5.3, 
3.0 Hz, 2H, CHaryl, H3, H16), 7.57 (dd, J = 5.4, 3.0 Hz, 2H, CHaryl, H4, H5), 7.54 – 7.46 
(m, 2H, CH2, H11, H21), 7.32 – 7.27 (m, 2H, CH2, H12, H20), 7.19 – 7.12 (m, 2H, CH2, 
H15, H19), 6.87 (t, J = 7.7 Hz, 2H, CH2, H16, H18), 1.48 (s, 9H, CH3, H9), 1.45 (s, 9H, 
CH3, H9’).  
13C NMR (126 MHz, CDCl3) δ 177.9, 150.2 (d, J = 6 Hz, C=O), 142.4 (d, J = 6 Hz, 
Cquaternary), 136.7 (d, J = 3 Hz, CH, C3 ), 133.6 (d, J = 3 Hz, CH, C4), 132.9 (d, J = 6 Hz, 
CH, C5), 132.0, 130.4 (d, J = 2 Hz, CHAryl), 128.9, 128.4, 126.9, 126.6 (d = J = 6 Hz, 
CHAryl), 126.0 (d, J = 45 Hz, CH, C17), 121.4, 37.8 (d, J = 25 Hz, CH, C10), 30.9 (d, J = 
6 Hz, CH3, C9 ). 
31P NMR (162 MHz, Chloroform-d) δ 58.18. 
 
These data are in good agreement with the literature values.3 
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5.4.2. N-(4-fluoropent-4-en-1-yl) phthalimide(282)1,4 
 
 
This compound was prepared following the synthetic procedure reported by Okoromoba 
et al.1,4  
N-(4-pentynyl)-phtalimide (1.00 g, 4.68 mmol, 1 equiv.) was loaded in a Teflon round 
bottom flask under an atmosphere of argon. Dry chloroform (24 mL) was added followed 
by 286 (prepared accordingly to the method described by Han et al.3 0.01 M stock 
solution in chloroform, 9.36 mL, 0.094 mmol, 0.02 equiv.) and DMPU-HF (65% w/w 0.501 
mL, 18.75 mmol. 4.00 equiv.) at room temperature. The reaction mixture was then stirred 
for 3 h at 55 °C. Upon completion, the reaction was quenched with a saturated sodium 
hydrogen carbonate solution (24 mL). The layers were separated and the aqueous 
phase was extracted with hexane (48 mL). The organic layers were combined and 
washed with brine (48 mL); dried onto anhydrous magnesium sulfate and filtered. The 
solvent was removed under reduced pressure and the residue was purified by flash 
column chromatography eluting with a mixture of 60/40 hexane: ethyl acetate to generate 
fluorovinyl phthalimide as a colorless oil (obtained 0.96 g, 4.10 mmol, 84% yield). 
1H NMR (400 MHz, CDCl3) δ 7.93 – 7.79 (m, 2H, CH2, H8, H12 ), 7.79 – 7.65 (dt, 2H, 
CH2, H9, H11), 4.53 (dd, J = 17.5, 2.9 Hz, 1H, CH2 , H1cis), 4.29 (dd, J = 50.1, 2.9, 0.9 
Hz, 1H, CH2, H1trans), 3.74 (t, J = 7.1 Hz, 2H, CH2, H5), 2.36 – 2.17 (m, 2H, CH2, H3), 
1.98 – 1.80 (m, 2H, CH2, H4).  
19F NMR (with proton coupled, 377 MHz, CDCl3) δ -95.14 (m,1F, CF). 
13C NMR (126 MHz, CDCl3) δ 168.3 (CO), 166.4 (CO), 134.0 (CAr, C9, C10), 132.0 (CAr 
C7, C12), 123.3 (CAr ), 90.1 (-C=CH2, C1), 37.2 (CH2, C5), 29.4 (CH2, C3), 25.0 (CH2, 
C4). 
m/z (ESI+): Found [M+Na]+ 256.0740 [C13H12O2NFNa] requires M+ 256.0740.  
These data are in agreement with the literature.1,4 
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5.4.3. 4-Fluoropent-4-en-1-amine (281)1 
 
 
  
Fluorovinyl phtalimide (0.12 g, 0.52 mmol, 1 equiv.) was dissolved in ethanol (2mL), 
hydrazine monohydrate (124µL, 2.57 mmol, 5 equiv.) was added and the reaction was 
stirred for 4h. After completion, 5M Hydrochloric acid (HCl) (80 µL ,2.62 mmol, 5 equiv.) 
was added and the solvent was removed under vacuum. The crude was diluted with 
water and saturated sodium hydroxide aqueous solution (50 µL ,2.62 mmol, 5 equiv.) 
was added adjusting the pH to 13-14. The water layer was extracted with 
dichloromethane (5 mL), dried over anhydrous magnesium sulfate and the solvent was 
cautiously removed under pressure. The resulting concentrated dichloromethane 
solution was used in the next step without further purification due to high volatile amine.1  
1H NMR (500 MHz, CDCl3) δ 4.54 (dd, J = 17.5 Hz, 2.7 Hz, 1H, CH2, H1cis), 4.26 (ddt, J 
= 50.2, 2.7 Hz, J = 0.9 Hz, 1H, CH2, H1trans), 2.77 (t, J = 7.0 Hz, 2H, CH2, H5), 2.35 – 
2.17 (m, 2H, CH2, H3), 1.80 – 1.57 (m, 2H, CH2, H4).  
19F NMR (with proton coupled, 471 MHz, CDCl3) δ -94.74 (m, 1F, CF). 
 m/z (ESI+): found [M+Na]+ 126.1402, [C5H10O2FNNa]+ requires M
+ 126.1410.1 
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5.4.4. (O,O’-Diacetyl)-S-N-(4-fluoropent-4-en-1-yl)-D-pantothenamide (280)1 
 
 
Fluorovinyl pentenamine 281 (0.21 g, 2.05 mmol, 1 equiv.) was dissolved in 
dichloromethane (8 mL), followed by O,O’-diacetyl-D-panthotenic acid (0.75 g, 2.46 
mmol, 1.2 equiv.), 1-hydroxybenzotriazole hydrate (0.36 g, 2.46 mmol, 1.2 equiv.) and 
triethylamine (0.87 mL, 6.15 mmol, 3 equiv.). The solution was cooled down to 0 °C and 
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.59 g, 3.08 mmol, 1.5 
equiv.) was added. The reaction was stirred for 30 min at 0°C and at room temperature 
for 18 h. The mixture was diluted with dichloromethane (10 mL) and washed with 1 M 
hydrochloric acid (20 mL) and saturated sodium hydrogen carbonate aqueous solution 
(20 mL). After drying over anhydrous magnesium sulfate, the product was purified by 
flash column chromatography eluting with a mixture of 95/5 dichloromethane: methanol 
as a colourless oil (obtained 0.24 g, 0.61 mmol, 30% yield).1 
[α]20D = + 12.4 ° (c 0.01, CHCl3) 
1H NMR (500 MHz, CDCl3) δ 6.92 (br t, J = 6.3, 1H, NH), 6.05 (br t, J = 6.2, 1H, NH), 
4.89 (s, 1H, CH, H12), 4.51 (dd, J = 17.5, 2.8 Hz, 1H, CH2, H1cis), 4.31 – 4.18 (dd, J = 
50.0 Hz, 3.0 Hz, 1H,   CH2, H1trans), 4.00 (d, J = 11.0 Hz, 1H, CH2, H14a, H14b), 3.82 (d, 
J = 11.0 Hz, 1H, CH2, H14a, H14b), 3.60 – 3.40 (m, 2H, CH2, H9), 3.20-3.31 (m, 2H, CH2, 
H5), 2.36 (t, J = 5.8 Hz, 2H, CH2, H8), 2.25 – 2.17 (m, 2H, CH2, H3 ), 2.13 (s, 3H, CH3, 
H17), 2.05 (s, 3H, CH3, H20), 1.70 (p, J = 7.2 Hz, 2H, CH2, H4), 1.04 (s, 3H, CH3, H22), 
1.00 (s, 3H, CH3, H21).  
19F NMR (with fluorine coupled, 471 MHz, CDCl3) δ -95.35 (m, 1F, CF). 
13C NMR (126 MHz, CDCl3) δ 171.8 (COCH3, C19), 171.2 (CONH, C11), 170.1 (COCH3, 
C16), 168.4 (CONH, C7), 166.9 (CF=CH, C2), 164.8 (CH=CF, C2), 90.5, 90.3 (CF=CH, 
C1), 77.3 (CH, C12), 69.5 (CH2, C14), 38.9 (CH2, C9), 35.4 (CH2, C8), 35.3 (CH2, C5), 
29.6, 29.4 (CH2, C3), 26.2 (CH2, C4), 21.5 (COCH3, C20), 21.0 (COCH3, C17), 21.0 (CH3, 
C22), 20.9 (CH3, C21).  
 m/z (ESI+): found [M+Na]+ 411.1897 [C18H29O6N2FNa]: requires M+ 411.1902.1 
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5.4.5. (O,O’-Dihydroxy)-S-N-(4-fluoropent-4-en-1-yl)-D-pantothenamide (259)1 
 
.  
Derivative 280 (0.042 g, 0.11 mmol, 1 equiv.) was dissolved in methanol (8 mL) and 
cooled down to 0°C. Sodium methoxide (5.4 M solution in methanol, 60 µL, 0.32 mmol, 
3 equiv.) was added and the reaction was stirred for 2h. The solvent was evaporated, 
water (5mL) was added and the crude was freeze dried. The crude product was purified 
by semipreparative HPLC (tr = 20.0 min, gradient elution method: acetonitrile / water 
containing 0.05 % trifluoroacetic acid, from 0% to 25% of acetonitrile in 10 min, then from 
25% to 60% for 10 min, 60% to 100% in 6 min to wash the column then down to 0% to 
equilibrate the column) to afford the product as a colourless deliquescent solid 
(obtained,15.1 mg, 0.050 mmol, 45 %).1 
1H NMR (400 MHz, CDCl3) δ 7.51 (br t, J = 6.5 Hz, 1H, NH), 6.52 (br t, J = 6.4 Hz, 1H; 
NH), 4.55 (dd, J = 17.5 , 2.8 Hz, 1H, CH2, H1cis), 4.27 (ddt, J = 50.3, 2.9, 0.8 Hz, 1H, 
CH2, H1trans), 4.02 (s, 1H, CH, H12), 3.62 – 3.43 (m, 4H, CH2, H14a, H14b, 8), 3.34 - 3.24 
(m, 2H, CH2, H8), 2.46 (t, J = 6.1 Hz, 2H, CH2, H5), 2.32 – 2.13 (m, 2H, CH2, H3), 1.73 
(p, J = 7.3 Hz, 2H, CH2, H4), 0.99 (s, 3H, CH3, H17), 0.93 (s, 3H, CH3, H16).  
19F NMR (with proton coupled, 471 MHz, CDCl3) δ -95.21 (m, J = 17.9 Hz, CF).  
13C NMR (126 MHz, CDCl3) δ 174.0 (CONH, C11) , 171.7 (CONH, C7) , 166.8 (CF=CH, 
C2) , 164.7 (CH=CF, C1), 90.5, 90.3 (CF=CH, C1), 77.4 (CH, C12), 70.8 (CH2, C14), 
39.4 , 38.9 (CH2, C8), 35.9, 35.4 (CH2, C9), 29.5, 29.3 (CH2, C3), 26.1 (CH2, 4), 21.4 
(CH3, C17), 20.6 (CH3, C16).  
m/z (ESI+): found [M+Na]+ 327.1686 [C14H25O4N2FNa]: requires M+ 327.1691.1  
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5.5.1. 5-penten-1-en-phthalimide (298)1,4 
 
 
This compound was prepared according to the procedure described by Qi et al.4  
5-bromopent-1-ene (2,00 g,13.42 mmol, 1 equiv.) was dissolved in dimethylfurane (16 
mL) then potassium phtalimide (2.48 g, 13.42 mmol, 1 equiv.) was added and the 
reaction was heated at 60°C for 20h. The solvent was removed under vacuum and the 
crude was diluted with water (16 mL). The water layer was extracted with diethyl ether 
(48 mL) and the solvent was removed under pressure to yield the product as a yellow oil 
without further purification (obtained 2.74 g,12.78 mmol, 65% yield).1,4  
1H NMR (400 MHz, CDCl3) δ 7.91 – 7.77 (m, 2H, CH, H8, H12), 7.75 – 7.65 (m, 2H, CH, 
H9, H11), 5.81 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H, CH, H2), 5.12 – 4.91 (m, 2H, CH2, H1), 
3.77 – 3.65 (m, 2H, CH2, H5), 2.12- 2.06 (m, 2H , CH2, H4), 1.78 (m, 2H, CH2, H3).  
m/z (ESI+): found [M+Na]+ 238.2400 [C13H13O2NNa] requires M+238.2401. 
These data are in agreement with the literature.1,4 
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5.5.2. Pentenyl-amine (299)1,5 
 
 
This substrate was synthetized following the procedure described by Du et al.5 
5-penten-1-en-phthalimide 298 (1.04 g, 4.83 mmol, 1 equiv.) was dissolved in ethanol 
(21 mL) and hydrazine monohydrate (1.18 mL, 24.16 mmol, 5 equiv.) was added to the 
mixture. The reaction was stirred for 5 h. After completion, 5M Hydrochloric acid (HCl) 
(18 µL, 24.15 mmol, 5 equiv.) was added and the solvent was removed under pressure. 
The crude was re-dissolved with water (20 mL), 5M sodium hydroxide aqueous solution 
(NaOH) (450 µL, 24.16 mmol, 5 equiv.) was added adjusting the pH to 14 and the 
aqueous phase was extracted with dichloromethane (20 mL). The solvent was carefully 
removed under pressure and the resulted dichloromethane solution was used in the next 
synthetic step thus avoiding the loss of high volatile amine.1,5 
 1H NMR (500 MHz, CDCl3) δ 5.80 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H, CH, H2), 5.09 – 4.84 
(m, 2H, CH2, H1), 2.69 (t, J = 7.1 Hz, 2H, CH2, H5), 2.20 – 2.00 (m, 2H, CH2, H3), 1.62 
– 1.45 (m, 2H, CH2, H4).  
m/z (ESI+): found [M+H]+ 86.0965, [C5H12N]+ requires M+ 86.0964.  
These data are in good agreement with the literature values.1,5  
 
5.5.3. (O,O’-Diacetyl)-S-N-(pent-4-en-1-yl)-D-pantothenamide (300)1 
  
 
Pentenylamine 299 (0.50 g, 5.90 mmol,1eq) was dissolved in dichloromethane (8 mL), 
followed by O,O’-diacetyl-D-panthotenic acid 294 (2.13 g, 7.10 mmol, 1.2 equiv.), 1-
hydroxybenzotriazole hydrate (1.00 g, 7.60 mmol, 1.3 equiv.) and triethylamine (2.5 mL, 
17.60 mmol, 3 equiv.). The solution was cooled down to 0 °C and N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (1.70 g, 8.80 mmol, 1.3 equiv.) 
was added. The reaction was stirred for 30 min at 0°C and at room temperature for 18 
h. The mixture was diluted with dichloromethane (10 mL) and washed with 1 M 
hydrochloric acid aqueous solution (20 mL) and saturated sodium hydrogen carbonate 
solution (20 mL). After drying over anhydrous magnesium sulfate, the product was 
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purified by flash column chromatography eluting with 95/5 dichloromethane: methanol to 
give the compound as a yellow oil (obtained , 0.87 g, 2.30 mmol, 40% yield).1 
1H NMR (500 MHz, CDCl3) δ 6.92 (br t, J = 6.5 Hz, 1H, NH), 5.84 – 5.71 (br t, J = 6.4 Hz, 
1H, NH, 1H, CH=CH2, H2), 5.06 - 4.98 (m, 2H, CH2=CH, H1), 4.93 (s, 1H, CH, H12), 
4.02 (d, J = 11.0 Hz, 1H, CH, H14a, H14b), 3.83 (d, J = 11.0 Hz, 1H, CH, H14a, H14b), 
3.61 – 3.43 (m, 2H, CH2, H9), 3.29 – 3.17 (m, 2H, CH2, H5), 2.36 (t, J = 5.8 Hz, 2H, CH2, 
H8), 2.14 (s, 3H, CH3, H20), 2.11 – 2.03 (m, 2H, CH2, H3), 2.06 - 2.05 (s, 3H, CH3, H17), 
1.64 – 1.52 (m, 2H, CH2, H4), 1.05 (s, 3H, CH3, H22), 1.01 (s, 3H, CH3, H21).  
13C NMR (126 MHz, CDCl3) δ 171.8 (COCH3, C19), 171.3 (CONH, C11) , 170.2 (COCH3, 
C16), 168.4 (CONH, C7), 137.9 (CH=CH2, C2), 115.7 (CH2=CH, C1), 77.6 (CH, C12), 
69.7 (CH2, C14a, C14b), 39.5 (CH2, C5), 37.5 (CH2, C9), 35.5 (CH2, C8), 31.4 (CH2, C3), 
29.0 (CH2, C4), 21.7 (CH3, C20), 21.3 (CH3, C17), 21.2 (CH3, C22), 21.1 (CH3, C21).  
m/z (ESI+): found [M+Na]+ found 393.1988 [C18H30O6N2Na]: requires M+ 393.1996.1 
5.5.4. 1 
 
 
Compound 286 (0.17 g, 0.45 mmol, 1 equiv.) was diluted in methanol (10 mL) and cooled 
down to 0°C. Sodium methoxide (5.4 M solution in methanol) (249 µL, 1.34 mmol, 3 
equiv. ) was added and the reaction was stirred for 1h. The solvent was evaporated, 
water was added and the crude was freeze dried. The crude was purified by flash column 
chromatography eluting with 90:10 dichloromethane: methanol to give the compound as 
a colourless oil (0.038 g, 0.13 mmol, 38% yield).1 
1H NMR (500 MHz, CDCl3) δ 7.26 (br t, J = 6.4 Hz, 1H, NH), 6.32 (br t, J = 6.5 Hz, 1H, 
NH), 5.74 (m, 1H, CH=CH2, H2 ), 4.79 – 4.59 (m, 2H, CH2=CH, H1), 3.67 (s, 1H, CH, 
H12), 3.38 – 3.03 (m, 4H, CH2, H9), 2.89 (q, J = 6.7 Hz, 4H, CH2, H14a, H14b, H5), 2.11 
(t, J = 6.2 Hz, 2H, CH2, H8), 1.75 (q, J = 7.4 Hz, 2H, CH2, H4), 1.27 (h, J = 7.3, 6.8 Hz, 
2H, CH2, H3), 0.65 (s, 3H, CH3, H17), 0.59 (s, 3H, CH3, H16). 
13C NMR (126 MHz, CDCl3) δ 174.4 (CONH, C11), 171.9 (CONH, C7), 137.9 (CH2=CH, 
C2), 115.7 (CH2=CH, C1), 77.5 (CH2, C12), 71.1 (CH2, C14) 39.5 (CH2, C8), 36.1, 35.6 
(CH2, C5), 31.4 (CH2, C3), 28.8 (CH2, C4), 21.6 (CH3, C17), 20.8 (CH3, C16).  
m/z (ESI+): found [M+Na]+ found 309.1783, [C14H26O4N2Na] requires M+ 309.1783.1 
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5.6.1. (O,O’-Diacetyl)-S-methylthio(dethia)-D-pantetheine (310)1 
 
 
 
 
3-methylthio propylamine (0.50 g, 4.80 mmol, 1 equiv.) was dissolved in 
dichloromethane (18 mL), followed by O,O’-diacetyl-D-panthotenic acid 294 (1.72 g, 5.70 
mmol, 1.2 equiv.), 1-hydroxybenzotriazole hydrate (0.83 g, 6.20 mmol, 1.3 equiv.) and 
triethylamine (2 mL, 14.00 mmol, 3 equiv.). The solution was cooled down to 0°C and N-
(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (1.36 g, 7.10 mmol, 1.5 
equiv.) was added. The reaction was stirred at 0 °C for 30 min then warmed up to room 
temperature and let it stirred for 18 h. The mixture was diluted with dichloromethane (18 
mL) and washed with 1 M Hydrochloric acid (36 mL) and saturated sodium hydrogen 
carbonate aqueous solution (36 mL). The crude was dried over anhydrous magnesium 
sulfate and concentrated to generate the product as a white solid (obtained 1.41 g, 3.60 
mmol, 76% yield).1 
m. p. 64 - 67 °C. [α]20D = + 15.7 ° (0.01, CHCl3) 
1H NMR (500 MHz, CDCl3) δ 6.91 (br t, J = 6.5 Hz, 1H, NH), 5.98 (br t, J = 6.3 Hz, 1H, 
NH), 4.91 (s, 1H, CH, H12), 4.01 (d, J = 11.0 Hz, 1H, CH2 , H14a, H14b), 3.82 (d, J = 
11.0  Hz, 1H, CH2, H14a, H14b), 3.60 – 3.43 (m, 1H, CH2, H9), 3.38 - 3.28 (m; 2H, CH2 , 
H4), 2.52 (t, J = 7.1, 4.6 Hz, 2H, CH2, H2), 2.37 (t, J = 5.8 Hz, 2H, CH2, H8), 2.14 (s, 3H, 
CH3, H20), 2.06 (s, 3H, CH3, H1), 2.09 (s, 3H, SCH3, H17), 1.85 – 1.74 (m, 2H, CH2, H3), 
1.05 (s, 3H, CH3, H22), 1.01 (s, 3H, CH3, H21).  
13C NMR (126 MHz, CDCl3) δ 171.6 (COCH3, C19), 171.5 (CONH2, C11), 171.0 (COCH3, 
C16), 170.0 (CONH, C7), 77.0 (CH, C12), 69.4 (CH2, C14a, C14b), 52.2 (CH2, C2), 38.6 
(CH2, C9), 35.1 (CH2, C8) , 31.6 (CH2, C5), 28.5 (CH2, C4) , 21.4 (COCH3, C20) , 21.0 
(COCH3, C17), 21.2 (CH3, C22), 20.4 (CH3, C21) , 15.4 (S-CH3, C1) . 
 m/z (ESI+): Found [M+Na]+ 413.1712  [C17H30O6N2NaS] requires M+413.1717.1  
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5.6.2. (O,O’-Diacetyl)-S-methyl-D-pantetheine sulfoxide (311)1 
  
 
Derivative 310 (1.40 g, 3.60 mmol, 1 equiv.) was dissolved in dichloromethane (25 mL), 
followed by the addition of meta-chloroperoxybenzoic acid (0.63 g, 3.60 mmol, 1 equiv.). 
The reaction was stirred for 3h at room temperature. The organic layer was washed with 
saturated sodium bicarbonate solution (75 mL) and dried onto magnesium sulfate and 
concentrated. The crude was purified by flash column chromatography eluting with a 
mixture of 90/10 (dichloromethane: methanol) to afford a yellow oil (obtained 0.32 g, 0.80 
mmol, 25% yield).1 
 1H NMR (500 MHz, CDCl3) δ 7.17 (br t, J = 6.4 Hz, 1H, NH), 6.94 (br t, J = 6.5 Hz, 1H, 
NH), 4.83 (s, 1H, CH, H12), 4.83* (s, 1H, CH, H12), 3.99* (dd, J= 11Hz , 1H, CH2 , H14a, 
H14b), 3.81 (d, J = 10.9 Hz, 1H, CH2, H14a, H14b ), 3.52 – 3.43 (m, 2H, CH2, H9), 3.43 - 
3.35 (m, 1H, CH2, H5), 3.35 - 3.25 (m, 1H, CH2, H7), 2.81 – 2.66 (m, 2H, CH2, H8), 2.56 
(d, 3H, CH3, H1), 2.36 (m, 2H, CH2, H4), 2.10 (s, 3H, CH3, H20), 2.03 (s, 3H, CH3, H17), 
2.03 - 1.89 (m, 2H, CH2, H3), 1.02 (s, 3H, CH3, H22), 0.99 (s, 3H, CH3, H21).  
13C NMR (126 MHz, CDCl3) δ 172.2, 172.1* (COCH3, C19), 171.0 (CONH, C11), 
170.3, 170.2* (COCH3, C16), 168.3, 168.2* (CONH, C7), 77.2 (CH, C12) , 69.4 (CH2, 
C14a, C14b), 51.9* (CH2, C3), 37.3, 38.5* (CH3, C1), 38.2, 37.2 ( CH2, C8), 35.5 , 35.5* 
(CH2, C9), 35.2, 35.2* (CH2, C5), 23.0 (CH2, C4), 21.4, 21.0, 20.9* (COCH3, C20, C17), 
20.8, 20.7* (CH3, C21, C22). 
m/z (ESI+) Found [M+Na]+: 429.1665, [C17H30O7N2NaS] requires M+ 429.1666.1 
*Double signals arising from two different isomers.1 
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5.6.3. (O,O’-Dihydroxy)-S-methyl-D-pantetheine sulfoxide (312)1 
 
 
 
Compound 311 (0.17 g, 0.47 mmol, 1 equiv.) was dissolved in ethanol (13 mL) and 
cooled down to 0°C using an ice bath. Sodium ethoxide (0.053 mL, 1.40 mmol, 3 equiv.) 
was added and the reaction was stirred for 1h. The solvent was evaporated, water was 
added (1mL) and the crude was freeze dried. The crude was purified by flash column 
chromatography eluting with a mixture of 90/10 dichloromethane: methanol to afford the 
product as colourless deliquescent solid (obtained 0.080 g, 0.25 mmol, 53 % yield).1 
1H NMR (400 MHz, D2O) δ 3.86 (s, 1H, CH, H12), 3.48, 3.16 (m, 6H, CH2, H14a, H14b, 
H8, H9), 2.88– 2.69 (m, 2H, CH2, H4), 2.59 (s, 3H, SOCH3, H1), 2.39 (t, J = 6.5 Hz, 2H, 
CH2, H5), 1.90 – 1.76 (m, 2H, CH2, H3), 0.80 (s, 3H, CH3, H17), 0.77 (s, 3H, CH3, H16). 
 13C NMR (126 MHz, D2O) δ 175.0 (CONH, C11), 174.0 (CONH, C7), 75.6 (CH, C12), 
68.3 (CH2, C14a, C14b, C5) , 45.0 (CH2, C3), 38.5 (CH2, C8) , 38.0 , 36.5 (SOCH3, C1), 
35.4 , 35.2* (CH2, C9), 22.0 (CH2, C4) , 20.4, 19.0 (COCH3, C16, C17). 
 m/z (ESI+): Found [M+Na]+ 345.1451 [C13H26O5N2NaS] requires M+ 345.1454.1  
* Double signals arising from the two different isomers1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
193 
 
 
5.7.1. (O,O’-Diacetyl)-S-(methoxycarbonylvinyl)-D-pantetheine((E)332/(Z)333)1 
 
 
 
(Z)-332 and (E)-333 were prepared accordingly to the method reported by Carney et al.6 
In a round bottom flask, (O,O-diacetyl)-pantetheine 331 (0.19 g, 0.68 mmol, 1equiv.) and 
methyl propiolate (65 µL, 0.91 mmol, 1.1 equiv.) were diluted in tetrahydrofuran (4 mL) 
at room temperature and the reaction was cooled down to 5 °C. Then 1,8-Diazabicyclo 
[5.4.0] undec-7-ene (10 µL, 0.067 mmol, 0.010 equiv.) was added over a period over 3 
minutes and the reaction was let stirred for 2h at room temperature. After completion, 
the solvent was removed under pressure and the residue was re-dissolved with 
dichloromethane and quenched with hydrochloric acid 1 M aqueous solution (5 mL). The 
organic layer was washed with brine (15 mL). After removing the solvent under reduced 
pressure, the crude was purified by column chromatography eluting with 95/5 
dichloromethane: methanol to give the isomeric mixture of diacetyl-thioalkene (E)-
333/(Z)-332 (40:60, isomeric ratio calculated by 1H NMR) (obtained 0.016 g, 0.51 mmol, 
75% yield).1 
1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 15.2 Hz, 1H, CH, H4vinyl, E), 7.06 (d, J = 10.1 
Hz, 1H, CH, H4vinyl , Z), 6.91 (t, J = 6.4 Hz, 1H, NH), 6.55 - 6.45 (t, J = 6.3 Hz, 2H, NH), 
5.92 – 5.87 (d, J = 10.0 Hz, 1H, CH, H3vinyl, Z) , 5.88 – 5.84 (d, J = 15.1 Hz, 1H, CH, 
H3vinyl, E), 4.85, 4.86 (s, 1H, CH, H14, E -Z )* 4.00 (dd, J = 11.0, 2.7 Hz, 1H, CH2, H16a, 
H16b), 3.82 (dd, J = 10.9, 2.0 Hz, 1H, CH2, H16a, H16b), 3.70, 3.69 (s, 3H, CH3, H1,  E-
Z)*, 3.58 – 3.35 (m, 4H, CH2, H11, H7), 3.00 – 2.85 (m, 2H, CH2, H6), 2.46 – 2.30 (m, 
2H, CH2, H10), 2.12 (s, 3H, CH3, H22), 2.04 (s, 3H, CH3, H19), 1.05 - 1.04 (s, 3H, CH3, 
H24), 1.01 - 0.99 (s, 3H, CH3, H123).  
13C NMR (126 MHz, CDCl3) δ 171.8, 170.8, 170.0, 169.9, 168.1, 168.1 (COCH3, CONH, 
C21, C14, C18, C9)*, 166.8, 165.5 (COCH3, C2, E-Z), 149.3 (CHvinyl, C4, Z), 145.8 
(CHvinyl, C4, E), 113.9, 113.4 (CHvinyl, C3, E-Z)*, 76.9 (CH, C14), 69.1 (CH2, C16), 51.4, 
51.1 (CH3, C1)*, 39.3, 38.1, 36.8, 35.2, 35.1, 34.9, 34.9, 34.8 , 31.1 (CH2, C11, C7, C10, 
C6)*, 21.1 (COCH3, C18), 20.7 (COCH3, C23), 20.6 (CH3, C21), 20.5 (CH3, C22); 
m/z (ESI+): Found [M+Na]+ 469.160, [C19H30O8N2NaS]  requires M+ 469.1615. 
*double signals arising from E-Z isomers.1 
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5.7.2. (O,O’-Dihydroxy)-S-(Methoxycarbonylvinyl)-D-pantetheine((E)-335/(Z)-334)1 
 
  
(Z)-332 and (E)-333 mixture (0.10 g, 0.22 mmol, 1 equiv.) was diluted in tetrahydrofuran 
(2.5 mL) then water (2.5 mL) and lithium hydroxide (0.034 g, 1.12 mmol, 5 equiv.) were 
added and the reaction was let stirred for 2h. After completion, tetrahydrofuran was 
removed under pressure and the crude was freeze dried to remove the remained water. 
The mixture of (E)/(Z) alkenes (60:40) were separated by semipreparative HPLC 
(gradient elution method acetonitrile / water containing 0.05 % of trifluoroacetic acid, 
Phenomenex Synergi® 4μ Polar-RP 80Å 250 x 10.0 mm, 0 to 20% acetonitrile in 10 min, 
then 20% acetonitrile for 10 min, then from 20% to 60% acetonitrile in 3 min to wash the 
column, then from 60% to 0% acetonitrile in 3 minutes, and 0% acetonitrile for 10 min to 
re-equilibrate the column) giving the (E)-335 (retention time = 20.1 min) (obtained 0.020 
g, 0.060 mmol, 25% yield) and the (Z)-334 (retention time = 19.8 min) (obtained 0.023 
g, 0.066 mmol, 30% yield) as a colourless oil. 1 
 
5.7.3. (E)-335 
 
1H NMR (500 MHz, D2O) δ 7.54 (d, J = 15.2 Hz, 1H, CH, H3vinyl), 5.85 (d,  
J = 15.2 Hz, 1H, CH, H2vinyl), 3.94 (s, 1H, CH, H13), 3.55 – 3.42 (m, 5H, CH2, H10, H6, 
H15a, H15b), 3.35 (d, J = 11.2 Hz, 1H, CH2, H15a, H15b), 2.99 (t, J = 6.4 Hz, 2H, CH2, 
H9), 2.46 (t, J = 6.5 Hz, 2H, CH2, H5), 0.88 (s, 3H, CH3, H18), 0.84 (s, 3H, CH3, H17). 
13C NMR (176 MHz, D2O) δ 175.0 (CONH, C12), 174.0 (CONH, C8), 163.1 (COOH, C1), 
117.1 (Calk, C2), 115.4 (CHalk, C3), 75.8 (CH, C13), 68.3 (CH2, C15), 38.5 (CH2, C6), 
38.1 (CH2, C10), 35.3, 35.2 (CH2, C5), 30.8 (CH2, C9), 20.4 (CH3, C18), 19.0 (CH3, C17).  
(m/z) ESI+, Found [M+Na]+ 371.1243, C14H24O6N2NaS  requires M+ 371.1247.1 
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5.7.4. (Z)-334 
  
1H NMR (500 MHz, D2O) δ 7.15 (dd, J = 10.1, 4.1 Hz, 1H, CH, H3vinyl), 5.82 (d, J = 
10.1Hz, 1H, CH, H1vinyl), 3.86 (s, 1H, CH, H13), 3.49 – 3.30 (m, 5H, CH2, H10, H6, H15a, 
H15b), 3.26 (d, J = 11.3 Hz, 1H, CH2, H15a, H15b), 2.84 (t, J = 6.5 Hz, 2H, CH2, H9), 2.38 
(t, J = 6.4 Hz, 2H, CH2, H5), 0.79 (s, 3H, CH3, H18), 0.75 (s, 3H, CH3, H17). 
13C NMR (176 MHz, D2O) δ 175.0 (CONH, C12), 174.0 (CONH, C8), 162.8 (COOH, C2), 
117.1 (S-CH=CH-COOH, C1), 115.6 (S-CH=CH-COOH, C3), 75.7 (CH, C13), 68.3 (CH2, 
C15), 39.2 (CH2, C6), 35.3 (CH2, C10), 35.2 (CH2, C9), 34.2 (CH2, C5), 20.4 (CH3, C18), 
18.9 (CH3, C17). 
(m/z) ESI+: Found [M+Na]+ 371.1243 C14H24O6N2NaS  requires M+ 371.1247.1 
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5.8.1. 2- iodosyl benzoic acid (484)7 
 
 
The compound was prepared according to the procedure described by Brand et al.7 
2-Iodo benzoic acid (10 g, 40.32 mmol, 1 equiv.) was dissolved in glacial acetic acid (30 
% v/v 80 mL) followed by the addition of sodium periodate (8.6 g, 40.32 mmol, 1 equiv.) 
was added to the mixture. The reaction was refluxed at 92 °C for 4 h. Upon completion, 
the reaction was quenched with cold water (210 mL) and allowed to cool down to room 
temperature. After 1 h, the product was filtered off and washed with cold water (100 mL) 
and cold acetone (100 mL). The desired photosensitive compound was dried affording a 
colourless solid. (obtained 9.50 g, 35.88 mmol, 89% yield). 
1H NMR (500 MHz, DMSO) δ 8.20 (s, 1H, OH), 8.16 (dd, J = 7.6, 1.5 Hz, 1H, CHAryl, H4), 
8.11 (td, J = 8.6, 7.2, 1.5 Hz, 1H, CHAryl, H3), 7.99 (dd, J = 8.4, 0.8 Hz, 1H, CHAryl, H1 ), 
7.85 (td, J = 7.3, 1.0 Hz, 1H, CHAryl, H2). 
The data are in agreement with the reported literature values.7  
5.8.2. Silyl Ethyl Benziodoxolone (366)7 
 
 
The title compound was prepared according to the procedure described by Brand et al.7 
Trimethylsilyl triflate (3 mL, 16.66 mmol, 1.1 equiv.) was added to a suspension of 
compound 484 (4.00 g, 15.15 mmol, 1 equiv.) in dichloromethane (50 mL) at room 
temperature. The resulting yellow mixture was stirred for 1 h, followed by the dropwise 
addition of bis-(trimethylsylil)-acetylene (3.8 mL, 16.66 mmol, 1.1 equiv.). The resulting 
suspension was stirred for 6 hours at room temperature. A colourless solid was formed 
to wich sodium carbonate aqueous solution (30 mL) was added and the reaction was 
stirred until complete solubilisation of the solid. The two layers were separated and the 
organic was extracted with saturated sodium hydrogen carbonate solution and dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. The resulting 
solid was re-crystallized with acetonitrile (50 mL) affording the compound as white 
crystals (obtained 3.49 g, 10.6 mmol, 70 % yield)  
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1H NMR (500 MHz, CDCl3) δ 8.52 – 8.32 (m, 1H, CHaryl, H4), 8.30 – 8.10 (m, 1H, CHaryl, 
H1), 7.78 (dtd, J = 8.5, 7.0, 1.6 Hz, 2H, CHaryl,, H2, H3), 0.32 (d, J = 6.6 Hz, 9H, CH3, 
H10). 
13C NMR (126 MHz, DMSO) δ 166.1 (C=O, C7), 134.9, 132.1, 131.4, 131.2, 127.1, (CH, 
C1, C2, C3, C4), 115.7, 114.3 (CHalk, C8, C9), 66.3, -0.5 (CH3, C10). 
The data are in agreement with the reported literature values.7  
5.8.3.  (O,O’-Diacetyl)-S-ethynyl-D-pantetheine (363)1,7,8  
 
 
Diacetyl pantetheine 331 (14.70 g, 40.7 mmol, 1equiv.) was dissolved in tetrahydrofuran 
(300 mL) and tetramethylguanidine (5.6 mL, 44.7 mmol, 1.1 equiv.) was added. The 
resulting mixture was vigorously stirred at room temperature and a solution of EBX-TMS 
366 (15.40 g, 44.7 mmol, 1.1 equiv. prepared according to the procedure reported by 
Waser et al.7,8), in tetrahydrofuran (50 mL), was slowly added. The resulting mixture was 
stirred for 2 hours at room temperature, then tetrabutylammonium fluoride trihydrate 
(14.10 g, 44.7 mmol, 1.1 equiv.) was added portionwise, and the resulting mixture was 
stirred for a further 4 hours. The mixture was then concentrated under reduced pressure, 
the resulting residue was taken up in dichloromethane (100 mL) and saturated aqueous 
sodium hydrogen carbonate (100 mL), the layers were separated and the aqueous layer 
was extracted with dichloromethane (2 x 100 mL). The combined organics were washed 
with brine (100 mL), dried onto magnesium sulfate, filtered and concentrated under 
reduced pressure. The residue was then purified by silica gel flash column 
chromatography eluting with a 5/95 mixture of methanol/dichloromethane gave the title 
compound as a colourless solid (obtained 10.10 g, 26. 05 mmol, 64% yield).1,9,10  
Mp: 105-106 ºC. [α]20D = + 16.5 ° (c 0.01, CHCl3) 
1H NMR (500 MHz, CDCl3) δ 6.86 - 6.82 (br t, J = 6.3 Hz, 1H, NH), 6.27 - 6.23 (br t, J = 
6.4 Hz, 1H, NH), 4.89 (s, 1H, CH, H12), 4.01 (d, J = 10.7 Hz, 1H, CH, H14a, H14b), 3.82 
(d, J = 10.7 Hz, 1H, CH, H14a, H14b), 3.68 - 3.47 (m, 4H, CH2, H9, H5), 2.87 - 2.84 (m, 
2H, CH2, H3), 2.78 (s, 1H, CH, H1), 2.40 (t, J = 5.91 Hz, 2H, CH2, H5), 2.14 (s, 3H, CH3, 
H20), 2.06 (s, 3H, CH3, H17), 1.05 (s, 3H, CH3, H22), 1.01 (s, 3H, CH3, H21); 
13C NMR (126 MHz, CDCl3) δ 171.9 (COCH3, C19), 171.1 (CONH, C11), 170.1 (COCH3, 
C16), 168.2 (CONH, C7), 82.8 (CHalk, C2), 77.2 (CH, C12), 73.3 (CHalk, C1), 69.4 (CH2, 
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C14), 38.5 (CH2, C8), 37.2 (CH2, C9), 35.3, 35.2 (CH2, C5), 34.4 (CH2, C4), 21.5 (CH3, 
C20), 21.1 (CH3, C17), 20.9 (CH3, C22), 20.9 (CH3, C21); 
m/z (NSI+): Found [M+H]+ 387.1584, C17H27O6N2S requires M+ 387.1584.1.9,10 
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5.9.1. (O,O-diacetyl)-S-methylthioster-D-pantetheine (365)9 
 
 
 
 
The compound was synthesised according to the procedure reported by Tsuji et al.9  
A oven dried flask containing palladium chloride (II) (0.00050 g, 0.0026 mmol, 0.02 
equiv.), coper chloride (II) (0.044 g, 0.33 mmol, 2.5 equiv.), sodium acetate (0.032 g, 
0.40 mmol, 3.0 equiv.) in dry methanol (0.58 mL) was fitted with a septum. The flask was 
then purged with a vacuum line to flash out the air and a rubber balloon with carbon 
monoxide (1 atm) was attached. When higher pressures of carbon monoxide (50 bars) 
were used, the reaction was set up using an autoclave. Then, a solution of thioalkyne 
363 (0.051 g, 0.13 mmol, 1 equiv.) in methanol (0.58 mL), was added to the mixture via 
cannula. The green solution turned to brown after 2.5 h and was stirred for 18h. Upon 
completion, the mixture was quenched with saturated aqueous ammonium chloride / 
ammonia (9:1). The aqueous phase was extracted with dichloromethane (10 mL). The 
combined organic layers were washed with brine (10 mL), dried over anhydrous 
magnesium sulfate, and concentrated under pressure. The residue was purified by silica 
gel column chromatography eluting with 95:5 dichloromethane: methanol to afford a 
yellow liquid (obtained 0.007 g, 0.017 mmol, 13 % yield). 
  
1H NMR (500 MHz, CDCl3) δ 6.82 (br t, J = 6.4 Hz, 1H, NH), 6.32 (br t, J = 6.5 Hz, 1H, 
NH), 4.88 (s, 1H, CH, H14), 4.01 (d, J = 11.0 Hz, 1H, CH2, H16a, H16b), 3.83 (d, J = 11.0 
Hz, 1H, CH2, H16a, H16b), 3.76 (s, 3H, CH3, H1), 3.69 – 3.47 (m, 4H, CH2, H11, H7), 2.96 
(td, J = 6.2, 2.0 Hz, 2H, CH2, H7), 2.42 (t, J = 5.8 Hz, 2H, CH2, H10), 2.14 (s, 3H, CH3, 
H22), 2.06 (s, 3H, CH3, H19), 1.03 (s, CH3, H24), 1.01 (s, CH3, H23).  
13C NMR (126 MHz, CDCl3) δ 172.1 (COCH3, C21), 171.1 (CONH, C13), 170.1 (COCH3, 
C14), 168.3 (CONH, C9), 153.3 (CO2CH3, C2), 87.6 (Calkyne, C3), 83.2 (Calkyne, C4), 77.0 
(CH, C14), 69.4 (CH2, C16), 52.7 (CH3, C1), 38.9 (CH2, C11), 35.2 (CH2, C10), 35.1 
(CH2, C6), 34.8 (CH2, C7), 21.5 (CH3, C22), 21.0 (CH3, C19), 20.9 (CH3, C24), 20.8 (CH3, 
C23).  
HRMS (ES+) m/z: found [M+Na+] 467.1456, [C19H28O8N2NaS] requires M
+ 467.1459.  
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5.9.2. Bis-acetylene (372) 
 
 
Bis acetylene was obtained as side product of the oxidative carbonylation of 
thioacetylene 363. 9 
1H NMR (500 MHz, CDCl3) δ 6.98 (br t, J = 6.5 Hz, 1H, NH),6.59 (br t, J = 6.3 Hz, 1H, 
NH), 4.92 (s, 1H, CH, H9, H9’), 4.03 (d, J = 11.0 Hz, 1H, CH2, H11a, H11b, H11’a, H11’b), 
3.83 (d, J = 11.0 Hz, 1H, CH2, H11a, H11b, H11’a, H11’b), 3.66 – 3.48 (m, 4H, CH2, H7, 
H7’, H4, H4’), 2.88 (td, 2H, CH2, H6, H6’), 2.44 (t, J = 5.8 Hz, 2H, CH2, H3, H3’), 2.16 (s, 
3H, CH3, H15, H15’), 2.08 (s, 3H, CH3, H13, H13’), 1.07 (s, CH3, H17, H17’), 1.05 (s, 
CH3, H16, H16’). 
13C NMR (126MHz, CDCl3) δ172.1 (CONH, C8, C8’),171.0 (COCH3, C14, C14’), 170.0 
(CONH, C5, C5’), 168.1 (COCH3, C12, C12’), 87.8 (Calk, C1, C1’), 82.6 (Calk, C2, C2’), 
77.5 (CH, C9, C9’), 69.3 (CH2, C11, C11’), 38.8 (CH2, C7, C7’), 37.1 (CH2, C4, C4’), 35.2 
(CH2, C3, C3’), 35.0 (CH2, C6, C6’), 21.3 (CH3, C15, C15’), 20.9 (CH3, C13, C13’), 20.8 
(CH3, C17, C17’), 20.7 (CH2, C16, C16’). 
m/z (NSI+): Found [M+Na]+793.2759, [C34H50O12N4S2Na]+ requires M
+ 793.2764. 
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5.9.3. N,N-diisopropyl-2,3-dimethyl-thio-imidazole (394)10 
 
 
 
The title compound was synthesised according to the procedure reported by Talavera et 
al.10  
Acetoin (10.13 g, 132.80 mmol, 1.2 equiv.) was added to a stirred solution of 
diisopropylthiourea (18.40 g, 115.00 mmol, 1 equiv.) in hexanol (110 mL) and the 
reaction was heated to 158°C for 12 h. Upon completion, the solution was cooled down 
to room temperature and the solid was filtered and washed with cold ethanol to afford 
the compound as a white solid (obtained 11.70 g, 80.50 mmol, 70 % yield).  
1H NMR (400 MHz, CDCl3) δ 5.17-6.22 (br s, 1H, CH, H5’), 2.16 (s, 6H, CH3, H7’, H8’), 
1.42 (d, J = 7.3 Hz, 12H, CH3, H6’). 
The data are in agreement with the reported literature values.10  
 
5.9.4. S-dibromo-N,N-diisopropyl-2,3-dimethyl-imidazole (395)10  
 
 
 
The title compound was synthesised according to the procedure reported by Talavera et 
al.10  
Thiourea derivative 394 (11.70 g, 31.18 mmol, 1 equiv.) was dissolved in dry 
dichloromethane (50 mL) followed by the addition of bromine (2.82 mL, 31.18 mmol, 1 
equiv.) at 0°C. The reaction was warmed up to room temperature and stirred for 3 hours. 
After the removal of all volatiles under reduced pressure, the product was generated as 
an orange solid (obtained 20.60 g, 0.071 mmol, 95 % yield).  
1H NMR (400 MHz, CDCl3) δ 5.67 (2H, hept, J = 7.1 Hz, 1H, CH, H5’), 2.37 (s, 6H, CH3, 
H7’, H8’), 1.68 (d, J = 7.1 Hz, 12H, CH3, H6’).  
The data are in agreement with the reported literature values.10 
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5.9.5. Ethyl thioester imidazolium derivative (382)10 
 
 
 
 
Silver ethyl propiolate (1.41 g, 6.87 mmol, 1.01 equiv.) was added to a solution of 
compound 395 (2.56 g, 6.87 mmol, 1.01 equiv.) in dry dichloromethane (20 mL) at room 
temperature. Silver hexafluoro antimonate (2.32 g, 6.75 mmol, 1 equiv.) was added after 
5 minutes and the reaction was stirred at room temperature for 45 minutes. Silver salts 
were then filtered off and the solvent was removed under vacuum. The solid was washed 
twice with diethyl ether (20 mL) to afford the compound as a brown solid (obtained 3.48 
g, 6.35 mmol, 93% yield).10 
1H NMR (400 MHz, CDCl3) δ 5.17 (hept, J= 7.0 Hz, 1H, CH, H5’), 4.21 (q, J= 7.1 Hz, 2H, 
CH2, H11’), 2.38 (s, 3H, CH3, H7’ ), 1.62 (d, J = 7.0 Hz, 12H, CH3, H6’), 1.24 (t, J = 7.1 
Hz, 3H, CH3, H12’). 
19F NMR (400 MHz, CDCl3) δ= -124.00 (sext, JF-121 Sb = 1931 Hz). 
13C NMR (126 MHz, CDCl3) δ 151.9 (COCH2CH3, C10’) , 132.2 (CH, C1), 88.2 (CH, C9’), 
72.3 (CH, C8’), 63.3 (CH, C11’), 54.8 (CH, C5’), 21.5 (CH3, C6’), 14.3 (CH3, C12’), 10.9 
(CH3, C7’). 
The data are in agreement with the reported literature values.10 
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5.9.6. (O,O-Diacetyl)-S-ethyl-thioester-D-pantetheine (398)10  
 
 
 
 
Compound 398 was prepared according to the procedure described by Alcarazo et al.10 
Diacetylated pantetheine 331 (0.092 g, 0.25 mmol, 1 equiv.) was dissolved in dry 
dichloromethane (0.9 mL). N,N-Diisopropylethylamine (44 µL, 0.30 mmol, 1.2 equiv.) 
followed by a dropwise addition of imidazolium sulfurane 382 (prepared according to 
Alcarazo et al.10) (0.17 g, 0.30 mmol, 1.2 equiv.) in dry dichloromethane (0.9 mL) at room 
temperature. The reaction was stirred for 1 h. The mixture was quenched with 1M of 
ammonium chloride aqueous solution (1.8 mL) and the aqueous layer was extracted with 
dichloromethane (2 mL). The combined organic layers were dried over magnesium 
sulfate and all the volatile components were removed under vacuum. The crude was 
purified sequentially by column chromatography eluting with 95:5 dichloromethane: 
methanol and HPLC (isocratic conditions acetonitrile: water 50:50) affording a white 
deliquescent liquid (obtained 11 mg, 0.025 mmol, 10 % yield).    
1H NMR (500 MHz, CDCl3) δ 6.85 (br t, J = 6.4 Hz, 1H, NH), 6.35 (br t, J = 6.4 Hz, 1H, 
NH), 4.88 (s, 1H, CH, H15), 4.22 (q, J = 7.1 Hz, 2H, CH2, H2) 4.01 (d, J = 11.0 Hz, 1H, 
CH2, H17a, H17b), 3.82 (d, J = 11.0 Hz, 1H, CH2, H17a, H17b), 3.70 – 3.46 (m, 4H, CH2, 
H12, H8), 2.96 (td, J = 6.2, 2.1 Hz, 2H, CH2, H7), 2.43 (t, 2H, CH2, H11), 2.14 (s, 3H, 
CH3, H23), 2.06 (s, 3H, CH3, H20), 1.29 (t, J = 7.1 Hz, 3H, CH3, H1), 1.07 (s, 3H, CH3, 
H25), 1.03 (s, 3H, CH3, H24). 
13C NMR (126 MHz, CDCl3) δ 172.0 (CONH, C14), 171.0 (COCH3, C22) , 170.9 (CONH, 
C10), 168.4 (COCH3, C19), 152.8 (COOCH2CH3, C3), 87.7 (Calk, C4), 82.6 (Calk, C5), 
77.5 (CH, C15), 69.3 (CH2, C17) , 62.0 (CH2, C2), 38.8 (CH2, C12), 35.2 (CH2, C8) , 35.0 
(CH2, C7) , 34.6 (CH2, C11) , 21.3 (CH3, C23), 20.9 (CH3, C20) , 20.8 (CH3, C25), 20.7 
(CH3, C24) , 14.1 (CH3, C1). 
HRMS (ES+) m/z: Found [M+Na+] 481.1607, [C20H30O8N2NaS] requires M
+ 481.1615.  
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5.9.7. (O,O-Diacetyl)-S-fluorovinylthio-acrylate-D-pantetheine (362) 
 
 
 
Compound 362 was prepared according to the procedure reported by Li et al.11  
Diacetyl methyl thioester 365 (0.016 g, 0.035 mmol, 1 equiv.) was dissolved in a mixture 
of 20:1 acetonitrile: water (437µL) followed by silver fluoride (0.091 g, 0.072 mmol, 2 
equiv.) and the reaction was stirred for 5 h at 80 °C in a stopped flask. The reaction was 
cooled down to room temperature. The solvent was removed carefully under pressure 
and the residue was re-diluted with ethyl acetate (3 mL). The solution was filtrated to 
remove silver salts and the solvent was removed under pressure to afford fluorovinyl 
thioacrylate as yellow oil without further purification (obtained 0.05 g, 0,010 mmol, 31 % 
yield). 
1H NMR (500 MHz, CDCl3) δ 6.76 (br t, J = 6.3 Hz, NH), 6.09 (br t, J = 6.5 Hz, NH), 5.54 
(d, 2JHFtrans = 31.0 Hz, 1H, CH, H3), 4.89 (s, 1H, CH, H14), 4.02 (d, J = 11.0 Hz, 1H, CH2, 
H16a, H16b), 3.84 (d, J = 11.0 Hz, 1H, CH2, H16a, H16b), 3.72 (s, 3H, CH3, H1), 3.60 – 
3.43 (m, 4H, CH2, H11, H7), 3.01 (t, 2H, J = 6.2, 2.0 Hz, 2H, CH2, H10), 2.41 (t, J = 5.7 
Hz, 2H, CH2, H6), 2.15 (s, 3H, CH3, H22), 2.07 (s, 3H, CH3, H19), 1.08 (s, CH3, H24), 
1.04 (s, CH3, H23). 
19F NMR (with proton decoupled, 470 MHz, CDCl3) δ -70.51 (s, CF=CH). 
HRMS (ES+) m/z: found [M+Na+] 487.1507 [C19H29O8N2FNaS] requires M
+ 487.1521.  
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5.10.1. (O,O-Diacetyl)-S-difluoro ethyl thioether-D-pantetheine (433)12 
 
  
Derivative 433 was synthesized following the procedure described by Bello et al.12 
In a polytetrafluoroethylene round bottom flask, O,O’-Diacetyl-S-ethynyl-D-pantetheine 
363 (0.12 g,0.31 mmol, 1 equiv.) was diluted in dry dichloromethane (5 mL)  and Olah’s 
reagent ( pyridine 30 %, hydrogen fluoride ~70 % 236 µL, 0.91 mmol, 3 equiv.) was 
added and the reaction was stirred for 15h . After completion, the reaction was quenched 
with a saturated sodium carbonate solution (20 mL) and extracted with dichloromethane 
(30 mL). The crude was purified by semipreparative HPLC (tr = 17.00 min, isocratic 
conditions of 90:10 acetonitrile: water for 30 min) to yield an oil (obtained 0.022 g, 0.052 
mmol, 17 % yield). 
1H NMR (500 MHz, CDCl3) δ 6.85 (br t, J = 6.3 Hz, 1H, NH), 6.07 (br t, J = 6.4 Hz, 1H, 
NH), 4.91 (s, 1H, CH, H12), 4.02 (d, J = 11.0 Hz, 1H, CH2, H14a, H14b), 3.83 (d, J = 11.0 
Hz, 1H, , CH2, H14a, H14b), 3.61 – 3.41 (m, 4H, CH2, H9, H5), 2.97 (t, J = 6.5 Hz, 2H, 
CH2, H4), 2.39 (t, J = 5.7 Hz, 2H, CH2, H8), 2.14 (s, 3H, CH3, H20), 2.06 (s, 3H, CH3, 
H17), 1.92 (t, J = 16.8 Hz, 3H, CH3, H1), 1.05 (s, 3H, CH3, H22), 1.01 (s, 3H, CH3, H21).  
19F NMR (with proton coupled, 471 MHz, CDCl3) δ -66.23 (m, J = 16.7 Hz, CF2).  
13C NMR (126 MHz, CDCl3) δ 171.8 (COCH3, C19), 171.1 (CONH, C11), 170.1 (COCH3, 
C16), 168.2 (CONH, C7), 77.3 (CH, C12), 69.4 (CH2, C14), 39.5 (CH2, C8), 35.2, 35.1 
(CH2, C4, C9), 28.3 (CH2, C5), 26.5 (CH3F2, JCF= 25.8 Hz, C1), 21.5 (CH3, C20), 21.0 
(CH3, C17), 20.9 (CH3, C22), 20.9 (CH3, C21).  
m/z (ESI+): Found [M+Na]+ 449.1521, C17H28O6N2F2NaS  requires M+ 449.1528 
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5.10.2.  (O,O-Dihydroxy)-S-difluoro ethyl thioether-D-pantetheine (415) 
 
 
 
In a round bottom flask, derivative 433 (0.036 g, 0.085 mmol, 1 equiv.) was dissolved in 
methanol (24 mL). Sodium methoxide (5.4 M in methanol, 40 µL, 0.26 mmol, 3 equiv.) 
was added and the reaction was stirred for 2h. After completion, the solvent was 
removed under vacuum and freeze dried. The crude was purified by semipreparative 
HPLC (tr =17.50 min, gradient elution method: acetonitrile / water containing 0.05 % 
trifluoroacetic acid, from 0% to 25% of acetonitrile in 10 min, then from 25% to 60% for 
10 min, 60% to 100% in 6 min to wash the column then down to 0% to equilibrate the 
column) to give a colourless oil. (obtained 0.015 g, 0.058 mmol, 69% yield) 
1H NMR (400 MHz, D2O) δ 7.39 (br t, J = 6.4 Hz, 1H, NH), 6.32 (br t, J = 6.3 Hz, 1H, 
NH), 4.00 (s, 1H, CH, H12), 3.67 – 3.35 (m, 6H, CH2, H14a, H14b, H9, H5), 2.98 (t, J = 
6.5 Hz, 2H, CH2, H4), 2.52 – 2.36 (m, 2H, CH2, H8), 1.93 (t, J = 16.8 Hz, 3H, CH3, H1), 
1.01 (s, 3H, CH3, H17), 0.92 (s, 3H, CH3, H16). 
19F NMR (with proton decoupled, 471 MHz, D2O) δ -75.67 (CF2). 
13C NMR (126 MHz, D2O) δ 173.9 (CONH, C11), 172.1 (CONH, C7), 77.5 (CH, C12), 
71.3 (CH2, C14), 39.9 (CH2, C8), 36.0, 35.6 (CH2, C4, C9), 28.5 (CH2, C5), 26.4 (CH3, 
JCF = 25.7 Hz, C1), 21.9 (CH3, C17), 20.8 (CH3, C16). 
m/z (ESI+): Found [M+Na] + 365.1311, C13H24O4N2F2NaS requires M+, 365.1317 
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5.11.1. Pantothenic acid acetonide (480)13 
 
 
The desired compound was prepared according to the procedure reported by Storz et 
al. 13 
D-pantothenic acid hemicalcium salt (10 g, 0.04 mmol, 1 equiv.) was dissolved in 
acetone (15 mL) followed by the addition of anhydrous oxalic acid (18 g, 0.2 mmol, 5 
equiv.). Then a solution of 2,2-dimethoxy propane (4.20 g, 0.04 mmol, 1 equiv.) in 
acetone (15 mL) was added and the reaction was refluxed for 16 h. Upon completion, 
the calcium oxalate was filtered off and the solvent was removed under pressure. The 
residue was dissolved in ethyl acetate (30 mL), washed with water (30 mL) and dried 
over magnesium sulfate. The solvent was removed under reduced pressure and the 
residue was triturated in hexane to give the desired compound as a white solid (obtained 
7.80 g, 0.03 mmol, 75% yield).  
m.p.87-89 °C 
1H NMR (400 MHz, CDCl3) δ 7.03 (br t, J = 6.4 Hz, 1H, NH), 4.10 (s, 1H, CH, H5), 3.73 
– 3.66 (d, J = 11.7 Hz, 1H, CH2, H8a, H8b), 3.65 – 3.55 (m, 1H, CH2, H3), 3.54 – 3.43 (m, 
1H, CH2, H3), 3.28 (d, J = 11.7 Hz, 1H, CH2, H8a, H8b), 2.62 (t, J = 6.2 Hz, 2H, CH2, H2), 
1.46 (s, 3H, CH3, H11), 1.43 (s, 3H, CH3, H10), 1.03 (s, 3H, CH3, H13), 0.97 (s, 3H, CH3, 
H12). 
These data are in agreement with the published procedure.13  
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5.11.2. α,β,β-trifluorocyclopropyl-carboxyamido-ethyl-carbamate (476)14 
 
 
 
The product was prepared according to the procedure reported by Thomson et al.14 
Carbamic acid (0.70 g,3.56 mmol, 5 equiv.) was dissolved in dimethylformamide (6 mL), 
followed by α,β,β-trifluorocyclopropane-1-carboxylic acid 457 (supplied by Dr Q. Zhang 
from the university of St Andrews)1 (0.10 g, 0.71 mmol, 1 equiv.), 1-hydroxybenzotriazole 
hydrate (0.19 g, 1.40 mmol, 2 equiv.) and triethylamine (501 µL, 3.60 mmol, 5 equiv.). 
The solution was cooled down to 0 °C. N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (0.27 g, 1.40 mmol, 2 equiv.) was added. The reaction was stirred for 30 
min on ice and at room temperature for 18 h. The solvent was removed under reduced 
pressure and the crude was re-dissolved in dichloromethane (20 mL). The organic layer 
was washed with 1 M hydrochloric acid solution (20 mL) and saturated sodium hydrogen 
carbonate solution, (20 mL). After drying over anhydrous magnesium sulfate, the product 
was purified by flash column chromatography eluting with a mixture of 95/5 
dichloromethane: methanol affording the product as a colourless oil (obtained 0.68 g, 
2.40 mmol, 68% yield). 
1H NMR (500 MHz, CDCl3) δ 7.29 (br t, J = 6.5 Hz, 1H, NH), 5.15 – 4.87 (br t, J = 6.4 Hz, 
1H, NH), 3.46 (m, 2H, CH2, H6), 3.33 (m, 2H, CH2, H7), 2.62 – 2.47 (m, 1H, CH, H2cis, 
H2trans), 2.10 – 1.91 (m, 1H, CH, H2cis, H2trans), 1.43 (s, 9H, CH3, H12, H13, H14). 
13C NMR (126 MHz, CDCl3) δ 163.7 (d, J2CF= 18.5 Hz, CONH, C4), 157.4 (CONH, C9), 
108.5 (tdd, 1JCF= 296.3 Hz, 2JCF=11.0 Hz, 2JCF = 4.6 Hz, CF2, C2 ), 77.8 (CF hidden by 
CDCl3 signal), 41.7 (CH2, C6), 40.1(CH2, C7), 28.7 (CH3, C12, C13, C14), 22.2 (q, J2CF 
= 12.1 Hz, J2 = 10.6 Hz , CH2, C2). 
19F NMR (with proton decoupled, 471 MHz, CDCl3) δ -139.30 (m, CF2), -202.20 (m, CF). 
m/z (ESI+): Found [M+Na] + 305.1078, C11H17O3N2F3Na requires M+, 305.1083 
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5.11.3. α,β,β-trifluorocyclopropyl-carboxyamido-ethyl amine (477) 
 
 
α, β, β-trifluorocyclopropyl-carboxyamido-ethyl carbamate 476 (0.060 g, 0.21 mmol, 
1equiv.) was dissolved in dichloromethane (7 mL) and trifluoro acetic acid (421 µL, 26.59 
mmol, 25 equiv.) was added to the mixture and the reaction was stirred for 3h. The 
solvent was removed under reduced pressure. The residue was diluted with water and 
the pH of the solution was adjusted to pH = 8 with a saturated aqueous solution of sodium 
hydrogen carbonate. The compound was loaded onto a C18 cartridge, washing first with 
water (10 mL) to remove the trifluoro acetic acid excess then with acetonitrile (10 mL) to 
flush down the compound. The solvent was carefully removed under pressure and the 
acetonitrile solution of amine was used in the next step to avoid the loss of the high 
volatile amine.   
1H NMR (400 MHz, MeOD) δ 3.65 – 3.45 (m, 2H, CH2, H6), 3.07 (td, J = 5.8, 1.9 Hz, 2H, 
CH2, H7), 2.48 (m, 1H, CH, H2cis, H2trans), 2.20 (m, 1H, CH, H2cis, H2trans). 
19F NMR (with fluorine decoupled, 377 MHz, MeOD) δ -77.14 (trifluoroacetic acid),  
-140.99 (ddd, 2JFF = 164.5 Hz, 122.2 Hz, 3JFF = 10.6 Hz,1.8 Hz, CF2), -203.96 (ddd, 3JFF 
= 47.6, 12.1, 1.8 Hz, CF). 
m/z (ESI+): Found [M+H] +183.0737, [C6H10ON2F3] requires M
+ 183.0740 
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5.11.4. (O,O-acetonide)-S-α,β,β-trifluorocyclopropyl-D-pantetheine (481)14 
 
 
 
α, β, β-trifluorocyclopropyl-carboxyamido-ethyl amine 477 (0.019 g, 0.10 mmol, 1 equiv.) 
was dissolved in dimethylformamide (3 mL) followed by derivative 480 (0.032 g, 0.12 
mmol, 1.2 equiv.), 1-hydroxybenzotriazole hydrate (0.018 g, 0.20 mmol, 2 equiv.) and 
triethylamine (43 µL, 0.31 mmol, 3 equiv.). The solution was cooled down to 0 °C and N-
(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.030 g, 0.15 mmol, 1.5 
equiv.) was added. The reaction was stirred for 30 min on ice bath and at room 
temperature for 18 h. The solvent was removed under reduced pressure and the crude 
was re-dissolved in dichloromethane (20 mL). The organic layer was washed with 1 M 
hydrochloric acid solution (5 mL) and saturated sodium hydrogen carbonate solution (5 
mL). After drying over anhydrous magnesium sulfate, the product was purified by flash 
column chromatography eluting with a mixture of 95/5 dichloromethane: methanol 
affording the product as a colourless oil (obtained 0.020 g, 0.047 mmol, 46% yield).  
1H NMR (500 MHz, CDCl3) δ 7.49 (br t, J = 6.3 Hz, 1H, NH), 7.04 (br t, J = 6.4 Hz, 1H, 
NH), 6.82 (br t, J = 6.5 Hz, 1H, NH), 4.07 (s, 1H, CH, H14), 3.67 (d, J = 11.7 Hz, 1H, 
CH2, H16a, H16b), 3.60 – 3.36 (m, 6H, CH2, H11, H10, H8), 3.27 (dd, J = 11.7, 1.9 Hz, 
1H, CH2, H16a, H16b), 2.55 (m, 1H, CH, H2cis, H2trans), 2.50- 2.43 (m, 2H, CH2, H6), 2.02 
(m, 1H, CH, H2), 1.45 (d, J = 1.5 Hz, 3H, CH3, H18), 1.41 (s, 3H, CH3, H19), 1.01 (s, 3H, 
CH3, H21), 0.95 (s, 3H, CH3, H20). 
19F NMR (with proton decoupled, 470 MHz, CDCl3) δ -75.17 (trifluoroacetic acid) -139.22 
(ddd, 2JFF = 165.1 Hz, 3JFF = 12.3 Hz, CF2), -202.10 (dd, 3JFFcis = 47.3 Hz, 12.0 Hz, CF). 
13C NMR (126 MHz, CDCl3) δ 172.4 (CONH, C1), 170.6 (CONH, C20), 163.3 (d, 2JCF= 
20.2 Hz, CONH, C4),106.7 (td, 1JCF = 295.5 Hz, 2JCF = 8.3 Hz, C1) 77.3 (CH, C14), (CF 
signal hidden by chloroform signal), 71.4 (CH2, C16), 40.6 (CH2, C11), 39.5 (CH2, C10), 
36.4 (CH2, C6), 34.9 (CH2, C7), 29.5 (CH3, C19), 22.1 (CH3, C18), 21.87 (q, 2JCF = 10.4 
Hz, CH2, C2), 18.8 (CH3, C21), 18.6 (CH3, C20). 
m/z (ESI+): Found [M+Na]+446.1864 [C18H28O5N3F3Na]+requires M
+ 446.1873 
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5.11.5. (O,O-acetonide)-S-α,β,β-trifluorocyclopropyl-D-pantetheine (478)  
 
 
 
Compound 478 was prepared according to the same procedure described for 481 using 
compound 294 as protected pantothenic acid. The crude was purified by flash 
chromatography with a mixture of 90/10 dichloromethane: methanol to afford the desired 
compound as a colourless oil (obtained 0.007 g, 0.016 mmol, 16 % yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.50 (br t, J = 6.5 Hz, 1H, NH), 6.86 (br t, J = 6.4 Hz, 1H, 
NH), 6.63 – 6.44 (br t, 6.4 Hz, 1H, NH), 4.85 – 4.72 (s, 1H, CH, H14), 4.02 (dt, J = 11.1, 
3.3 Hz, 1H, CH2, H16a, H16b), 3.84 (dd, J = 11.0, 5.6 Hz, 1H, CH2, H16a, H16b), 3.73 – 
3.23 (m, 4H, CH2, H11, H7), 2.53 (m, 1H, CH, H2cis, H2trans), 2.47 – 2.31 (m, 1H, CH, 
H2cis, H2trans), 2.14 (s, 3H, CH3, H22), 2.10-1.97 (m, 2H, CH2, H10), 2.06 (s, 3H, CH3, 
H19), 1.34 - 1.20 (m, 2H, CH2, H6), 1.05 (s, 3H, CH3, H24), 1.03 (s, 3H, CH3, H23). 
19F NMR (with proton coupled, 470 MHz, CDCl3) δ -139.20 (m, CF2), -201.98 (m, CF). 
m/z (ESI+): Found [M+Na]+ 490.1768, [C19H29O7N3F3Na]+requires M
+ 490.1800 
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5.11.6. (O,O-Dihydroxy)-S-α,β,β-trifluorocyclopropyl-D-pantetheine (479)  
 
 
 
Derivative 481 (0.043 g, 0.10 mmol, 1 equiv.) was dissolved in a mixture of 
tetrahydrofuran: water (2:1, 4 mL) followed by the addition of para-toluene sulfonic acid 
(0.031 g, 0.16 mmol, 1.6 equiv.) and the reaction was stirred for 2h. Upon completion, 
the solvent was removed under pressure and the residue was freeze dried to remove 
the last traces of water. The crude was purified by semipreparative HPLC (rt = 20 min 
gradient elution method: acetonitrile / water containing 0.05 % trifluoroacetic acid, from 
0% to 25% of acetonitrile in 10 min, then from 25% to 60% for 10 min, 60% to 100% in 
6 min to wash the column then down to 0% to equilibrate the column) to give the desired 
compound as colourless deliquescent solid (obtained 0.021 g, 0.056 mmol, 56% yield). 
1H NMR (500 MHz, D2O) δ 3.99 (s, 1H, CH, H14), 3.59 – 3.28 (m, 8H, H16a, H16b, H11, 
H10, H7), 2.60 – 2.51 (m, 1H, CH, H2cis, H2trans), 2.49 (t, J = 6.6 Hz, 2H, CH2, H6), 2.34 
(m, 1H, CH, H2cis, H2trans), 0.92 (s, 3H, CH3, H18), 0.89 (s, 3H, CH3, H17). 
13C NMR (126 MHz, D2O) δ 175.1 (CONH, C13), 174.3 (CONH, C9), 163.0 (q, 2JCF = 
35.6 Hz, CONH, C4), 116.37 (q, 1JCF = 291.8 Hz, CF2, C2), 75.8 (CH2, C14), (CF signal 
hidden by CDCl3 signal), 68.4 (CH2, C16), 38.9, 38.6, 38.5 (CH2, C7), 35.4, 35.3 (CH2, 
C5, C11), 21.7 (q, 2JCF = 10.5 Hz, CH2, C3), 20.4 (CH3, C18), 19.1 (CH3, C17).  
19F NMR (with proton decoupled, 471 MHz, D2O) δ -75.17 (trifluoro acetic acid), -139.63 
(ddd, 2JFF = 164.6 Hz, CF2), -201.86 (dd, 3JFFcis = 47.2 Hz, 12.0 Hz, CF).  
m/z (ESI+): Found [M+Na]+406.1557 [C15H24O5N3F3Na]+ requires M
+ 406.1560. 
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The cloning and overexpression of PanK, PPAT and DPCK enzymes was carried out by 
Dr. Nouchali Bandaranayaka from the University of St. Andrews according to published 
procedures.2,15 The plasmids were gifted by Dr. Manuela Tosin from the University of 
Warwick. 15  
PanK, PPAT, and DPCK were PCR amplified from E.Coli K12 genomic DNA using the 
following primer pairs.  
 
PanK enzyme  
Primers used for pET-29b plasmid 
PanK p1 ACATGCATATGAGTATAAAAGAGCAAACGT NdeI  
PanK p2 CTCCCCTCGAGATTATTTGCGTAGTCTGAC XhoI  
 
PPAT enzyme 
Primers used for pET-29b plasmid 
PPAT1 forward GTCTCTAGAGCTAGCATGCAAAAACGGGCGATTTAT NheI  
PPAT2 reverse CGCGGATCCAAGCTTCTACGCTAACTTCGCC BamHI  
 
DPCK enzyme 
Primers used for pETHISTEV plasmid 
DPCKFP – 5’GGAACTGGATCCATGAGGTATATAGTTGCCTTAACGGGA BamHI 
DPCKRP - CCGATTCTCGAGTTACGGTTTTTCCTGTGAGACAAACTG XhoI 
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The enzymatic synthesis and characterization of the products have been performed 
following the protocol used for Fluoro vinylthioether-CoA 212.1  
The diol derivative (259, 260, 312, (Z)-334,(E)-335, 479, 20 mg) was dissolved in 200 µL 
of a 1M aqueous buffer solution of Tris-HCl at pH 7.8 (50 mM) followed by adenosine 5’-
trisphosphate disodium salt hydrate (40 mg, 20 mM), an aqueous solution of magnesium 
chloride (2 mM, 4µL). The resulting mixture was diluted with Milli-Q® water (1 mL). The 
pH was adjusted to 7.5 using a 30% aqueous solution of sodium hydroxide, and the stock 
solutions of PanK (5 mg/mL, 1 mL) and PPAT (5 mg/mL, 1 mL) were added, followed by 
Milli-Q® water to adjust the final volume to 4 mL. The resulting mixture was incubated 
for 20 hours at 37 ºC, then it was treated with chloroform (4 mL) to precipitate the 
enzymes. The mixture was shaken thoroughly and centrifugated at 4000 rpm for 10 
minutes. The aqueous supernatant was pipetted out, and fresh Milli-Q® water (2 mL) 
was added, the protein pellet re-suspended and the mixture centrifugated at 4000 rpm 
for a further 10 minutes. The aqueous supernatant was removed and the combined 
aqueous layers were frozen in liquid nitrogen and freeze-dried. The crude material was 
purified by semipreparative HPLC using a linear gradient of acetonitrile and water 
containing 0.05 % trifluoroacetic acid and a Phenomenex Synergi® 4μ Polar-RP 
80Å 250 x 10.0 mm. The eluted fractions were pooled, combined and the pH was 
corrected to slightly above 7.0 using a concentrated aqueous solution of ammonium 
hydroxide. The resulting mixture was gently concentrated under reduced pressure or a 
stream of argon gas to remove the acetonitrile, then it was frozen in liquid nitrogen and 
freeze dried, to afford the desired dephospho-coenzyme A intermediate as an 
ammonium salt.  
The final phosphorylation at the 3’ position on the ribose ring was achieved by dissolving 
the material obtained in the biotransformation described above (purified by HPLC) in 
Tris-HCl at pH 7.8 (200 µL, 50 mM). Adenosine 5’-trisphosphate disodium salt hydrate 
(40 mg, 20 mM) and an aqueous solution of MgCl2 (2 mM, 4µL) were added, and the 
resulting mixture was diluted with Milli-Q® water (1 mL) and the pH was adjusted to 7.5 
using a 30% aqueous solution of sodium hydroxide. Stock solutions of DPCK (5 mg/mL, 
1mL) was added, followed by Milli-Q® water to bring up the final reaction volume to 4 
mL. The resulting mixture was incubated for 20 hours at 37 ºC, then it was treated with 
chloroform (4 mL) to precipitate the protein. The mixture was shaken and centrifugated 
at 4000 rpm for 10 minutes. The aqueous supernatant was pipetted out, and fresh Milli-
Q® water (2 mL) was added, the protein pellet re-suspended and the mixture 
centrifugated at 4000 rpm for a further 10 minutes. The aqueous supernatant was 
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removed and the combined aqueous layers were frozen in liquid nitrogen and freeze-
dried. The resulting material was purified by semipreparative HPLC (Phenomenex 
Synergi® 4μ Polar-RP 80Å 250 x 10.0 mm). The eluted fractions were pooled, combined 
and the pH was adjusted to slightly above 7.0 using a concentrated aqueous solution of 
ammonium hydroxide. The resulting mixture was gently concentrated under reduced 
pressure and freeze dried to afford the final coenzyme-A analogue as an ammonium 
salt.1 
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5.13.1. S-Fluorovinyl-dethia-coenzyme A (261)1 
 
 
 
 
 
Compound 261 was synthesised accordingly to the general procedure described above. 
Fluoro dethia vinyl diol 259 (0.020 g, 0.025 mmol) was converted to Coenzyme A 
analogue 261 which was obtained as a colourless, highly hydroscopic solid in an overall 
yield of 25% (0.005 g as an ammonium trifluoroacetate salt) after purification by 
semipreparative HPLC chromatography using a Phenomenex Synergi® 4μ Polar-RP 
80Å 250 x 10.0 mm column and a linear gradient of water and acetonitrile containing 
0.05% trifluoroacetic acid (0 to 15% acetonitrile in 10 min, then 15% acetonitrile for 10 
min, then from 15% to 80% acetonitrile in 3 min to wash the column, then from 80% to 
0% acetonitrile in 3 minutes, and 0% acetonitrile for 10 min to re-equilibrate the column). 
Retention time: 15.0 min (detector: 215 nm).1 
1H NMR (700 MHz, D2O) δ 8.54 (s, 1H, CH, H2), 8.25 (s, 1H,CH, H6), 6.15 (d, J = 6.7 
Hz, 1H, CH, H1’), 4.84 - 4.73 (2H, m, CH, H2’ and H3’, signals partially hidden by water 
peak), 4.57 (s, 1H, CH, H4’), 4.51 (ddd, J FH(cis)  = 18.5, 3.0 Hz, 1H, CH, H23cis), 4.35 – 
4.24 (dd, JFH(trans) = 50.0 , 3.0 Hz, 1H, CH, H23trans), 4.22 (s, 2H, CH2, H5’a, H5’b), 3.99 
(s, 1H, CH, H12), 3.81 (dd, J = 10.1, 3.6 Hz, 1H, CH, H10a, H10b), 3.53 (dd, J = 10.1, 3.4 
Hz, 1H, CH, H10a, H10b), 3.47 – 3.38 (m, 2H, CH2, H15), 3.13 (t, J = 6.9 Hz, 2H, CH2, 
H19), 2.41 (t, J = 6.6 Hz, 2H, CH2, H16), 2.20 – 2.13 (m, 2H, CH2, H21), 1.62 (p, J = 7.2 
Hz, 2H, CH2, H20), 0.86 (s, 3H, CH3, H24), 0.73 (s, 3H, CH3, H25).  
19F NMR (with proton decoupled, 659 MHz, D2O) δ -76.01 (trifluoro acetic acid), -95.93 
(m, CH2=CHF).  
m/z (ESI-): Found [M-H]- 792.1585, C24H38O16N7FP3 requires M- 792.1577. 
1H NMR peak values were assigned by using 2D experiments (DQF-COSY) reported in 
Chapter 2 and by comparison with the structure of compound 212.1 
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5.13.2. S-Vinyl-dethia-coenzyme-A1(262) 
 
 
 
 
Compound 262 was prepared accordingly to the general procedure described above. 
Starting from diol 260 (0.020 g, 0.026 mmol), the coenzyme A mimetic 262 was obtained 
as a colourless, highly hydroscopic solid in an overall yield of 25% (0.005 g as an 
ammonium trifluoroacetate salt) after purification by semipreparative HPLC 
chromatography using a Phenomenex Synergi® 4μ Polar-RP 80Å 250 x 10.0 mm 
column and a linear gradient of water and acetonitrile with 0.05% trifluoroacetic acid (0 
to 15% acetonitrile in 10 min, then 15% acetonitrile for 10 min, then from 15% to 80% 
acetonitrile in 3 min to wash the column, then from 80% to 0% acetonitrile in 3 minutes, 
and 0% acetonitrile for 10 min to re-equilibrate the column). Retention time: 15.1 min 
(detector: 215 nm).1 
1H NMR (500 MHz, D2O) δ 8.50 (s, 1H, CH, H2), 8.21 (s, 1H, CH, H6), 6.12 (d, J = 6.9 
Hz, 1H, CH, H1’), 5.76 (ddt, J = 17.0, 10.3, 6.6 Hz, 1H, CH, H22), 5.01 – 4.88 (m, 2H, 
CH2, H23, H23’), 4.84 - 4.73 (m, 2H, CH, H2’ and H3’, signals partially hidden by water 
peak), 4.53 (br, 1H, CH, H4’), 4.18 (s, 2H, CH2, H5’a, H5’b), 3.95 (s, 1H, CH, H12), 3.77 
(dd, J = 9.8, 4.8 Hz, 1H, CH, H10a, H10b), 3.49 (dd, J = 9.8, 4.8 Hz, 1H, CH, H10a, H10b), 
3.40 (td, J = 6.5, 3.0 Hz, 2H, CH2, H15), 3.05 (t, J = 7.0 Hz, 2H, CH2, H19), 2.38 (t, J = 
6.6 Hz, 2H, CH2, H16), 1.96 (q, J = 7.1 Hz, 2H, CH2, H20), 1.47 (p, J = 7.2 Hz, 2H, CH2, 
H21), 0.83 (s, 3H, CH3,  H24), 0.69 (s, 3H, CH3, H25). 
 m/z (ESI-): Found [M-H]- 774.1679, C24H39O16N7P3 requires M- 774.1672. 
1H NMR peak values were assigned by using 2D experiments (DQF-COSY) reported in 
Chapter 2 and by comparison with the structure of compound 261.1 
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5.13.3. S-Sulfoxide-Coenzyme-A (305)1 
 
 
 
 
 
 
Compound 305 was synthesised following the general procedure described above. Diol 
312 (0.020 g, 0.062 mmol) was converted to coenzyme A mimic 305 which was obtained 
as a colourless, highly hydroscopic solid in an overall yield of 30% (6 mg as an 
ammonium trifluoroacetate salt) after purification by semipreparative HPLC 
chromatography using a Phenomenex Synergi® 4μ Polar-RP 80Å 250 x 10.0 mm 
column and a linear gradient of water and acetonitrile containing 0.05% trifluoroacetic 
acid (0 to 15% acetonitrile in 10 min, then 15% acetonitrile for 10 min, then from 15% to 
80% acetonitrile in 3 min to wash the column, then from 80% to 0% acetonitrile in 3 
minutes, and 0% acetonitrile for 10 min to re-equilibrate the column). Retention time: 
13.6 min (detector: 254 nm).1 
1H NMR (500 MHz, D2O) δ 8.52 (s, 1H, CH, H2), 8.24 (s, 1H, CH, H6), 6.14 (d, J = 6.7, 
1H, CH, H1’), 4.78 - 4.73 (m, 1H, CH, H2’ and H3’, signals partially hidden by water 
peak), 4.54 (br s, 1H, CH, H4’), 4.21 (br s, CH, 2H, H5’a, H5’b), 3.97 (s, 1H, CH, H12), 
3.78 (dd, J = 9.9, 4.4 Hz, 1H, CH2, H10a, H10b), 3.52 (dd, J = 8,6 Hz, 1H, CH2, H10a, 
H10b), 3.43 (t, J = 6.6 Hz, 2H, CH2, H15), 3.25 ( t, J = 6.9 Hz, 2H, CH2, H19), 2.89 - 2.76 
(m, 2H, CH2, H21), 2.65 (s, 3H, CH3, H23), 2.42 (t, J = 6.6 Hz, 2H, CH2, H20), 1.92 - 1.83 
(m, 2H, CH2, H16), 0.84 (s, 3H, CH3, H24), 0.72 (s, 3H, CH3, H25); 
m/z (ESI-): Found [M-H]- 810.1341, C23H39O17N7P3S requires M- 810.1341.  
1H NMR peak values were assigned by using 2D experiments (DQF-COSY) reported in 
Chapter 2 and by comparison with the structure of compound 261 .1 
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5.13.4. Purification and separation of Co-enzyme-A analogues (Z)-319 and (E)-3201 
 
Compound (E)-320 and compound (Z)-319 were synthesised accordingly to the general 
procedure described above. As described in Chapter 2, isomers diol (E)-335 and (Z)-
334 (20.0 mg, 0.055 mmol) were progressed as a mixture to generate intermediates (E)-
337 and (Z)-336 which were separated at this stage. Intermediates (E)-337 and (Z)-336 
were finally converted to coenzyme-A analogues (E)-320 and (Z)-319.1 
5.13.5. S-(Z-propenoic-3-yl)-coenzyme A (Z)-3191 
 
 
 
 
 
Compound (Z)-319 was synthesised as a colourless, highly hydroscopic solid in an 
overall yield of 13% (0.006 g as an ammonium trifluoroacetate salt) after purification by 
semipreparative HPLC chromatography using a Phenomenex Synergi® 4μ Polar-RP 
80Å 250 x 10.0 mm column and a linear gradient of water and acetonitrile containing 
0.05% trifluoroacetic acid (0 to 15% acetonitrile in 10 min, then 15% acetonitrile for 10 
min, then from 15% to 80% acetonitrile in 3 min to wash the column, then from 80% to 
0% acetonitrile in 3 minutes, and 0% acetonitrile for 10 min to re-equilibrate the column). 
Retention time: 14.4 min (detector: 215 nm). 
1H NMR (500 MHz, D2O) δ 8.55 (s, 1H, CH, H2), 8.28 (s, 1H, CH, H6), 6.93 (d, JZ = 10.1 
Hz, CH, 1H, CH, H21), 6.18 (d, J = 6.4 Hz, 1H, CH, H1’), 5.85 (d, JZ = 10.0 Hz, 1H, CH, 
H22), 4.84 - 4.73 (m, 2H, CH2, H2’ and H3’, signals partially hidden by water peak), 4.60 
(br s, 1H , CH, H4’), 4.25 (s, 2H, CH2, H5’a, H5’b), 4.01 (s, 1H, CH, H12), 3.83 (dd, J = 6.7 
Hz , 1H , CH2, H10a, H10b), 3.60 (dd, J = 6.6 Hz, 1H, CH2, H10a, H10b), 3.47 (t, J = 6.7 
Hz, 2H, CH2, H15), 3.40 (t, J = 6.7 Hz, 2H, CH2, H16), 2.85 (t, J = 6.8 Hz, 2H, CH2, H19), 
2.45 (t, J= 6.8 Hz, 2H, CH2, H20), 0.89 (s, 3H, CH3, H23), 0.76 (s, 3H, CH3, H24).  
m/z (ESI-): Found [M-H]- 836.1145, C24H37O18N7P3S requires M- 836.1134 .  
1H NMR peak values were assigned by using 2D experiments (DQF-COSY) reported in 
Chapter 2 and by comparison with the structure of compound 261.1 
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5.13.6. S-(E-propenoic-3-yl)-coenzyme A (E)-3201 
 
 
 
 
 
 
Coenzyme A mimic (E)-320 was obtained as a colourless, highly hydroscopic solid in an 
overall yield of 15% (0.007 g as an ammonium trifluoroacetate salt) after purification by 
semipreparative HPLC chromatography using a Phenomenex Synergi® 4μ Polar-RP 
80Å 250 x 10.0 mm column and a linear gradient of water and acetonitrile containing 
0.05% trifluoroacetic acid (0 to 15% acetonitrile in 10 min, then 15% acetonitrile for 10 
min, then from 15% to 80% acetonitrile in 3 min to wash the column, then from 80% to 
0% acetonitrile in 3 minutes, and 0% acetonitrile for 10 min to re-equilibrate the column). 
Retention time: 13.9 min (detector: 215 nm).1 
1H NMR (500 MHz, D2O) δ 8.54 (s, 1H, CH, H2), 8.26 (s, 1H, CH, H6), 7.47 (d, JE = 15.3 
Hz, 1H, CH, H21), 6.16 (d, J = 6.4 Hz, 1H, CH, H1’), 5.79 (d, JE = 15.2 Hz, 1H, CH, H22), 
4.84 - 4.73 (2H, m, H2’ and H3’, signals partially hidden by water peak), 4.57 (br, 1H, 
CH, H4’), 4.22 (s, 2H, CH2, H5’a, H5’b), 3.98 (s, 1H, CH, H12), 3.79 (dd, J = 6.7 Hz, 1H, 
CH2, H10a, H10b), 3.57 – 3.48 (dd, 1H, CH2, H10a, H10b), 3.43 (t, J = 6.5 Hz, 2H, CH2, 
H15), 3.39 (t, J = 6.5 Hz, 2H, CH2, H16), 2.92 (t, J = 6.5 Hz, 2H, CH2, H19), 2.42 (t, J = 
6.5 Hz, 2H, CH2, H20), 0.87 (s, 3H, CH3, H24), 0.74 (s, 3H, CH3, H23).  
m/z (ESI-): Found [M-H]- 836.1146, C24H37O18N7P3S requires M- 836.1134. 
1H NMR peak values were assigned by using 2D experiments (DQF-COSY) reported in 
Chapter 2 and by comparison with the structure of compound 261.1 
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5.13.7. S-α,α,β-trifluorocyclopropyl-Coenzyme-A (462) 
 
 
 
Compound 462 was prepared accordingly to the general procedure described above. 
Starting from a sample of diol 479 (0.020 g, 0.023 mmol), the coenzyme A analogue 462  
was obtained as a colourless, highly hydroscopic solid in an overall yield of 10% (0.003 
g as an ammonium trifluoroacetate salt) after purification by semipreparative HPLC 
chromatography using a Phenomenex Synergi® 4μ Polar-RP 80Å 250 x 10.0 mm 
column and a linear gradient of water and acetonitrile containing 0.05% trifluoroacetic 
acid (0 to 15% acetonitrile in 10 min, then 15% acetonitrile for 10 min, then from 15% to 
80% acetonitrile in 3 min to wash the column, then from 80% to 0% acetonitrile in 3 
minutes, and 0% acetonitrile for 10 min to re-equilibrate the column). Retention time: 
16.2 min (detector: 215 nm). 
1H NMR (500 MHz, D2O) δ 8.51 (s, 1H, CH, H2), 8.22 (s, 1H, CH, H8), 6.13 (d, J = 6.6 
Hz, 1H, CH, H1’), 4.93 - 4.67 (m, 2H, CH, H2’ and H3’, signals partially hidden by water 
peak), 4.54 (s, 1H, CH, H4’), 4.19 (s, 2H, CH2, H5’a, H5’b), 3.96 (s, 1H, CH, H12), 3.78 
(dd, J = 9.8, 4.1 Hz, 1H, CH, H10a, H10b), 3.51 (dd, J = 9.8, 4.0 Hz, 1H, CH, H10a, H10b), 
3.43 – 3.32 (m, 4H, CH2, H15, H19), 3.27 (dq, J = 6.1, 3.6, 3.0 Hz, 2H, CH2, H16), 2.52 
– 2.41 (m, 1H, CH, H21cis, H21trans), 2.38 (t, J = 6.7 Hz, 2H, CH2, H20), 2.34 – 2.14 (m, 
1H, CH, H21cis, H21trans), 0.83 (s, 3H, CH3, H25), 0.71 (s, 3H, CH3, H24). 
19F NMR (with proton decoupled, 471 MHz, D2O) δ -75.76 (trifluoroacetic acid), -139.82 
(m, CF2, 2JFF = 164.7 Hz), -201.83 (m, CF). 
m/z (ESI+): Found [M+Na]+ 895.1157, C25H40F3N8NaO17P3 requires [M++ Na] 895.1170. 
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5.14.1. Materials and methods1 
 
Porcine heart Citrate Synthase was purchased from Sigma-Aldrich (C3260-KU, 1000 
units) as an ammonium sulfate suspension. It was diluted with water (5 mL), affording a 
concentration of 13.47 µM (0.58 mg/mL, determined by using the A280 method on a 
Nanodrop® UV-Vis spectrophotometer). This mixture was then further diluted with TRIS 
buffer (200 mM, pH = 8.0) to afford stock solutions at the required concentrations as 
described for each assay. 
Oxaloacetate (OAA) and dithionitrobenzoic acid (DTNB) were purchased from Sigma-
Aldrich and the stock solutions and buffers prepared using MilliQ® water obtained from 
a MilliQ® apparatus. These were either used immediately or frozen in liquid nitrogen and 
stored at - 80 ºC. 
Acetyl CoA trilithium salt was purchased from Sigma-Aldrich and diluted with phosphate 
buffer (5 mM, pH 6); the concentration of the resulting stock solution was then checked 
on a Thermo Spectrophotometer (path length 1 cm) at 260 nm (ε260 = 15400 cm-1 M-1) 
and diluted accordingly using the phosphate buffer to the desired concentrations. Due to 
the intrinsic instability of acetyl CoA in solution, the mixture were either used immediately 
or frozen in liquid nitrogen and stored at - 80 ºC. 
 
5.14.2. Determination of IC50 and Kiapp for the inhibition of citrate synthase 
 
The procedure used to assess IC50 and Kiapp of compounds 261, 262, 305, (Z)-319, (E)-
320, 462 is fully described in Chapter 2.  
IC50 values were estimated according to the protocol described in Chapter 2, using the 
software GraphPad® and applying the log (inhibitor) vs. response - variable slope model 
(Y = bottom + (Top - bottom) / {1+ 10^ [(Log IC50 - X)*HillSlope]}). The reported errors 
propagation values on IC50 and Kiapp measurements were derived from a standard error 
propagation calculator.  
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5.14.3. Fluorovinyl-dethia-coenzyme-A (261) IC50 and Kiapp 1 
 
The following results were obtained for compound 261 applying the general procedure 
described above. Stock solutions of compound 261 in MilliQ® water were prepared and 
their concentration accurately measured spectrophotometrically by using standard 
curves obtained from coenzyme A. The measurements were then carried out gradually 
increasing the concentration of compound 261 (20 μM, 63 μM, 282 μM, 489 μM, 1 mM) 
in duplicates. 
Computed values for compound 261: 
 
IC50 = 238.8 (± 47.9) µM 
Kiapp = 44.8 (± 9.2) µM 
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5.14.4. Vinyl-dethia-coenzyme-A (262) IC50 and Kiapp 1 
 
The following data were acquired for compound 262 as described in the general 
procedure reported above. Stock solutions of compound 262 in MilliQ® water were 
prepared and their concentration accurately determined spectrophotometrically by using 
standard curves obtained from coenzyme A. The measurements were then carried out 
gradually increasing the concentration of compound 262 (163 μM, 245 μM, 490 μM, 1.2 
mM) in duplicates. 
Computed values for compound 262: 
 
IC50 = 281.9 (± 32.4) µM 
Kiapp = 53.1 (± 6.5) µM 
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5.14.5. Sulfoxide Coenzyme A (305) IC50 and Kiapp 1 
 
The following data were obtained for compound 305 as described in the general 
procedure reported above and they are related to the diastereoisomeric mixture. Stock 
solutions of compound 305 in MilliQ® water were prepared and their concentration 
accurately determined spectrophotometrically by using standard curves obtained from 
coenzyme A. The measurements were then carried out gradually increasing the 
concentration of compound 305 (25 μM, 50 μM, 75 μM, 300 μM, 500 μM, 1.0 mM) in 
duplicate repeats. 
Computed values for compound 305: 
 
IC50 = 59.2 µM (±4.4) µM 
Kiapp = 11.1 µM (±0.9) µM 
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5.14.6. α, α, β-trilfuoro cyclopropyl-coenzyme-A (462) IC50 and Kiapp 1 
 
The following data were calculated for compound 462 according to the general 
procedure reported above. Stock solutions of compound 462 in MilliQ® water were 
prepared and their concentration accurately determined spectrophotometrically by using 
standard curves obtained from coenzyme A. The measurements were then carried out 
gradually increasing the concentration of compound 462 (26µM, 75 µM,250 µM,500 
µM,1.1 mM) in duplicate repeats. 
Computed values for compound 462: 
 
IC50 = 346.1 (± 56.4) µM 
Kiapp = 65.2 (± 11.0) µM 
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